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Abstract 
 The cytochrome P450 enzyme PikC has been explored as a robust biocatalyst for 
late-stage directed C-H hydroxylation reactions in organic synthesis.  A collaborative 
effort between the Sherman, Houk, Podust, and Montgomery labs has resulted in the 
engineering of a highly active triple mutant fusion protein, PikCD50ND176QE246A-RhFRED. 
The unique mode of substrate binding to PikC allows for a substrate engineering 
approach to be employed whereby removable auxiliaries, termed anchors, can render 
compounds as suitable substrates for PikC oxidations.   
 Previous studies had illustrated that unnatural substrates can be designed to 
enable the oxidation of inert C-H bonds.  However, the ability to tune and reverse the 
regioselectivity of oxidations was not possible in prior efforts.  This dissertation describes 
the application of a substrate engineering approach for site-selective oxidation of small 
molecules with a triply mutated form of the PikC biocatalyst using synthetic anchoring 
groups.  Oxidations performed using this approach are highly site- and diastereoselective, 
and the selectivities seen using PikC are orthogonal to those obtained using transition 
metal based approaches.  Application of anchoring group technology is further 
streamlined though the development of triazole-based anchors.  With this class of 
directing groups, greater anchoring group structural diversity can be sampled in a high 
throughput approach.  This technology was applied to the site-selective oxidation of 
unnatural 11- and 12-membered macrocycles synthesized via regiodivergent nickel-
catalyzed macrocyclization.  In this study, the first example of anchoring group-promoted 
xx 
 
differential site selectivity is demonstrated and the results are rationalized through 
computational investigations. 
1 
 
Chapter 1: Aliphatic C-H Oxidation Approaches and Their Application in the 
Synthesis of Complex Molecules 
 
1.1 Introduction 
The synthesis of complex, oxygen-containing molecules has a storied history in 
the field of organic chemistry.  For decades, chemists have sought to replicate the diverse 
natural products effortlessly synthesized by nature using available chemical methods.  
Traditional target-oriented synthesis often requires extensive manipulations to 
incorporate oxidative complexity throughout compound assembly.  Achieving the 
appropriate oxidation patterns while simultaneously forging necessary carbon-carbon 
bonds often requires numerous functional group interconversions, protecting group 
manipulations, as well as various oxidations and reductions.  The result is often a 
synthetic sequence that is elegant, but ultimately inefficient.1  This is exemplified in 
Nicolaou’s total synthesis of taxol (Scheme 1.1A), which necessitated the use of several 
protective group manipulations as well as oxidation state changes prior to key C-C bond 
forming reactions.2–6   
On the other hand, nature often accomplishes the synthesis of complex natural 
products using a fundamentally different approach.  The core connectivity of the molecule 
is first established, then the oxidation state of the molecule is manipulated.  In the context 
2 
 
of the biosynthesis of taxol, the all-carbon framework of the molecule is assembled from 
geranylgeranyl diphosphate by taxadiene synthase (Scheme 1.1B).7  Subsequent 
cytochrome P450-mediated oxidations then selectively increase oxidation state of taxa-
4(5), 11(12)-diene to that of taxol.  A key transformation in this sequence is the selective 
functionalization of aliphatic C-H bonds to C-O bonds, which nature can perform with the 
use of enzymes.8   
 
Scheme 1.1: Approaches towards the synthesis of taxol. A. Nicolaou’s total synthesis.  
B. The biosynthesis of taxol.  C. Baran’s two-phase approach towards taxol.   
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With the development of numerous methods to convert C-H bonds to C-O bonds9, 
chemists have begun to adopt nature’s late-stage functionalization approach in the 
synthesis of complex molecules.  These efforts represent a fundamental change in the 
manner in which chemists approach organic synthesis.1,10  An important demonstration 
of this paradigm shift is Baran’s efforts towards taxol mimicking nature’s two-step process 
(Scheme 1.1C).11  While the synthesis of taxol has yet to be achieved using this 
approach,12 this endeavor is another demonstration of how late-stage C-H 
functionalization streamlines synthesis.  Additionally, late-stage C-H oxidation reduces 
the need for protecting groups as functionalities do not need to be carried throughout an 
entire synthesis.  For this approach to be viable, methods need to be developed that are  
capable of installing aliphatic oxygenation with site-, stereo-, and chemoselectivity.1  This 
is complicated by the fact that numerous C-H bonds often exist in organic molecules that 
only possess subtle differences in steric or electronic factors.13  This necessitates the use 
of a variety of approaches ranging from organometallic to biocatalytic to obtain the desired 
selectivity in any given system.  This purpose of this chapter is to summarize approaches 
to aliphatic C-H oxidation employing different controlling factors for achieving selectivity 
as well as their application in the late-stage oxidation of complex molecules.   
 
1.2 Transition Metal Based C-H Oxidation Strategies 
 Transition metals are capable of a myriad of organic transformations.  Rightly so, 
their ability to metalate C-H bonds or form a high valent oxidizing species has been 
recognized by many chemists as a tool for sp3 oxyfunctionalization.  The key challenge 
in this area is the ubiquity of the C-H bond: achieving oxidation of the desired C-H bond 
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in the presence of numerous others.  To achieve this goal several strategies have been 
leveraged for the selective oxidation of C-H bonds using a catalytic transition metal.   
 
1.2.1 Directed C-H Functionalization 
 The use of a substrate-bound directing group is a powerful method for achieving 
site-selectivity in transition metal based aliphatic C-H oxidation reactions.  By 
incorporating a functionality that can serve as a ligand, the metal is adjacent to C-H bonds 
proximal to the directing functionality (Scheme 1.2).  The transition metal can then 
metalate proximal C-H bonds, the selectivity of which is governed by the formation of a 
5- or 6-membered transition state.14  In some instances, the metalacyclic adduct formed 
can be isolated under stoichiometric metal conditions and subjected to further reactions.  
An external oxidant then oxidizes the metal center to promote the delivery of the oxidizing 
functionality.  The use of a removable directing group increases the utility of these 
reactions as many substrates do not possess the appropriate intrinsic functional groups 
nor are most directing groups part of the desired target.   
 
Scheme 1.2: General mechanism for directed transition metal C-H oxidation.   
Early work in this area was performed by the Sames group with the development 
of a reaction for the C-H lactonization of amino acids using catalyst system employed in 
the Shilov process (Scheme 1.3).15  The carboxylate and amino groups serve as ligands 
for Pt(II), which is oxidized to Pt(IV) by copper and insert into aliphatic side chain C-H 
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bonds.  Reductive elimination affords the ɣ-lactone product and regenerated the platinum 
catalyst.  Moderate diastereoselectivity was observed, and competing formation of cyclic 
amines also arose.  While the substrate scope was limited, this work was an important 
early contribution to the field of directed C-H oxidations.   
 
Scheme 1.3: Platinum-catalyzed lactonization of amino acids.   
Palladium-catalyzed C-H oxidation reactions have also been well studied.  A 
seminal report in this area was disclosed by Sanford whereby O-methyl oximes and 2-
pyridyl groups were explored as competent directing functionalities for a palladium 
catalyzed acetoxylation.16  Oxyfunctionalization was observed beta to both directing 
groups, which is consistent with the proposed 5-membered palladacyclic intermediate.  
Also, selectivity for the oxidation of primary carbons over secondary was observed.  This 
was attributed to the steric preference for formation of a palladacycle incorporating a less 
hindered carbon.  Mechanistically, the reaction occurs through a Pd(II)/Pd(IV) cycle where 
Pd(II) first coordinates to the directing group and inserts into a beta C-H via concerted 
metalation/deprotonation.  The resulting palladacycle is oxidized to Pd(IV) by PhI(OAc)2, 
and reductive elimination affords the acetoxylated product with concurrent regeneration 
of the Pd(II) catalyst.   Similar conditions could be applied to the sp2 acetoxylation of biaryl 
substrates using pyridines as a directing group.17 This oxime directed C-H oxidation 
reaction has been applied towards in the synthesis of several natural products18,19, 
notably Sorensen’s enantiospecific total synthesis of the natural product jiadifenolide 
(Scheme 1.4B).20   
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Scheme 1.4: A. O-Methyl oxime directed acetoxylation.  B. Application of oxime directed 
acetoxylation in the total synthesis of jiadifenolide.   
 
Using the Sanford precedent, Dong developed a modified oxime directing group 
for the synthesis of 1,2-diols using a Pd(II)Pd(IV) catalyst system and PhI(OAc)2 as the 
terminal oxidant.21  In a separate study, substrates containing a benzyl, TBS, or free 
hydroxyl could be used as in internal nucleophile for the formation of cyclic ethers.22  4-7 
membered rings as well as spirocyclic ethers could effectively be synthesized followed by 
a Zn mediated reductive cleavage of the directing group to unmask the 1,2-diol 
functionality (Scheme 1.5A). Yu has leveraged the Pd(II)/Pd(IV) catalytic cycle for the 
acetoxylation of methylamines and alkyl groups using the Boc group and enantioenriched 
oxazoles respectively.23,24  A highlight of the latter work is that the chirality of the directing 
group allows for diasteroselective oxidation (Scheme 1.5B).   
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Scheme 1.5: Additional directed acetoxylation reactions.  A. Dong’s exo-oxime directed 
oxidation to form 1,2-diols.  B. Yu’s diastereoselective acetoxylation using a chiral 
directing group.   
 
Hartwig devised a clever approach for the synthesis of 1,3-diols using a one-pot, 
three-step sequence.25  In this method, diethyloxysilane serves as the directing group and 
can be installed by the dehydrogenative silylation of an alcohol or hydrosilylation of a 
ketone by the same iridium catalyst (Scheme 1.6A).  Addition of more iridium precatalyst, 
3,4,7,8-Me4phen, and norbornene catalyzes the dehydrogenative silylation of a ɣ C-H 
bond to form a 5-membered oxasilolane with norbornene as the hydrogen acceptor.  
Quenching the reaction with base and hydrogen peroxide oxidizes the Si-C bond to give 
the final diol product.  Like Sanford’s O-methyl oxime directed oxidation, Hartwig’s 
approach is selective for the oxidation of primary carbons over secondary.  Since the 
dehydrogenative silylation is performed under mild reducing conditions, a variety of 
functional groups can be tolerated such as aryl bromides and chlorides as well as silyl 
protected alcohols, acetals, and internal double bonds (Scheme 1.6B).  However, esters, 
amides and other carbonyl containing functional groups were prone to hydrosilylation.  
Subsequent work by Hartwig focused on the development of modified conditions for the 
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dehydrogenative silylation of secondary alcohols by increasing the amount of iridium and 
ligand for the C-H silylation step as well as the reaction temperature.26   
 
Scheme 1.6: Iridium-catalyzed C-H silylation followed by Si-C oxidative cleavage.  A. The 
one-pot, three step reaction sequence.  B.  Oxidation substrate scope.   
 
In the examples shown, the success of the directing group strategy has relied upon 
the formation of a thermodynamically favorable 5- or 6-membered metallocyclic 
intermediate.  Consequently, most strategies employing a directing group are only 
capable of oxidizing C-H bonds proximal to the directing functionality.  Crabtree 
developed a ligand scaffold that enabled functionalization distal to the catalyst 
coordinating functionality.27  Leveraging the propensity for carboxylic acids to form stable 
hydrogen bonded dimers, Crabtree developed a manganese-terpyridine dimer catalyst 
containing a conformationally restricted carboxylic acid functionality (Scheme 1.7).  The 
catalyst-bound carboxylic acid forms a hydrogen bond to a substrate bound carboxylic 
9 
 
acid and position the substrate proximal to a transient oxidative manganese center 
whereupon C-H oxidation occurs.  This catalyst system was used for the remote-directed 
oxidation of the benzylic position of ibuprofen to the corresponding ketone with high 
turnovers and selectivity.  The authors noted that the use of a control catalyst that lacked 
the coordinating -COOH functionality resulted in greatly diminished selectivity.  Although 
this system lacks broad applicability, it serves as a key example of the power of directing 
groups to achieve high selectivity remote from the site of catalyst binding.   
 
Scheme 1.7: Remote-directed oxidation of Ibuprofen using a manganese catalyst.   
1.2.2 Non-Directed C-H Bond Oxidation 
 Significant effort by numerous groups has been devoted to the development of 
transition metal catalysts capable of selectively oxidizing C-H bonds without the use of a 
substrate-bound directing group.  As a result, oxidation selectivity is determined by the 
steric and electronic properties of the substrate.  Use of a non-directed catalyst system 
offers several advantages, notably, the minimization of concession steps required for the 
installation and removal of a directing functionality.  However, the trade-off is reduced 
site- and chemoselectivity, especially as substrates become more functional group rich 
and complex.  To overcome this hurdle, the development of novel ligand frameworks and 
optimized reaction conditions have been leveraged to provide predictable selectivity using 
these systems.   
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 In most cases, non-directed C-H oxidation catalysts operate under a different 
mechanism from that of their directed analogs.  Instead of metalation of a C-H bond to 
form a C-[M] complex as is common with many directed systems, non-directed catalysts 
are oxidized to form a high-valent metal-oxo or peroxo- species.  The oxidized metal can 
then oxidize C-H bonds through a rapid, two-step hydrogen atom abstraction/hydroxyl 
rebound process, by a concerted, 3-centered oxygen insertion, or a [3+2] addition 
process. Alternatively, catalysts can oxidize alkanes through the generation of reactive 
oxygen free radicals.  Irrespective of the mechanistic pathway, the process remains an 
outer-sphere transformation.10  Numerous metal systems using Mn,28 Ni,29 Co,30,31 Cr,32 
Fe,33 Re,34 Cu,35 Pt,36 Ir,37 and Ru38 catalysts have been developed for these oxidation 
processes.  The recent development of two catalyst systems will be the focus of the 
remainder of this section.   
 The use of electrophilic, non-heme iron catalysts are one of the thoroughly 
investigated systems for aliphatic C-H bond oxidation.  The use of a tetradentate N-donor 
ligand serves as a mimic for the porphyrin ring seen in heme containing enzymes and 
stabilizes the formation of an iron (V) oxo as the reactive oxidation intermediate.39  The 
White group has developed a discreet iron catalyst capable of selective sp3 C-H oxidation 
in good yields.  Initial investigations into an iron (II) catalyst stabilized with the bulky (S,S-
PDP) ligand resulted in selective oxidation of 3° carbons over 2° and 1° (Scheme1.8A).40  
Subsequent studies showed that the same catalyst was effective for the oxidation of 
unactivated methylenes to ketones when the appropriate substrate is chosen.41  
Predictable functionalization of electron rich carbons is observed as oxidation occurs at 
the most highly substituted carbon distal from electron withdrawing substituents.   
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Scheme 1.8: Reactions using White’s non-heme iron catalysts. A. 3° and 2° oxidation 
using Fe(S,S-PDP).  B. Differential oxidation of artemisinin by employing catalyst control.  
C. Directing oxidation using Fe(PDP) catalysts by masking amines as the ammonium salt.  
D. Influencing the oxidation site by transiently masking amides as the electron deficient 
methyl ether.   
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White and coworkers also developed a sterically bulkier variant of the PDP catalyst 
containing two 2,6-trifluoromethylphenyl substituents that was selective for 2° oxidations 
in the presence of 3° carbons.42  The enhanced selectivity is attributed to the electron 
withdrawing nature of the added substituents to the 5-positions of the pyridine ring 
attenuating catalyst reactivity towards more electron rich carbons.  Additionally, added 
steric bulk restricts access to the transiently generated high-valent iron species.  The 
authors demonstrated the effectiveness of this catalyst on the selective oxidation of 
artemisinin (Scheme 1.8B).  Recent efforts have been focused on developing strategies 
to direct the site of functionalization using these iron catalysts by transiently masking 
specific functional groups.  Amine-containing substrates can be oxidized at remote 
carbons by masking the nitrogen as the HBF4 salt or BF3 adduct (Scheme 1.8C).43  Also, 
amide substrates could be oxidized at distal methylenes upon O-methylation with MeOTf 
(Scheme 1.8D).44    
 The Du Bois lab has made significant progress in the development of Ru-based 
reactions for non-directed C-H oxidation.  Early work resulted in a 3-selective reaction 
using a RuCl3 precatalyst and KBrO3 oxidant.45  Under these conditions, the transient 
formation of a RuO4 species that was proposed to undergo C-H oxidation via [3+2] 
addition transition state (Scheme 1.9A) .  Further investigations showed that the use of 
the Me3tacn ligand increased conversions and selectivity when compared to the RuCl3 
system (Scheme 1.9B).46  A recent disclosure from the Du Bois and Sigman groups 
involves the development of a non-directed reaction catalyzed by cis-[Ru(dtbpy)2Cl2] that 
does not oxidize nitrogen groups such as pyridines and amines (Scheme 1.9C).47  Using 
an acid-stable Ru catalyst allows the reaction to be performed using acetic acid as a co-
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solvent and stochiometric trifluoromethanesulfonic acid.  With these conditions, basic 
nitrogen groups are protonated and thus protected from further chemical oxidation.  C-H 
oxidations performed using this reaction are stereoretentive, a significant improvement 
over the previous stereoablative [Ru(Me3tacnCl3)] system.   
 
Scheme 1.9: Du Bois’ development of electrophilic Ru catalysts for C-H oxidation.  A. 
Employing simple ruthenium salts.  B. Using the discreet tacn ligand framework.  C.  
Oxidation of basic nitrogen-containing substrates in acidic aqueous solvent using a 
discreet ruthenium catalyst.   
 
1.2.3 Biomimetic C-H Bond Oxidation 
 Nature employs enzymes as powerful catalysts for the selective oxidation of C-H 
bonds with selectivity determined by a myriad of weak non-covalent interactions within 
the enzyme active site.  De novo design of an entirely new enzyme for selective oxidation 
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has not been achieved.  Breslow,48–53 Hennig,54 and others55,56 have attempted to 
replicate the selectivity observed through enzymatic catalysis with the development of 
biomimetic C-H oxidation catalysts.  Based on the reactive co-factor of cytochrome P450 
enzymes, these catalysts employ a metal-porphyrin decorated with a macrocyclic 
cyclophane or cyclodextrin groups.  Over the past several decades, Breslow has 
developed a manganese catalyst with four appended B-cyclodextrin rings (Scheme 
1.10A).51  Substrates modified with tert-butylphenyl containing auxiliaries are positioned 
near the reactive metal center through hydrophobic interactions between the auxiliaries 
and cyclodextrin rings.  This approached was applied to the benzylic hydroxylation of 
dihydrostilbene substrates with good conversion.49  Further efforts afforded the highly 
selective oxidation of the alpha face of the B-ring of androstane-3,17-diol using 10 mol% 
of Mn catalyst 1 (Scheme 1.10B).52  Improved Mn catalyst 2 containing perfluoroaryl 
groups which were predicted to prevent oxidative decomposition of the catalyst resulted 
in greater catalytic efficiency for the hydroxylation of the androstane diol substrate.50,53   
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Scheme 1.10: Breslow’s biomimetic manganese catalysts.  A. The structure of the 
manganese porhyrin catalyst with four pendant β-cyclodextrin rings.  B. Application of Mn 
catalysts for the selective oxidation of a steroid framework.   
 
1.3 Organic C-H Bond Oxidation Methods 
 Electrophilic O-atom transfer reagents are a useful alternative to metal-based C-H 
oxidation methods.  Dioxiranes are among the most commonly used class of organic 
reagents used for these types of transformations.  Pioneered by Murray57 and Curci,58,59 
dimethyldioxirane (DMDO) and trifluoromethyldioxirane (TFDO) can be prepared from the 
corresponding ketones and stored for long terms at low temperatures.  These compounds 
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are proposed to insert directly into sp3 C-H bonds through a concerted oxygen transfer to 
furnish the resulting hydroxylated product and an equivalent of ketone, but there is also 
evidence for a stepwise radical-based process (Scheme 1.11A).58  Selectivity for C-H 
insertion favors more electron rich carbons.  Despite the high reactivity and thermal 
instability of these compounds, they have been successfully employed for the late-stage 
hydroxylation of organic compounds.  Baran utilized TFDO for the installation of a tertiary 
hydroxyl group en-route to the synthesis of the terpene natural product 4-epiajanol 
(Scheme 1.11B).60  The highly-selective equatorial C-H oxidation in the presence of 
several other 3° carbons was attributed to substrate strain release in the transition state 
of the oxygen transfer.61  Wender leveraged a DMDO oxidation for the selective 
hemiketalization of an electron rich pyran ring of a bryostatin analogue in high yield 
(Scheme 1.11C).62  The latter example is a remarkable demonstration of the application 
of these reagents as both free hydroxyl groups, electron rich, and electron deficient olefins 
are tolerated.   
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Scheme 1.11: C-H functionalization using dioxirane reagents.  A. Proposed mechanism 
for dioxirane C-H oxidation.  B. Baran’s application of TFDO in the synthesis of 4-
epiajanol.  C.  Wender’s application of DMDO in the synthesis of hydroxylated bryostatin 
analogues.   
 
A significant hurdle to the more mainstream application of these reagents is their 
instability, requiring storage at cryogenic temperatures for extended use.57  Additionally, 
stoichiometric use of these oxidants is required.  An attractive alternative to the use of 
TFDO and DMDO is the use of a suitably reactive ketone that can be oxidized into a 
dioxirane in situ from inexpensive oxidants, such as hydrogen peroxide or persulfates.  
Hilinski and Pierce developed a trifluoromethyl aryl ketone catalyst that could be used in 
20 mol % for C-H oxidation with hydrogen peroxide as the oxidant (Scheme 1.12A).63  Du 
Bois and coworkers engineered benzoxathiazine catalysts capable of in situ oxidation to 
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the corresponding oxaziridine as the active species (Scheme 1.12B).64  In both examples, 
the oxidation selectivity is analogous to DMDO and TFDO oxidations.  In lieu of a catalyst 
for intramolecular oxidation, Inoue created a removable trifluoromethyl ketone auxiliary 
for intramolecular hydroxylation (Scheme 1.12C).65  This group could promote the 1,3-
axial hydroxylation of cyclohexanols and steroids.  It was observed that the oxidation 
selectivity was significantly eroded when an equatorial alcohol was used to tether the 
auxiliary to the substrate.   
 
Scheme 1.12: In situ generated dioxiranes and oxaziridines for C-H oxidation.  A. 
Wender’s trifluoromethyl aryl ketone catalyst.  B. DuBois’ benzoxathiazine catalyst.  C.  
A tethered auxiliary for in situ dioxirane generation.   
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1.4 Biocatalytic C-H Oxidation Methods 
 The greatest challenge in chemical oxidation methods is controlling the site- and 
stereoselectivity of functionalization.  As mentioned earlier, nature has overcome these 
hurdles by implementing metalloenzymes for aliphatic C-H oxidation.  One of the largest 
classes of enzymes leveraged for this transformation across species ranging from 
bacteria and fungi to humans is the cytochrome P450.  As an alternative approach to 
small molecule methods, scientists have sought to harness the natural reactivity of these 
enzymes for the selective oxidation of non-native substrates.   
 
1.4.1 Conserved Structural Features and the Cytochrome P450 Catalytic Cycle 
 Aside from the sequence homology among different cytochrome P450 enzymes, 
one of the main conserved structural features is the iron protoporphyrin IX cofactor 
(Scheme 1.13A) with an axial cysteine ligand.  This metal center serves as the reactive 
site for oxygenation while the surrounding residues determine the orientation of the 
substrate within the active site through a myriad of non-covalent interactions.   
 The resting state of the enzyme is an Fe(III) species with an axial water ligand.  
Upon substrate binding to the enzyme, the water ligand is removed and the spin state of 
the iron changes to allow single electron reduction of the iron by a redox partner (Scheme 
1.13A).66–68  The redox partner can exist as a separate domain within the P450, or in an 
entirely different protein.  The electrons provided to the redox partner typically come from 
the oxidation of NADH or NADPH.  The reduction of the P450 Fe(III) to Fe(II) allows the 
incorporation of an axial oxygen.  Another single electron transfer from the redox partner 
and double protonation allows for the reductive scission of the oxygen-oxygen bond and 
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results in the formation of an Fe(IV) oxo with a radical cation delocalized in the 
surrounding porphyrin cofactor.  This intermediate, commonly known as compound I, is 
the reactive species that oxidizes proximal substrate C-H bonds.  Once the substrate is 
oxidized, it is ejected from the enzyme and replaced by a water ligand to return the 
enzyme to its Fe(III) resting state.   
 Numerous deuterium labelling and radical clock experiments have determined that 
substrate oxidation by compound I proceeds through a radical rebound mechanism 
(Scheme 1.13B).68  This occurs through a stepwise process where a hydrogen atom is 
abstracted from the substrate to generate a radical and an Fe(IV) hydroxyl species.  The 
substrate radical can then recombine with the iron hydroxyl to install form the oxidized 
product and reduce the iron species to Fe(III).  Independent syntheses of Fe(IV) hydroxyl 
compounds with modified porphyrin rings have been shown to undergo hydroxyl rebound 
when subjected to the trityl radical to give Fe(III) and the corresponding organic alcohol.69   
This radical rebound process is so rapid that the substrate radical cannot isomerize or 
reorient within the active site.  Thus, reactions performed by P450s are stereoretentive 
despite proceeding through a short lived radical.   
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Scheme 1.13: The P450 catalytic cycle. A: General catalytic cycle for P450 mediated 
C-H hydroxylation.  B.  Radical rebound oxidation of substrates from compound 1.   
 
1.4.2 Methods for Modifying Enzymatic Reactivity 
 Cytochrome P450 enzymes are highly efficient catalysts for their native substrate.  
However, it is typically observed that their effectiveness decreases as substrates deviate 
from the natural scaffold.  Repurposing enzymes to accept substrates of varying size and 
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complexity remains a challenge in the implementation of biocatalysis.  To overcome this 
problem, the sequence of the protein can be altered through amino acid mutation.  
Rational mutagenesis and directed evolution are the two strategies routinely used to alter 
enzyme activity.    
 Rational mutagenesis70 requires knowledge of the enzyme structure either through 
crystal structure or modeling of the active site.  Using this information, mutations can be 
made at specific sites to alter the reactivity of the enzyme.  Directed evolution67,70,71 relies 
on the random generation of numerous mutants, then assessing their reactivity using an 
assay for a specific trait (i.e. reactivity towards a new substrate).  Mutants that displayed 
improved characteristics can then be subjected to additional rounds of mutation/assaying 
in an iterative process to further increase efficiency.  Since this process occurs through 
random mutation, little to no structural knowledge of the enzyme is required.  These 
methods are not restricted to the alteration of the enzyme substrate tolerance.  Rational 
and directed mutagenesis can be used to increase site selectivity, stereoselectivity, 
thermal stability, coupling efficiency, and organic solvent tolerance to name a few traits.   
 A third approach that has recently been pioneered by Watanabe72,73 and Reetz74 
is the use of non-oxidizable activators to trick the enzyme into accepting unusual 
substrates.  These activators bind the P450 and induce the formation of compound I, but 
do not undergo oxidation.  Instead, compounds that are unsuitable substrates can enter 
the active site and undergo oxidation by the activated P450.    
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1.4.3 Examples of Biocatalytic C-H Oxidation 
 The strategies previously described have been used with remarkable success for 
the implementation of P450s for the oxyfunctionalization of aliphatic C-H bonds.  The 
Urlacher group employed a rational mutagenesis approach to develop mutants of the 
P450 BM3 from Bacillus megaterium for the regioselective allylic hydroxylation of β-
cembrenediol (Scheme 1.14A).75  The two mutants displayed exquisite regiocontrol for 
two adjacent allylic positions, however minimal diastereoselectivity was observed.   
 
Scheme 1.14: Applications of P450 engineering for divergent selectivity.  A. Rational 
mutagenesis applied to the generation of BM3 mutants for the oxidation of β-
cembrenediol.  C. Directed evolution of BM3 variants for a combined chemoenzymatic 
fluorination protocol.   
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Arnold leveraged a directed evolution approach to identify several BM3 mutants 
capable of selective hydroxylation of a series of small molecule scaffolds (Scheme 
1.14B).76  Using the BM3 mutant var-G4, oxidation of the benzylic methylene of ibuprofen 
was obtained, which offers analogous selectivity to Crabtree’s manganese-terpyridine 
catalyst (vide supra).  Switching to mutant var-B4 afforded methine oxidation.  
Enzymatically oxidized products were then subjected to deoxygenative fluorination using 
DAST to demonstrate a two-step protocol for late-stage chemoenzymatic fluorination.  
Finally, Watanabe exploited the use of perfluorinated carboxylic acid activators to 
promote the P450 BM3 catalyzed hydroxylation of small hydrocarbons.   
 While the highlighted examples showcase the utility of P450s as a robust method 
for oxygen incorporation, methods that display the orthogonality of biocatalysis compared 
to chemical methods are of interest.  This is especially so in the context of late-stage 
oxygenation of complex, functional group rich molecules.  Fasan and coworkers identified 
several P450 BM3 mutants using a directed evolution/fingerprinting approach that 
displayed remarkable site-and stereoselectivity functionalization of artemisinin (Scheme 
1.15A).77,78  Using different mutants, hydroxylation of the C14 methyl and C9 methylene 
as either the R or S stereoisomer are obtained.  In contrast, White’s iron-based PDP 
approach is selective for functionalization of the C10 methine of artemisinin and over-
oxidation of C9 to the corresponding ketone.42  Recently, Arnold and Stoltz disclosed a 
fantastic example of the unique selectivity of P450s compared to chemical methods for 
the completion of the total synthesis of nigelladine A (Scheme 1.15B).79 Numerous 
chemical allylic oxidation methods based on Se, Cr, Pd, and Rh failed to oxidize the 
desired C7 position and resulted an undesired selectivity or a mixture of products.  After 
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screening a library of engineered P450s, a single variant was identified that was selective 
for hydroxylation at C7.  The synthesis was completed after DMP oxidation to the 
corresponding ketone in 21% yield over two steps.   
 
Scheme 1.15: Biocatalytic oxidation applied to late-stage synthesis.  A. Biocatalytic 
oxidation to generate artemisinin derivatives.  B.  Selective installation of the final site of 
oxidation by biocatalysis to complete the total synthesis of nigelladine A.   
 
1.5 Conclusions and Outlook 
 With the ubiquity of the C-H bond in organic molecules, it is abundantly clear that 
no single aliphatic C-H bond oxidation method can conduct every desired transformation.  
Instead, chemists must carefully select the appropriate method from the available toolbox 
of C-H oxidation technologies.  New methods are constantly under development that 
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operate under unique principles for controlling selectivity, with the underlying goal of 
targeting a previously inaccessible class of C-H bonds for oxidation.  As briefly outlined 
in this chapter, biocatalysis offers unique modes of determining selectivity as well as 
oxidation patterns that are analogous or orthogonal to chemical methods.  Enzymes can 
be mutated to target unactivated bonds regardless of steric or electronic environments.  
 Chapter 2 focuses on a specific cytochrome P450, PikC, from its discovery in the 
genome of Streptomyces venezualae through its development into a robust biocatalyst.  
Within these studies, discovery of the unique mode of substrate binding allows for 
elements of directed oxidation as well as enzymatic methods to be incorporated in a single 
platform.  Chapter 3 outlines the use of this biocatalyst to perform oxidation on unnatural 
scaffolds where regioselectivity is determined by the identity of the directing group.   
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Chapter 2: Development of the Cytochrome P450 PikC as a Biocatalyst for Late-
Stage C-H Oxidation 
 
2.1 Introduction 
 As delineated in the previous chapter, biocatalysis is a powerful complement to 
chemical aliphatic C-H oxidation methods.  Unlike chemical systems that are created 
upon the fundamental understanding of chemical reactivity, suitable biocatalysts need to 
be discovered in nature.  This is often achieved by probing biosynthetic pathways in 
bacteria, fungi, and plants.  This chapter entails the discovery, characterization, and 
development of a unique cytochrome P450 as a potent biocatalyst for late-stage C-H 
hydroxylation.   
 
2.2 The Biosynthesis of Natural Product Macrolide Antibiotics Encoded in the pik 
Gene Cluster in Streptomyces venezualae 
 Macrolides are an important class of bacterial antibiotics, with erythromycin (Figure 
2.1A) being the first to see clinical use.  Since then, several other potent macrolides have 
been adopted for human use.  These antibiotics are capable of binding to the 23S 
bacterial ribosome subunit and preventing translation ultimately resulting in cell death.80  
Understanding the mechanism of their biological synthesis would allow the manipulation 
of the bacterial genome to create new antibiotic analogs.81,82   
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Figure 2.1: Macrolide antibiotics A. Clinically used macrolide antibiotic Erythromycin.  B. 
Macrolide antibiotics produced by Streptomyces venezuelae.  C. The gene cluster 
encoding the four macrolide antibiotics shown in panel B.   
 
Methymycin, neomethymycin, pikromycin, and narbomycin are four macrolides 
produced by the bacteria Streptomyces venezuelae (Figure 2.1B).  Investigations by 
Sherman and coworkers have shown that the ~60 kB pik gene cluster contains the 
biosynthetic machinery responsible for the synthesis of all four macrolide natural products 
(Figure 2.1C).83  The pik cluster is comprised of 18 genes.  Of note, pikAI, pikAII, pikAIII, 
and pikAIV encode a polyketide synthase (PKS), a multifunctional series of proteins 
responsible for the synthesis of the polyketide backbone.  These PKS systems are 
observed across numerous macrolide and polyketide biosynthetic pathways.84,85  The pik 
PKS is comprised of six modules, which are responsible for the synthesis of the linear 
backbone of the macrolide aglycone.  Subsequent macrolactonization by a thioesterase 
(TE) encoded in pikAIV or pikAV affords 12-membered aglycone 10-deoxymethynolide 
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(10-dml) from PKS module 5 or 14-membered aglycone narbonolide from PKS module 6.  
Downstream of pikA are the seven genes comprising pikB.  These are responsible for the 
synthesis of the deoxyaminosugar desosamine.  A single flexible glycosyltransferase 
encoded in desVII appends desosamine to both 10-dml and narbonolide aglycones to 
make YC-17 and narbomycin (Figure 2.2).   
 
Figure 2.2: The structure and biosynthesis of 10-dml, narbonolide, YC-17, and 
narbomycin.   
 
30 
 
Further downstream, the gene pikC encodes a single cytochrome P450 
monooxygenase.  The PikC enzyme is responsible for the hydroxylation of both C10 and 
C12 of YC-17 to form methymycin and neomethymycin in a 1:1 ratio (Scheme 2.1).  
Additionally, PikC catalyzes the hydroxylation of 14-membered narbomycin to pikromycin 
and neopikromycin in a 38:1 ratio.86  The final incorporation of a hydroxyl group enhances 
the effectiveness of these compounds as antibiotics compared to their unfunctionalized 
analogs.  Post-synthetic modifications to increase activity, such as hydroxylation, are  
common in biosynthetic pathways.   
 
Scheme 2.1: Endogenous reactions of the cytochrome P450 PikC.   
Analysis of the co-crystal structures of 10-dml and narbomycin bound to PikC 
reveals a unique mode of substrate binding.87  PikC contains a buried pocket and a 
solvent-exposed pocket both adjacent to the heme-containing active site.  Within these 
remote pockets are carboxylate containing residues that form salt bridge and electrostatic 
interactions with the protonated aminosugar desosamine present in both endogenous 
substrates.  The dimethylamine moiety of desosamine was calculated to have a pKa of 
31 
 
8.85, thus adopting a protonated state at biological pH further enhancing the stability of 
necessary electrostatic interactions.  Subsequently, the distal hydrophobic macrolactone 
is positioned adjacent to the iron heme through hydrophobic interactions.  The 
desosamine of YC-17 occupies the buried pocket of PikC, forming a salt bridge with E94 
and an ionic pair with E85 (Figure 2.3A).  Alternatively, the desosamine of narbomycin is 
anchored in the solvent exposed binding pocket through a salt bridge with E85 and an 
electrostatic interaction with D50 (Figure 2.3B).   
 
Figure 2.3: Co-crystal structures of native substrates with PikC.  A. Co-crystal structure 
of narbonolide bound PikC.  B. Co-crystal structure of YC-17 bound PikC.   
 
2.3 Initial Developments of the Cytochrome P450 PikC 
 PikC is unique among cytochrome P450s due to its ability to accept large 
substrates of varying ring sizes. Such substrate flexibility is rare among enzymes and 
many engineering efforts are focused on increasing the size of the active site to 
accommodate larger substrates.  Altering site-selectivity requires additional modifications 
as well.  A biocatalyst that has the innate ability to oxidize large molecules with flexibility 
as seen in the oxidation of 10-dml to two distinct products in a 1:1 ratio would serve as a 
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robust platform for further enzyme engineering efforts.  Additionally, the anchoring mode 
of substrate binding is seldom observed compared to the usual induced fit binding 
mechanism with only a few examples reported to date.88,89 These atypical characteristics 
warrant further development of PikC into a biocatalytic platform.   
 
2.3.1 Initial Enhancements to PikC Through Rational Mutagenesis 
 The discovery of the unique binding of endogenous substrates to PikC via co-
crystal structures facilitates site-directed mutagenesis to probe the requirements of the 
electrostatic interaction between the protonated dimethylamine moiety and carboxylate 
residues Asp-50, Glu-85, and Glu-94.  Mutating Glu-94 to non-polar alanine or polar 
glutamine eliminates PikC reactivity with YC-17 and produces minimal conversion of 
narbomycin.  Analogous mutations to Glu-85 greatly reduce conversion of both 
endogenous substrates.  These results align with the binding shown in the co-crystal 
structure as YC-17 associates with Glu-85 and Glu-94 in the buried pocket and 
narbomycin with Glu-85 and Asp-50 in the solvent exposed pocket.  The respective ionic 
contacts formed with these residues 85 and 94 are essential for catalysis.  Interestingly, 
mutation of Asp-50 to asparagine (D50N) results in enhanced catalytic activity towards 
both YC-17 and narbomycin.87   
 Analysis of the co-crystal structure of PikCD50N with narbomycin reveals a shift in 
binding from the surface exposed pocket (Figure 2.4A) to the buried pocket (Figure 2.4B) 
with ionic contacts between the protonated dimethylamine and Glu-85 and Glu-94.  This 
structural insight coupled with the enhanced catalytic reactivity of PikCD50N with 
narbomycin indicates that binding to the surface exposed pocket is transient and serves 
to facilitate the transition of substrates to the buried, catalytically active pocket.90  Kinetic 
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binding studies show that PikCD50N binds faster to narbomycin than wild type PikC 
(PikCWT) (822.8 s-1 vs. 703.0 s-1).  Glu-85 likely aids substrate relocation from the transient 
to the catalytic pocket as it is essential for productive binding to both pockets. The 
mutation of this residue to glutamine drastically reduces the binding rate to 421.4 s-1.  
From the PikCD50N co-crystal structures as well as kinetic data, it is evident that substrate 
binding to PikC occurs in two steps: substrate binding to the transient, solvent exposed 
pocket followed by a rate-limiting transition to the catalytically active buried pocket.  The 
D50N mutation destabilizes the interaction between the substrate and the transient 
pocket, thus lowering the kinetic barrier for relocation to the catalytic buried pocket.  A 
general reaction coordinate for substrate binding is shown in Figure 2.4D.   
 
Figure 2.4: Narbomycin bound to PikC.  A. Narbomycin bound in the transient pocket.  
B. Narbomycin bound in the catalytically active pocket.   C. Dispersion of charged 
residues.  D.  General reaction coordinate for substrate binding to PikCWT (black) and 
PikCD50N (red). 
 
2.3.2 Development of a Catalytically Self-Sufficient PikC Fusion Protein and 
Incorporation of a NADPH Recycling System 
 An integral component of P450 catalysis is the presence of a reductase, which 
shuttles electrons from NADPH to the heme iron allowing the reductive scission of 
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molecular oxygen and subsequent generation of reactive compound I. A desirable trait 
among P450s developed as biocatalysts, such as BM3, is the presence of an endogenous 
reductase domain that allows the enzyme to be catalytically self-sufficient.91  Without this 
endogenous domain, expensive exogenous reductase partners are required to 
reconstitute P450 activity in vitro.  This presents a significant barrier to the implementation 
of many enzymes as biocatalysts.  
 PikC does not contain an endogenous reductase domain and in vitro reconstitution 
requires the use of expensive spinach ferrodoxin reductase (Fdr) and ferrodoxin (Fdx), a 
system that is commonly employed (Figure 2.5A).92,93  This necessitates the use of three 
independent components to achieve PikC reactivity and is highly cumbersome.  To 
circumvent this drawback, PikC was covalently linked at the N-terminus to RhFRED, a 
reductase domain from the bacteria Rhodococcus sp. NCIMB 9784 (Figure 2.5B).94  The 
resulting fusion protein can be expressed as a single catalytically active unit, thus 
eliminating the need for expensive exogenous partners.  The PikC-RhFRED fusion 
protein displays enhanced catalytic activity towards the native substrates, YC-17 and 
narbomycin, when compared to the three component PikC/Fdr/Fdx system.  This shows 
that the fused protein complex is more efficient at transferring electrons from NADPH.95   
 
Figure 2.5 Two PikC redox partner systems.  A. The three-component redox system.  B. 
The one component RhFRED system.    
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Another improvement to the PikC reaction conditions is eliminating the use of 
stochiometric NADPH as a reducing agent as it is expensive and unstable.  This can be 
achieved by coupling the reaction of PikC-RhFRED to glucose-6-phosphate 
dehydrogenase.96  This added enzyme catalyzes the oxidation of inexpensive glucose-6-
phosphate to 6-phosphoglucono-δ-lactone with concurrent reduction of the less 
expensive NADP+ to NADPH (Figure 2.6).  With this recycling system, glucose-6-
phosphate serves as an alternative terminal reducing reagent for NADPH, which is 
generated catalytically in situ from NADP+.   
 
Figure 2.6: NADPH recycling system catalyzed by glucose 6-phosphate dehydrogenase 
(G6PDH).   
 
2.4 The Substrate Engineering Approach to PikC Biocatalysis 
 The unique salt bridge anchoring of substrates to PikC allows a substrate 
engineering approach97 to be employed for the use of PikC as a biocatalyst.  This strategy 
entails functionalizing substrates with a PikC-compatible auxiliary (termed anchoring 
group) that contains a basic tertiary amine moiety capable of forming the necessary salt-
bridge and electrostatic interactions (Figure 2.7A).  This substrate can then be subjected 
to the PikC oxidation conditions to obtain hydroxylated product(s) (Figure 2.7B).  
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Subsequently, the anchoring group can be removed.  The overall strategy is analogous 
to transition metal based directing group approaches outlined in chapter 1.  However, with 
the PikC system functionalization occurs distal to the directing/anchoring functionality 
whereas most of contemporary approaches promote oxidation proximal to the directing 
group.   
 
Figure 2.7: The substrate engineering approach to biocatalysis.  A. The general method 
used to functionalize substrates for PikC oxidation.  B. Representation of the 
enzyme/substrate interaction promoted by the removable anchoring group.   
 
2.4.1 Desosamine as an Anchoring Group 
 Initial investigations into the substrate engineering approach with PikC focused on 
the use the endogenous aminosugar desosamine as a competent directing group for the 
oxidation of non-native aglycones.  Instead of chemically synthesizing desosamine, the 
sugar was obtained via hydrolysis from erythromycin A (Scheme 2.2).98  The harvested 
sugar was then protected and converted to the glycosyl fluoride.99  The resulting 
desosamine fluoride (Des-F) was then used as a donor for facile desosaminylation of a 
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variety of aglycones.  Glycosylations with Des-F were performed in good yield and were 
highly selective for the β-anomer.  PikC compatible substrates were prepared from 
alcoholic aglycones ranging from 12- to 15-membered carbocycles, bicycles, steroids, 
and aromatics.100   
 
Scheme 2.2: Synthesis of desosamine fluoride (Des-F) from erythromycin A.    
Glycosylated substrates were subjected to enzymatic oxidation using the single 
mutant PikC fusion protein PikCD50N-RhFRED and the reactions analyzed by LCMS 
(Table 2.1).  Larger carbocyclic substrates were shown to be effectively hydroxylated by 
PikC with the 13-membered substrate undergoing 65% conversion.  Despite good 
reactivity, these substrates were converted to ≥6 oxidation products compared to only two 
products obtained using the endogenous substrate YC-17.  The lack of selectivity was 
attributed to the flexibility of the 12- to 15-membered carbocycles within the active site 
indiscriminately positioning sp3 C-H bonds adjacent to the heme iron.  Comparison of the 
LCMS retention times of authentic standards of putative hydroxylated products of the 12-
membered carbocyclic substrate and showed that PikC oxidation occurs at the methylenic 
carbons distal to the desosamine anchoring group.  Co-crystal structures of the 12-
membered carbocyclic substrate with PikC corroborated these results, indicating that the 
three distal methylenes (two of which are degenerate) are all within ~1 A of the heme iron.  
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These results demonstrate that PikC is an effective catalyst for remote-directed sp3 C-H 
hydroxylation.  
 
Table 2.1: Hydroxylation of desosamine anchored unnatural aglycones with PikCD50N-
RhFRED.   
 
Smaller cyclohexanol and trans-decalin did not undergo PikC hydroxylation, which 
was attributed the inability of the substrate to reach the heme iron while bound to the 
catalytic buried pocket due to size limitations.  Alternatively, a rigid steroid was not 
hydroxylated as it was presumed to be too large to fit into the active site.  An aromatic 
substrate was oxidized in 4% to a single product.  This is of interest as the reaction of 
PikC with sp2 C-H bonds was previously unknown and the instability of an aryl radical 
generated through the radical rebound mechanism of P450 oxidation.   
 
2.4.2 Synthetic PikC Anchors 
 With the demonstrated success of the substrate engineering approach using 
desosamine as an anchoring group, ensuing efforts focused on the development of more 
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synthetically useful PikC anchors.  This stemmed from the non-trivial removal of 
desosamine following PikC oxidation.  New synthetic PikC anchors were designed to be 
appended to substrates by an ester linkage rather than an anomeric bond.  Such a 
connection facilitates rapid attachment to substrates from the corresponding carboxylic 
acid and easy removal under hydrolytic conditions.  Additionally, a variety of spacing 
groups separating the ester linkage from the necessary tertiary amine could be sampled 
to identify optimal anchor structures to enhance PikC/substrate binding.101   
 Synthetic anchors were appended to the endogenous aglycone 10-dml and the 
resulting substrates subjected to oxidation using PikCD50N-RhFRED accompanied by the 
NADPH regenerating system (Table 2.2).  Linear aliphatic anchors ranging from 1 to 3 
methylene spacers were effective at promoting monohydroxylation in greater than 80% 
conversion.  Of note, marginal hydroxylation regiocontrol was observed using different 
synthetic anchors.  Shorter aliphatic anchors with 1 or 2 methylene spacers resulted in a 
slight preference for oxidation at exocyclic methylene C12 while a longer 3 methylene 
spaced anchor favored oxidation at tertiary allylic C10.   
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Table 2.2: Hydroxylation of 10-dml using synthetic anchoring groups.   
 It was hypothesized that increasing the rigidity of the anchor would result in 
increased selectivity for a single hydroxylated product.  Employing (R)- or (S)-N-
methylproline resulted in >90% conversion with increased selectivity for C10 oxidation 
(3:1 and 1.8:1, respectively).  The discrepancy in selectivity between the two proline 
enantiomers was attributed to a match/mismatch relationship between the chirality of the 
anchors and the inherently chiral environment of the enzyme active site.  Use of para- 
and meta- benzyl amine based anchors resulted in the greatest C10:C12 selectivity with 
the former producing 10:1 selectivity and the latter >20:1. These results are in stark 
contrast to the endogenous directing group, desosamine, which only affords a 1:1 ratio of 
C10:C12 oxidation.  Employing an ortho- benzyl amine anchor resulted in a reversal of 
hydroxylation selectivity, affording a 1:4 ratio of C10:C12.  The unprecedented control of 
the C10:C12 oxidation site represents the first demonstration of regiocontrol determined 
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by the structure of the anchoring group.  Leveraging this strategy on different substrates 
would allow regiochemical alterations without altering the P450 through mutation.   
 
2.5 Computationally-Guided Mutagenesis and Small Molecule Oxidation with PikC 
 PikC has shown remarkable success for the oxidation of substrates similarly sized 
to that of the native aglycones 10-dml and narbonolide.  However, deviation from these 
scaffolds results in a dramatic loss of enzymatic activity.  Expansion of the accepted 
substrate classes is warranted to make PikC a broadly applicable biocatalyst.  As 
previously shown, small ring systems such as cyclohexane and cis-decalin are unable to 
be oxidized by PikC using desosamine as an anchor.  A combined synthetic, 
computational, and biochemical approach was used to develop a robust PikC mutant for 
the oxidation of small molecules using synthetic anchoring groups.   
 
2.5.1 Development of a Highly Active PikC Triple Mutant 
 Menthol was selected as the initial substrate for enzymatic studies as it possesses 
several methyl, methylene, and methines in varying steric environments.  Several groups 
have used the menthol core for C-H oxidation studies with transition metal-based 
catalysts,40,102–104 which allows the comparison of PikC reactivity and selectivity to 
previously disclosed methods.  A suite of (+)- or (-)-menthol substrates with appended 
PikC synthetic anchors were prepared (Table 2.3).  Anchoring groups were selected to 
maximize varying length and rigidity. Aliphatic substrates 1-4 ranging from two to six 
carbons.  Rigid ortho-, meta-, and para- benzyl amine compounds 5-7 were also 
prepared.105   
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Table 2.3: Menthol derived substrates with synthetic anchors.    
Molecular dynamics (MD) simulations using PikCWT and PikCD50N revealed that 
compound 1 possessing a short dimethyl glycine anchor is unable to form favorable 
electrostatic contacts with residues E85 and E94 in the catalytic buried pocket (Figure 
2.8A).  Instead, the substrate forms a catalytically unproductive hydrogen bond with 
nearby E246.  Substrate interactions with this residue cause a shift in the tertiary structure 
of the protein to the apo, or “open,” form. This has previously been shown to be a 
conformation of PikC unbound to substrate, and thus catalytically inactive (Figure 2.8B).  
Simulations of (-)-menthol substrates (-)-5 and (-)-6 possessing a longer anchor favors 
electrostatic interactions with E85 and E94 in the catalytically active buried pocket.  A 
new interaction between the protonated amine and E48 located in the buried pocket is 
also observed and is not seen in previous crystallographic studies.  Despite substrate 
binding in the desired buried pocket, noticeable fluctuations between the unfavorable 
‘open’ and active ‘closed’ conformation are observed, which is attributed to dynamic 
binding between the E85/E94/E48 triad.   
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Figure 2.8: Substrate binding and tertiary structure of PikC variants observed in MD 
simulations.  A. Detrimental binding of (-)-1 to E246 in PikCWT.  B. Space-filling 
representation of (-)-1 bound in PikCWT in the open conformation.  C. Desired binding of 
(-)-6 to PikCD50ND176QE246A showing electrostatic contacts to key residues E85/E94/E48.  
D. Space-filling representation of (-)-6 bound PikCD50ND176QE246A in the desired closed 
conformation.   
 
Based on these simulations, it was hypothesized that increasing the persistence 
of substrate binding to E85 would favor the desired ‘closed’ tertiary structure, thus 
enhancing catalytic activity.  This could be accomplished by eliminating residues that lead 
to unproductive binding, namely E246 and D176, which were identified through MD 
simulations (Figure 2.8C and 2.8D).  Incorporation of mutations at E246 and D176 to the 
already reactive D50N mutant lead to the creation of a PikCD50ND176QE246A that could be 
combined with the exogenous RhFRED domain to create catalytically a self-sufficient 
triple mutant fusion protein PikCD50ND176QE246A-RhFRED.  As predicted, additions of the 
E246A and D176Q mutations as well as use of longer anchors as in substrate (-)-6 favor 
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binding to the buried pocket as well as a ‘closed’ catalytically active tertiary structure.  Use 
of this computationally derived triple mutant resulted in dramatically increased total 
turnover numbers (TTN) for (-)-menthol substrates 1-8 when compared to reactions 
employing PikCWT-RhFRED or PikCD50N-RhFRED.   
Computational studies using (+)-menthol derivatives 1-8 with PikCWT and PikCD50N 
resulted in unilaterally unfavorable binding due to unfavorable interactions between 
substrate and enzyme chirality.  This is corroborated by experimental data showing low 
TTNs with this series of substrates.  Changing biocatalysts to the triple mutant improves 
TTNs, however the change is not as significant as observed with the (-)-menthol series 
of substrates.   
 
2.5.2 Site-Selectivity and Scope of Enzymatic Small Molecule Oxidations 
 Upon development of a more active PikC mutant, efforts were focused on 
determining the site- and stereoselectivity of enzymatic oxidation products.  Density 
functional theory (DFT) and quantum mechanics (QM) calculations of the hydrogen atom 
abstraction transition states between a truncated (-)-menthol substrate and iron oxo 
compound I indicated favorable reactivity at the C4 position.  MD simulations of (-)-5 in 
the PikC active site revealed that the C4 equatorial hydrogen is located closer to the iron 
oxo and is bound closer to the calculated transition state geometry throughout the lifetime 
of the simulation when compared to its geminal axial counterpart.  Scaled up reactions of 
both (-)-5 and (-)-6, followed by product isolation and subsequent removal of the 
anchoring group by LiAlH4 reduction matched the computationally predicted selectivity to 
afford diol 9 (Scheme 2.3).  This outcome contrasts with other small molecule oxidation 
methods that preferentially oxidize the more electron-rich tertiary carbons of menthol.  
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The orthogonal selectivity obtained through PikC demonstrates the use of this system to 
achieve new reactivity rather than a complement to other small molecule approaches.   
 
Scheme 2.3: PikCD50ND176QE246A-RhFRED hydroxylation of (-)-5 and (-)-6.   
 As a control, desosamine bound (-)-menthol 10 was subjected to oxidation by the 
PikC triple mutant.  No conversion to hydroxylated product was observed indicating that 
desosamine is unsuitable for bridging the gap between the catalytically active buried 
pocket and the iron oxo (Table 2.4).  This result further validates use of synthetic anchors 
over the endogenous directing group for unnatural substrate oxidation.   
Experimental examination of (+)-menthol based substrates 1-8 align with 
computationally predicted reactivity in that reactions result in low conversion and at least 
five isomeric products.   The broad utility of the PikC triple mutant was demonstrated 
across a series of stereodefined small molecules (Table 2.4).  Terpene substrates derived 
from (+)-α-terpineol and (-)-isopulegol are hydroxylated at the allylic methyl and C4 
methylene to give 11 and 12.  Enantioenriched tetrahydronaphthol and indanol based 
substrates are oxidized at the most electronically activated benzylic position to give 13 
and 14.  Finally, bridged bicyclic (+)-fenchol based substrate is oxidized at a distal 
methylene to afford 15.  In each instance of methylene oxidation, the hydroxylation 
stereochemistry is anti- to that of the site of anchor attachment, resulting in predictable 
selectivity for this small molecule oxidation approach.    
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Table 2.4 Scope of site-selective oxidation with PikCD50ND176QE246A-RhFRED.  Sites of 
hydroxylation are indicated in red. Values in parentheses are total turnover numbers 
(TTN) 
 
2.6 Conclusions and Outlook 
 From its discovery in the genome of Streptomyces venezuelae to the generation 
of a self-sufficient triple mutant fusion protein, significant strides have been made in the 
development of PikC as a general and robust biocatalyst for late-stage C-H oxidation.  
However, despite the numerous successes with large and small molecule oxidation, the 
ability to control hydroxylation regiochemistry based on the anchoring group has only 
been demonstrated on the native aglycone 10-dml with the less active PikCD50N-RhFRED 
fusion protein.   
 Advances in anchoring group technology, while significantly improved over the use 
of desosamine, require further refinement before further exploration of regiochemical 
alterations can be made.  The ensuing chapter will focus on the development of a new, 
modular class of PikC compatible anchors and their implementation to control oxidation 
regiochemistry using unnatural substrates and the triple mutant fusion protein described 
in this chapter.   
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Chapter 3: Synthesis of Diverse 11- and 12-Membered Macrolactones From a 
Common Linear Substrate Using a Single Biocatalyst 
 
3.1 Introduction 
The late-stage functionalization of sp3 C-H bonds is a powerful strategy for the 
incorporation of oxidative functionality to increase molecular diversity.  Chemists have 
access to numerous methods based on transition metals, biocatalysts, and reactive 
organic reagents to target specific bonds for oxidation, as outlined in chapter 1.  For a 
given method, selectivity for a specific hydrogen is governed by different factors and 
altering the site of oxidation often requires employing a different catalyst or reagent.  The 
development of a method that allowed tunable site selectivity using a single catalyst would 
drastically reduce the need to screen different oxidation conditions.   
While the late-stage functionalization approach allows for the rapid generation of 
oxidized analogs, a disadvantage is that preparation of a late-stage intermediate often 
requires a significant linear synthesis that ultimately leads to derivatives with a similar 
core structure.  To change make significant structural changes to the scaffold, the 
synthesis of the common intermediate needs to be redesigned.  This problem can be 
solved by the incorporation of a regiodivergent process that allows the cyclization of a 
single substrate to form two or more different scaffolds.  Coupling a regiodivergent 
synthesis with late-
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stage C-H oxidation would streamline the synthesis of a variety of compounds varying in 
core structure and oxidation patterns (Figure 3.1).   
 
Figure 3.1: General approach for combining a regiodivergent cyclization followed by site-
selective C-H oxidation into a diversity-oriented synthesis.   
 
This chapter focuses on the regiodivergent synthesis of macrocyclic substrates 
from a common intermediate via nickel-catalyzed reductive coupling.  Diverse scaffolds 
prepared by this method are then hydroxylated using PikCD50ND176QE246A-RhFRED.  The 
site of oxidation can be tuned to specific C-H bonds by employing a new class of triazole-
based PikC anchors and does not require any modifications to the biocatalyst.   
 
3.2 A Brief Overview of Regiocontrol in Inter- and Intramolecular Nickel-Catalyzed 
Reductive Couplings of Aldehydes and Alkynes 
 The nickel-catalyzed reductive coupling of aldehydes and alkynes is a powerful 
tool for the construction of C-C bonds.  The allylic alcohol motif obtained from these 
reactions is commonly seen across many natural products and can be used for further 
synthetic manipulations.106  The Montgomery107 group and others108,109 have 
longstanding interests in the discovery, development, understanding, and application of 
this technology for the synthesis of complex molecules.  Recently, the discoveries of N-
heterocyclic carbene (NHC) ligands as effective promotors and silanes as competent 
reducing agents have allowed remarkable advances in regiocontrol of the coupling of 
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aldehydes with unsymmetrical alkynes.  The combination of a small NHC ligand, such as 
IMes or i-Pr-BAC with a small silane favors C-C bond formation with the less hindered 
alkyne terminus (Scheme 3.1A).  Use of large ligands such as SIPr or 21 results in 
coupling of the more hindered alkyne terminus (scheme 3.1B).110  Mechanistic studies111 
have shown that these reactions proceed through a rate-determining metallocyclization 
with the regiochemistry determined by the interaction between alkyne and ligand 
sterics.112  A post rate-limiting sequential sigma bond metathesis with the silane and 
reductive elimination regenerates the Ni(0) catalyst.   
 
Scheme 3.1: Reductive coupling regiochemistry determined by ligand sterics. A. Small 
ligand protocol.  B. Large ligand protocol.   
 
Alternatively, coupling of the hindered alkyne terminus can be achieved employing 
both a large NHC ligand (SIPr) and large silane (i.e. (t-Bu)2MeSiH).113  Greater 
regioselectivities can be achieved using this protocol, which employs a commercially 
available ligand, thus conferring a significant preparative advantage (Scheme 3.2).  
Kinetic studies of the large ligand large silane protocol show that formation of major and 
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minor regioisomers 18 and 19 form under different mechanistic pathways.  Unlike 
previously studied reactions, the cyclization of 16a to 17a is reversible and the rate-
determining step is the sigma bond metathesis between 17a and silane.  Employing a 
bulky silane greatly increases the barrier for this step and favors the irreversible 
cyclization to form 17b, which can undergo a post rate limiting sigma bond metathesis 
with the bulky silane due to greater steric accessibility of the nickel center. 
 
Scheme 3.2: Reductive coupling regiochemical control using the large ligand and large 
silane protocol.   
 
 Advances in the regiocontrol of intermolecular aldehyde/alkyne reductive 
couplings using different NHC/silane combinations were applied to intramolecular 
reactions to afford macrocyclic products.  The ability to control ring size through the 
synthesis of exo- or endo-macrocycles using this approach was first demonstrated in the 
chemical synthesis of 10-dml.114  A key disconnection in this approach is the use of a 
nickel catalyzed reductive coupling of 23 using the small NHC ligand IMes and small 
silane Et3SiH to afford silyl-protected allylic alcohol 25 in 58% as an inconsequential 4:1 
mixture of diastereomers as deprotection and oxidation afforded the desired natural 
product aglycone (Scheme 3.3).  If the ligand used in the macrocyclization of 23 is 
changed to bulky DP-IPr, 11-membered exo-macrocycle 24 is obtained in 59% as a single 
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diastereomer.  Subsequent investigations afforded a general and highly regioselective 
exo-macrocyclization protocol using the bulky, electron deficient NHC IPrCl and i-
Pr3SiH.115  Exo-cyclizations using this approach are proposed to operate under a similar 
mechanistic pathway outlined in scheme 3.2, with cyclization to form the endo-
metallacycle proceed through a reversible metallocyclization followed by an unfavorable 
rate-determining sigma bond metathesis with the bulky silane reducing agent leading to 
favorable formation of the exo-product.     
 
Scheme 3.3: Regiodivergent nickel-catalyzed macrocyclization applied in the synthesis 
of 10-dml and unnatural regioisomer 24.   
 
3.3 Substrate Design and the Regiodivergent Synthesis of 11- and 12-Membered 
Macrolactone Substrates 
 Several factors need to be considered in the design of macrocyclic substrates to 
accomplish a synthesis that incorporates a regiodivergent cyclization as well as 
controllable site-selective C-H oxidation.  Arguably the most significant hurdle is the 
development of substrate scaffolds that are capable of undergoing differential oxidation 
by PikC based solely on synthetic anchoring group structure; a transformation that has 
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not been accomplished on an unnatural substrate.  Surveying substrates subjected to 
PikC oxidation revealed that unfunctionalized carbocyclic substrates afforded numerous 
oxidation products indicating that multiple oxidation products could be achieved, but with 
little possibility of site control (Figure 3.2).100  At the other end of the spectrum, the native 
aglycone 10-dml as a substrate results in exquisite regiocontrol for two sites of 
oxidation,101 but structures derived from this scaffold would be too complex for a 
streamlined synthetic approach.  It was hypothesized that substrates of intermediate 
complexity would be suitable for this study as incorporated functionality would mitigate 
indiscriminate PikC reactivity and substrates would be synthetically accessible.   
 
Figure 3.2: Spectrum of macrocyclic substrates subjected to PikC oxidation.    
Another major consideration is the nature of the regiodivergent reaction to be 
employed.  The nickel-catalyzed reductive coupling reaction of aldehydes and alkynes 
has been demonstrated to be suitably robust for the regiodivergent cyclization of late-
stage intermediates in preparatively useful yields, which makes it an optimal choice for 
this application.  Prepared substrates would also need to be enantioenriched to avoid 
complicated diastereo- and regioisomeric mixtures that would arise from the 
matched/mismatched reaction of chiral PikC with a racemic substrate.  While significant 
strides have been made in the development of intermolecular enantioselective reductive 
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coupling reactions using enantioenriched NHC ligands,116,117 an analogous asymmetric 
intramolecular variant for the synthesis of macrocycles has yet to be developed.  
Fortuitously, Ni(0) macrocyclizations have been demonstrated to be highly 
diastereoselective.  Employing an enantioenriched ynal would therefore lead to a single 
enantiomer of an allylic alcohol.115   
 
3.3.1 The Synthesis of Enantioenriched Ynal Starting Material 
Ynal 33 was selected as a common linear intermediate for regiodivergent 
cyclization and site-selective oxidation studies.  Previous studies had shown that the exo-
macrocyclization proceeds with both high diastereo- and regioselectivity.  Therefore, a 
synthesis was developed to produce 33 on multigram scales in high enantiomeric excess 
(Scheme 3.4).  Enantioenriched alcohol serves as the starting material and is 
commercially available from the chiral pool.  TBDPS protection of the alcohol and 
controlled DIBAL-H reduction of the resulting silyl ether affords aldehyde intermediate 27.  
Horner-Wadsworth-Emmons olefination using in-situ deprotonated phosphonocrotonate 
ester affords 28 as an inconsequential mixture of E/Z diastereomers.  The mixture of 
dienes is carried on to a Pd/C hydrogenation to give silyl ether 29 in 77% yield over four 
steps.  Basic hydrolysis of 29 affords the corresponding carboxylic acid, which was carried 
on directly to the Steglich esterification with but-3-yn-1-ol to give alkyne 31 in 91% over 
two steps.  Subsequent TBAF deprotection unmasks primary alcohol 32, which can then 
be oxidized to desired aldehyde 33.  Owing to the instability of aliphatic aldehydes, alcohol 
oxidation was performed immediately prior to macrocyclization to avoid decomposition or 
epimerization of the chiral alpha-carbon.  The Dess-Martin periodinane (DMP) oxidant 
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was selected for this reaction as it proceeds to full conversion in ~1 h and is sufficiently 
mild.   
 
Scheme 3.4: Synthesis of enantioenriched ynal 33. 
3.3.2 Regiodivergent Macrocyclizations 
 With ynal 33 in hand, efforts were focused on implementation of Ni(0) cyclization.  
Subjection of 33 to published exo-cyclization conditions using IPrCl•HCl and KOt-Bu 
resulted in good yield of desired product 34 in >95:5 dr and rr.  Upon TBAF deprotection 
and acylation to form the corresponding Mosher ester, it was apparent that the er of the 
product had eroded from >99% to 84:16 (Table 3.1, entry 1).  It was reasoned that 
epimerization of the alpha methyl group during the reaction was responsible for the loss 
of enantiopurity.  Using the free carbene of IPrCl instead of an in-situ deprotonation to 
eliminate the needed for the potentially culpable KO-t-Bu base resulted in nearly identical 
yield and er (Table 3.1, entry 2).  Lowering the reaction temperature from 90 °C to 60 °C 
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resulted in an improvement in yield to 61% and an er of 95:5 (Table 3.1, entry 3).  Further 
reduction of the temperature led to both diminished yields and er (Table 3.1, entries 4-6).  
Due to the ease of preparation and reaction assembly, the free carbene of IPrCl was 
continued to be used instead of the HCl salt even though KO-t-Bu was shown not to be 
detrimental to the reaction.   
 
Table 3.1: Optimization of the nickel-catalyzed exo-macrocyclization of 33. 
 Previously published reaction conditions for the endo-macrocyclization using IMes 
and Et3SiH afforded the desired macrolactone in good yields, >95:5 rr, and 97:3 dr.  
Gratifyingly, no loss in enantiopurity was observed upon deprotection of the silyl ether 
and conversion to the corresponding Mosher ester.  In both exo- and endo-cyclizations, 
the stereochemistry of the resulting allylic alcohol is syn to the vicinal methyl group as 
determined by both NOE.  The syn stereochemical assignment is corroborated in both 
cases by the assignment of the absolute stereochemistry using Mosher ester analysis.   
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Scheme 3.5: Regiodivergent nickel-catalyzed macrocyclization of 33.   
 The high diastereoselectivity of both cyclizations is rationalized by the ability of 33 
to adopt a favorable conformation, where the aliphatic alkyne substituent is perpendicular 
to the aldehyde carbonyl (Scheme 3.6).  In this conformation, the Ni(0) NHC catalyst can 
coordinate to the aldehyde and alkyne to give putative intermediates 36a and 36b.  The 
orientation of the alkyne substituent in 36a/36b is determined by the identity of the NHC 
ligand, with the large ligand large silane combination favoring the formation of 37a and 
small ligand/ small silane favoring 37b.115  Post-oxidative cyclization steps afford 34A and 
35A with the observed stereochemical outcome.   
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Scheme 3.6: Rationale behind the observed macrocyclization diastereoselectivities.  A. 
Exo-cyclization to give 34A.  B. Endo-cyclization to give 35A.   
 
3.4 Triazole-Based Anchors 
 Previous studies have shown the utility of benzyl amine-based anchors as a 
synthetically useful alternative to the endogenous desosamine for PikC reactions.  
However, a new versatile anchoring strategy is needed discover the unknown structural 
requirements for PikC oxidation where the identity of the anchor determines the site of 
hydroxylation using a non-native substrate.  The envisaged approach necessitates 
modular assembly to maximize structural diversity, the ability for high-throughput 
synthesis, and facile removal of the anchor following PikC oxidation.  A strategy 
combining these factors was developed based on a 1,2,3-triazole assembled through a 
metal-catalyzed azide/alkyne cyclization (scheme 3.7).  Anchors are appended to a 
substrate through a two-step sequence first undergoing an esterification with an azido-
acid and then a metal catalyzed cyclization with an acetylenic amine (scheme 3.7A).   
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 An important feature of this anchoring strategy is the access of a variety of modular 
components.  Azido acid building blocks are easily accessed from amino acids through a 
stereoretentive diazo transfer reaction.  As such, the wealth of natural and unnatural 
amino acids can serve as potential scaffolds for anchor assembly.  Also, numerous 
acetylenic amines are commercially available.  Changing the metal catalyst used in the 
azide/alkyne cyclization can also alter the regiochemistry of the anchor scaffold allowing 
another method to control anchor structure.  Employing a copper catalyst gives the 1,4-
triazole118,119, while using a ruthenium catalyst affords the 1,5- regioisomer (Scheme 
3.7B).120  Sharpless and Fokin have shown that both metal reactions are highly 
regioselective for their respective isomer and can tolerate a myriad of functional groups,  
affording high yields under mild conditions.  Using this modular approach, it was 
hypothesized that the identity of spacer elements S1 and S2 as well as the triazole 
regioisomer would dictate which substrate C-H bond is positioned proximal to the Fe 
heme upon binding to PikC (Scheme 3.7C).  Since this anchoring strategy is broadly 
applicable, it was reasoned that regiodivergent oxidation could be rapidly optimized for 
different macrocycles 34A, and 35A.   
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Scheme 3.7: General approach towards the synthesis of triazole-based anchors.  A. Two-
step assembly.  B. Regiodivergent azide/alkyne cyclization.  C. Representation of triazole 
substrates bound to PikC where S1 and S2 elements determine which hydrogen are 
proximal to the heme iron.   
 
3.5 PikC Catalyzed Macrolactone Oxidation 
3.5.1 Oxidation of an 11-Membered Macrolactone 
 The triazole based anchoring strategy outlined in section 3.4 was applied to the 
11-membered exo-macrocycle 34A synthesized using nickel catalysis as the key 
cyclization step.  Macrocycle 34A was deprotected using TBAF buffered with AcOH to 
remove the silyl protecting group and prevent transesterification with the resulting 
hydroxide.  With the free alcohol in hand, a suite of triazole-based anchors were 
appended to give 38a-n, which were then subjected to PikC oxidation using the self-
sufficient triple mutant fusion protein PikCD50ND176QE246A-RhFRED on an analytical scale.  
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Upon quenching, the crude reactions were analyzed by reverse phase LCMS to 
determine conversions and the number of hydroxylation isomers.   
 From the analytical reactions, it was observed that 1,5-triazole anchors based on 
glycine or alanine (a-d) resulted in low conversion to hydroxylated products with anchor 
d achieving the highest selectivity among this series in a 4:1 ratio in favor of a single 
oxidation product (Table 3.2 entries 1-4).  The use of the analogous 1,4- regioisomers e-
h conferred higher selectivity and better conversion (Table 3.2 entries 5-8).  Anchor, h 
displayed the highest selectivity for a single product in a 96:4 ratio.  Interestingly, the S 
enantiomer g resulted in a mixture of five oxidation products, indicating that the selective 
incorporation of chirality in the anchor can serve as a means of effectively controlling 
product distribution.  Longer, more rigid biaryl triazole anchors i-l were also surveyed 
(Table 3.2 entries 9-12).  Anchors j-l all resulted in >30% conversion with at least a ~3:1 
selectivity for a major product.  Switching from para- anchor j to ortho- anchor l resulted 
in a change in the order of elution of the major product from the LCMS, indicating a 
potential change in hydroxylation regiochemistry.  Control substrate 38m containing an 
isopropyl group instead of a dimethylamine was not oxidized by PikC, showing the 
necessity of the key electrostatic interaction between the protonated substrate and the 
enzyme (Table 3.2 entry 13).  Switching the dimethylamine for a basic imidazole as in 
38n did not result in oxidation, indicating that a tertiary amine is the optimal basic 
functionality for this transformation (Table 3.2 entry 14).   
 To determine the site- and stereochemistry of hydroxylation, PikC reactions of 
interest were scaled, the products isolated by preparative HPLC and characterized by 2D 
NMR spectroscopy.  Alternatively, the product identification was accomplished through 
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the chemical synthesis of authentic standards.  These compounds were used to identify 
PikC reaction products by the comparison of their LCMS retention times in single injection 
and co-injection experiments as well as through 1H NMR analysis.  The synthesis and 
application of these authentic standards for product characterization will be discussed in 
the following section.   
 Rigid biaryl anchors j and k afforded allylic oxidation product 39j and 39k, 
respectively, as the major product.  With both anchors, the allylic product is obtained as 
a single diastereomer syn to the adjacent ester and methyl functionalities (Table 3.3).  
Switching to a shorter alanine anchor h resulted in a shift of oxidation site to give alpha 
hydroxyl 40h.  A third site of oxidation is obtained using the ortho- biaryl anchor l giving 
41l, where oxidation occurs β- to the macrolactone.  β-macrolactone oxidation selectivity 
is of interest as oxidation at this position does not benefit from stabilization of a radical 
intermediate from the presence of neighboring pi systems and oxidation at this position 
occurs in the presence of more reactive C-H bonds.  Characterized minor oxidation 
products are shown to be regioisomeric mixtures of 39, 40 or 41, with other diastereomers 
not observed. Additionally, epoxidation of the exocyclic olefin or formation of the 
corresponding N-oxides was not observed displaying the high functional group tolerance 
of this enzymatic approach.  These results represent the first example of anchor-
controlled selective oxidation of an unnatural substrate using PikC. The ability of PikC to 
control the site of oxidation based on substrate/anchor conformation and geometry within 
the active site, thus overriding steric or electronic factors, shows the complementarity of 
this approach in relation to other C-H oxidation methods.   
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Table 3.2: PikC oxidation of exo-macrocycle substrates functionalized with triazole 
anchors.   
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Table 3.3: Anchor-controlled site-selective hydroxylation of macrolactone 38.    
Subjecting acetylated macrolactone 34c to contemporary aliphatic C-H oxidation 
approaches, such as White’s non-heme Fe catalyst,40,41 resulted in epoxidation as the 
sole product (Scheme 3.8).  While unsuccessful at hydroxylation, the exploration of PikC 
oxidation of more highly oxidized substrates is of interest.  Chemical oxidation of 34B to 
spirocyclic epoxide 43 is achieved quantitatively and as a single diastereomer upon 
switching oxidants to mCPBA.  Subsequent attachment of para-biaryl anchor j and 
subjection to PikC oxidation gives alpha hydroxyl 44 in 41% and a 95:5 ratio.  The shift in 
the oxidation site of 44j compared to 39j is likely due to the loss of allylic stabilization of 
the radical intermediate upon conversion to the epoxide.  
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Scheme 3.8: Combined chemical and enzymatic oxidation.   
3.5.2 Synthesis of 11-Membered Macrolactone Authentic Standards 
 Several PikC oxidation products were characterized by the comparison to putative 
authentic standards as mentioned earlier.  Upon discovery of the three major sites of 
oxidation 39-41 though scaled reactions and product isolation, syntheses were devised 
to prepare authentic allylic and alpha- oxidation products for further compound elucidation 
(Scheme 3.9).  The synthesis of alpha hydroxyl standards was first accomplished by 
deprotonation of macrocycle 34 using KHMDS, then treatment of the in situ formed 
enolate with Davis’ oxaziridine to furnish 45 as a single diastereomer.  Absolute 
stereochemical assignment of this product was determined using Mosher ester analysis.  
Deprotection of monoprotected diol 45 using TBAF afforded 46, which was used for the 
assignment of 40h by 1H comparison.  A two-step protecting group manipulation 
sequence afforded alpha- monoprotected THP diol 47 in 88% over two steps.  
Esterification of the free alcohol with ortho-, meta-, or para- azidobenzoic acid and 
subsequent removal of the THP group gave 48a-c in good yields.  Finally, copper-
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catalyzed azide/alkyne cyclization gave chemically prepared standards 40j, 40k, and 40l.  
Comparison of the LCMS retention times of these standards to PikC reactions 
conclusively showed that these three compounds are products of their respective 
enzymatic reactions.   
 
Scheme 3.9: Synthesis of α-hydroxylated authentic standards 
Allylic oxidation standard 39k was prepared using 49, an intermediate prepared en 
route to 38k (Scheme 3.10A).  Subjection of this compound to oxidation conditions using 
SeO2 and pyridine N-oxide resulted in the formation of 50 as a single diastereomer in 
48% yield.  The remaining mass balance was converted to the corresponding unsaturated 
ketone.  The copper-catalyzed cyclization of 50 gave chemically prepared 39k, the 
stereochemistry of which was determined by NOE and matched the LCMS retention time 
of its PikC counterpart.  The site of oxidation of 44j was determined by 2D NMR methods, 
but direct stereochemical assignment of this isolated product remained elusive.  An 
authentic standard was prepared by first epoxidizing intermediate 48a using mCPBA to 
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give 51 as a 94:6 mixture of diastereomers (Scheme 3.10B).  The stereochemistry of the 
intermediate was not determined as copper azide/alkyne cyclization gave 44j, the 1H 
specrtrum of which matched its enzymatically prepared counterpart allowing both the 
assignment of the epoxide and the alpha hydroxyl.    
 
Scheme 3.10: Synthesis of additional oxidation standards.  A. Synthesis of allylic 
standard 39k.  B. Synthesis of epoxide standard 44j.   
 
3.5.3 Enzymatic Oxidation of the Enantiomeric 11-Membered Macrocycle 
 Studies conducted with PikC and the menthol series of substrates showed that 
substrate chirality has a dramatic impact on conversion as well as product distribution.  
To probe whether chirality of 38 has an effect on enzymatic reactivity, the (R,R) 
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enantiomer of the 11-membered macrolactone, 52, was prepared.  This macrocycle was 
prepared following the same steps in the preparation of 33 to give (R)-33, upon which 
Ni(0) cyclization afforded the corresponding macrocycle with identical yield, dr, rr, and er.  
Subsequently, 52 was functionalized with anchors j, k, h, and l and subjected to PikC 
oxidation conditions.  Products from the enzymatic reactions were characterized by 
comparison to authentic standards through LCMS retention times and 1H NMRs.  Unlike 
38j and 38k, the major product of 52 with anchors j and k is α-hydroxylation rather than 
allylic oxidation (Table 3.4).  Furthermore, anchor h is selective for β-oxidation product 54 
rather than α-oxidation as seen with 38.  Despite the drastic differences in site-selectivity 
observed with the previous three anchors, l results in the same β-oxidation site and 
relative stereochemistry with both 38 and 52.  The discrepancies between oxidation 
profiles of the two macrocycle enantiomers indicate that anchor optimization is necessary 
between substrates, supporting the use of this modular, high-throughput approach.   
 
Table 3.4: PikC oxidation of (R,R) macrocycle 52.  
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3.5.4 12-Membered Endo-Macrolactone PikC Oxidation 
 Upon Ni(0) cyclization using the small NHC ligand IMes and small silane Et3SiH, 
the resulting 12-membered macrolactone 35 was deprotected and functionalized with 
several PikC triazole anchors to give 55j,l,o (Table 3.5).  Para-biaryl triazole anchor j 
afforded allylic oxidation product 56j in a ~2:1 ratio.   The same site of oxidation was 
obtained using alanine anchor o, albeit with significantly greater selectivity.  The use of a 
diethylamine in o instead of the dimethylamine used in h was found to decrease the 
amount of demethylation byproduct.  As with the 11-membered macrolactone series, 
anchor o directed oxidation β- to the macrolactone ester with the minor oxidation product 
affording allylic oxidation.  These results show that the ability to control hydroxylation 
regiochemistry is not limited to a single substrate and has the potential to be broadly 
applicable.   
 
Table 3.5: PikC oxidation of the 12-membered endo-macrolactone 55.   
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3.6 Anchoring Group Removal 
 A critical component of directing group design is facile removal following C-H 
functionalization.  The choice of an ester linkage in previous and current anchoring groups 
was to allow removal under basic conditions.  Employing macrolactone substrates 
presents the added complication of chemoselectivity.  To probe if this can be 
accomplished, unoxidized 38h was subjected to transesterification using K2CO3 in MeOH 
and macrolactone 34B was cleanly recovered in 81%.  However, subjecting PikC 
hydroxylated product 40h to the same conditions resulted in macrolactone 
transesterification to give a linear triol product (Scheme 3.11).  It was hypothesized that 
the addition of the α-hydroxyl group could increase the electrophilicity of the macrolactone 
carbonyl by engaging in intramolecular hydrogen bonding.  Protection of 40h as the TBS- 
ether followed by hydrolysis was able successfully remove the anchor to give 
monoprotected diol 58.   
 
Scheme 3.11: Two-step removal of PikC anchors.   
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Removal of the biaryl triazole anchors from 38j, 38k, and 38l proved to be 
significantly more challenging as the same conditions used on 38h exclusively resulted 
in macrolactone scission.  Screening commonly employed hydrolysis and 
transesterification conditions were unable to provide the desired reactivity (Table 3.6 entry 
1).  To overcome this pitfall, it was hypothesized that the incorporation of electron 
withdrawing groups ortho- to the triazole would increase the electrophilicity of the aryl 
ester allowing for selective removal.  Fluorine was selected as the desired substituent as 
to maintain a similar steric profile to anchor j to give fluorinated anchor p.  Subjection of 
38p to methanolysis resulted in a 68% yield of 34B (Table 3.6 entry 2).  Further 
optimization showed that anchor p can be removed in 90% using a mixture of THF/H2O 
and LiOH (Table 3.6 entry 3).  To prove that modified anchor p affords a similar reaction 
to profile to its non-fluorinated analog, the reaction of 38p was scaled and the major 
product was confirmed as 39p, the same oxidation selectivity afforded by 38j (Table 3.7).  
Upon TBS- protection, anchor p was successfully cleaved from 39p in 69% over two 
steps.   
 
Table 3.6: Removal of the fluorinated aryl anchor.   
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Table 3.7: PikC oxidation of fluorinated substrate 38p.   
3.7 Computationally Rationalized PikC Selectivity 
 PikC directed biocatalytic oxidations do not rely on C-H bond strength, acidity, 
steric accessibility, inductive influences, or proximity to the directing functionality.  Instead 
selectivity is dictated by interactions between the active site residues matched with the 
structure, stereochemistry, and conformation of the substrate and triazole anchors.  The 
compounded weak interactions that lead to differential selectivity make rationalization 
difficult.  Therefore, a combined density functional theory (DFT) and molecular dynamics 
(MD) approach was used to simulate structural interactions within the PikC active site to 
elucidate the factors controlling hydroxylation regioselectivity.  This combined approach 
was applied to rationalize the selective formation of 39j, 40c, and 41l derived from 38j,c,l 
(Table 3.3).  
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3.7.1 DFT Calculations of Low Energy Conformers and Transition States 
 DFT calculations were first used to determine the lowest energy conformers of a 
truncated methyl ester derivative of 38.   From these calculations, two low energy 
conformers were identified that differ by 0.9 kcal/mol (Figure 3.3A).  The next highest 
energy conformer was >2 kcal/mol higher in energy than conformer 1, making it unlikely 
to be accessible.  The spatial orientations of hydrogens within conformers 1 and 2 are 
largely identical, the only major difference between the two being the configuration of the 
macrolactone carbonyl relative to the exocyclic olefin (conformer 1: syn, conformer 2: 
anti).  Following ground state optimization, the DFT barriers to hydrogen atom abstraction 
were computed for C3 and C10 for both conformers.  The barriers for abstraction shown 
in purple and green were the lowest for each site and corresponded to the observed 
products 39 and 40 (Figure 3.3A).   
 Next, the optimal transition state geometries of the four possible 
monohydroxylation products at C3 and C10 in conformer 1 were computed using an 
isolated heme iron-oxo compound 1.  Inspection of the transition state structures reveals 
that pseudo-equatorial hydrogen (purple) at C3 benefits from developing conjugation with 
the neighboring exocyclic olefin (Figure 3.3B).  In contrast, the germinal C3 hydrogen is 
perpendicular to the olefin in the transition state and does not benefit from the resulting 
allylic radical stabilization (Figure 3.3C).  A similar conjugation effect is seen for the 
oxidation at C10 with the green hydrogen benefitting from overlap with the adjacent 
carbonyl (Figure 3.3D).  For the C10 blue hydrogen to overlap with the carbonyl, the 
macrolactone ring must distort, which results in a higher energy conformation, and is thus 
thermodynamically unfavorable (Figure 3.3E).   
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Figure 3.3: DFT computed low energy conformers and optimized transition states A. 
Lowest energy conformers of a model of structure 38, with DFT barriers (kcal/mol) to C-
H abstraction at C3 and C10.  B. Transition structure of C3 (purple) hydrogen abstraction.  
C. Transition structure of C3 (yellow) hydrogen abstraction.  D. Transition structure of C10 
(green) hydrogen abstraction.  E. Transition structure of C10 (blue) hydrogen abstraction.   
 
3.7.2 Molecular Dynamics Simulations 
 Molecular dynamics (MD) simulations were performed using PikCD50ND176QE246A 
and conformer 1 with anchors j and h appended.  The simulations were conducted for 
500 ns, during which interconversion between conformer 1 and 2 was observed.  The 
critical salt bridge interaction between residues E85 and E94 was also observed with both 
substrates 38j and 38h.  Although the anchors result in similar binding, their length, 
flexibility, and stereochemistry results in different oxidation selectivity.  Determining how 
these factors lead to different products is the goal of the MD simulations.   
Figures 3.4A and 3.4B show that anchor h positions C3 closest to the iron oxo with 
an average distance of 3.3 A during the lifetime of the simulation.  Conversely, j positions 
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C10 closest with an average distance of 4.1 A. During the lifetime of the simulation, the 
purple pseudo-equatorial hydrogen of 38j is closer on average to the iron oxo than the 
germinal yellow hydrogen (Figure 3.4C).   Analysis of the plot of the Hsubstrate-Oiron 
distances versus the C-H-O angles over the lifetime of the simulation using 38j shows 
that the purple hydrogen is closest to the computed DFT transition state (shown in red) 
(Figure 3.4D).  Collectively, the calculations show that the purple hydrogen is intrinsically 
more reactive as shown by the DFT barriers to abstraction as well as being positioned 
closest to the iron oxo using anchor j.  Figures 3.3E and 3.3F show that the blue hydrogen 
of C10 is closest to the iron oxo as well as the optimized transition state geometry 
throughout the lifetime of the simulation.  However, the barrier to abstraction of the blue 
hydrogen is 1.1 kcal/mol greater than that of the green hydrogen.  Even though h can 
position C10 closest to the iron oxo, the intrinsic reactivity of the green hydrogen overrides 
the proximity of the blue hydrogen.   
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Figure 3.4: Molecular dynamics simulations.  A. Snapshot of MD trajectory of 38h 
overlaid with a snapshot of 38j.  B. Closeup of Figure 3.4A snapshot with average C-OFe 
distances shown.  C. Snapshot of 38j with average H-O bond distances shown.  D. Plot 
of hydrogen abstraction (of substrate C3) to oxygen (of iron-oxo) distances vs C-H-O 
angles throughout the MD trajectory with transition state (TS) geometry shown in red.  E. 
Snapshot of 38h with average H-O distances shown.  F. Plot of hydrogen (of substrate 
C10) to oxygen (of iron-oxo) distances and C-H-O angles throughout the MD trajectory, 
with TS geometry shown in red.   
 
3.7.3 Rationalization of β-Oxidation Selectivity 
Determining the factors contributing to the β-oxidation of 38l is of a fundamental 
interest as the oxidized hydrogens do not benefit from conjugative overlap with 
neighboring π-systems.  The stereochemistry of β-hydroxylated product 41l was 
conclusively determined by 2D NOESY.  Analysis of proton coupling constants and 
through-space interactions facilitated the development of a low energy conformer of 41l, 
which agreed with computationally derived conformers of this product (Figure 3.5 A and 
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B).  Upon inspection of the computed barriers to hydrogen atom abstraction of conformer 
1, it was observed that oxidation of the β-up hydrogen of 38l to give 41l was disfavored 
by >4 kcal/mol (Figure 3.5C).  A dramatic shift in abstraction barrier energy for both β 
hydrogens was observed upon rotation to conformer 2 favoring the oxidation of the β-up 
hydrogen by >6 kcal/mol (Figure 3.5D).  The basis for this large change in abstraction 
energy is not fully understood, but a likely contributor is the change in dipole of the 
carbonyl inductively influencing abstraction barriers.  MD simulations of 38l show that the 
β-up hydrogen resulting in 41l is closest to the iron oxo for the majority of the simulation, 
but is removed from the reactive center after ~300 ns (Figure 3.6 A and B).  The β-down 
hydrogen remains ~4 Å from the iron center, which is seemingly too far removed to 
facilitate catalysis.   
 
Figure 3.5: Stereochemical assignment and lowest energy conformers of 41l.  A.  
Truncated conformer of 41l elucidated by 2D NOESY. B.  Selected key NOE correlations.  
C.  Low energy conformer of truncated 38 with unfavorable computed barriers to H 
abstraction (in kcal/mol) for observed stereochemistry.  D. Higher energy conformer of 
truncated 38 with favorable computed barriers to H abstraction (in kcal/mol) for observed 
stereochemistry.   
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Figure 3.6: A. MD simulation of 41l.  B. Plot of simulation time (ns) vs hydrogen atom 
distance from the iron-oxo.   
 
3.8 Computationally Guided Mutagenesis to Develop PikC Tetramutants 
 An interesting observation was made during the analysis of the MD simulations 
involving substrates 38h and 38j.  During the lifetime of the simulation, anchor j is more 
proximal to E85 while anchor h favors interactions with E94 as seen in Figure 3.7.  It was 
hypothesized that eliminating a favorable electrostatic contact by selective mutation of 
one of these residues to non-interacting alanine could promote a reorientation of the 
substrate within the active site resulting in a new oxidation profile.  To this end, two novel 
PikC tetramutant fusion proteins, PikCD50ND176QE246AE85A-RhFRED (Triple+E85A) and 
PikCD50ND176QE246AE94A-RhFRED (Triple+E94A), were created.   
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Figure 3.7: Overlaid MD snapshots of 38j and 38h showing the preferential electrostatic 
interaction of j with E85 and h with E94.   
 
 Compounds 38h,j,l were subjected to oxidation employing both PikC tetramutants 
and the standard NADPH recycling system.  Conversion to hydroxylation and product 
ratios were determined by LCMS.  The major and minor products were identified 
whenever possible by comparison to the LCMS traces of the corresponding reactions 
performed with the PikC triple mutant.  38h exhibited identical reactivity and selectivity 
with the PikC triple mutant and the Triple+E85A tetramutant to give 40h (Table 3.8 entries 
1-2).  Use of the Triple+E94A tetramutant favored formation of 40h, but with reduced 
conversion and selectivity (Table 3.8 entry 3).  A loss of conversion and selectivity is 
expected as the E94 residue is favored by anchor h, however E85 alone can achieve a 
comparable level of reactivity.  A similar trend is observed with 38j and 38l using the 
Triple+E85A tetramutant.  The oxidation profiles are similar to the triple mutant, except 
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with reduced conversion and selectivity for the same major products 39h and 41l (Table 
3.8 entries 5-6 and 9-10).  Interestingly, using the Triple+E94A tetramutant with substrate 
38j results in 40j formed as the major product (Table 3.8 entry 7).  This change was 
unexpected as it was predicted that the mutation of E85 should result in a new mode of 
binding based on the MD simulations.  The use of the Triple+E94A tetramutant with 38l 
results in improved ~4:1 selectivity for 41l compared to the ~3:1 selectivity obtained with 
the PikC triple mutant (Table 3.8 entry 11).  Further investigation of the effects of these 
new PikC mutants is required for a better understanding of these key substrate/residue 
interactions.   
81 
 
 
Table 3.8: Reactions of 38h, 38j, and 38l with PikC triple mutant and PikC tetramutant 
fusion proteins.   
 
3.9 Conclusion 
 This study121 shows that a variety of macrocyclic compounds varying in ring size 
and oxidation patterns can be prepared from a single ynal substrate.  Employing catalyst 
control, the ynal can be cyclized to give 11- or 12-membered macrolactones with high 
regio- and diastereoselectivity.  Coupling this regiodivergent synthesis with late-stage C-
H oxidation using a computationally engineered P450 PikC allows for the tunable site- 
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and stereoselective hydroxylation of obtained macrolactone cores using diverse, triazole-
based PikC directing groups.  This synthetic strategy has the potential to be applied to 
other scaffolds, increasing the molecular diversity obtained from a common intermediate.   
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Chapter 4: Conclusions and Future Directions 
 
4.1 Conclusions 
 In summary, the synthetic benefit for the application of a late-stage C-H 
oxyfunctionalization approach has been described.  Due to the ubiquity of the C-H bond, 
several strategies for functionalization have been described.  Special emphasis has been 
placed on biocatalysis as a method for the above transformation as the principles for 
selectivity are often drastically different compared to chemical transformations.   
 Studies from the Sherman, Houk, Podust, and Montgomery labs have engineered 
PikC from a wild type P450 to a potent catalyst for remote directed C-H bond 
hydroxylation.  The development of a triple mutant fusion protein, PikCD50ND176QE246A-
RhFRED, combined with synthetic anchors has expanded the class of substrates to small 
molecules.  Oxidations performed using this approach are predictably selective and can 
be rationalized through quantum mechanical and molecular dynamics simulations.  
Hydroxylations are performed with exquisite site- and regioselectivity.   
 Further investigations into anchoring group structures have yielded modular, 
triazole-based anchors.  This high-throughput anchoring strategy has been applied to the 
late-stage, site-selective hydroxylation of 11- and 12-membered macrolactones, which 
were prepared via regiodivergent, nickel-catalyzed macrocyclization from a common 
linear intermediate.  The result is an overall synthetic approach where multiple scaffolds 
can be accessed from a single substrate, then oxidized at specific C-H bonds using a 
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single PikC mutant (Scheme 4.1).  The selectivity of these oxidations is dictated by the 
structure of the anchoring group as well as the stereochemical configuration of the 
substrate and its interactions with the PikC active site.   
 
Scheme 4.1 Regiodivergent cyclization of a common intermediate followed by selective 
PikC hydroxylation.   
 
4.1 Future Directions 
 Three sites of oxidation of macrocycle 38 have been obtained by only varying the 
identity of the PikC anchor.  However, studies have shown that mutations to the PikC 
triple mutant are capable of drastically altering the oxidation profile of 38 in combination 
with various triazole anchors.  Future studies will focus on the synergy between 
computationally guided mutagenesis of PikC and triazole anchors to target new sites C-
H bonds of 38 for oxidation.  This could be achieved by moving the key salt bridge forming 
residues to different positions in the active site, thus forcing derivatives of 38 to be 
repositioned in the active site.   
85 
 
Alternatively, the use of a P450 homologous to PikC that relies on critical salt 
bridge interactions for substrate binding could result in unique selectivity. Such enzymes, 
(i.e. JuvD) have been isolated by the Sherman group and been recently employed in 
chemoenzymatic syntheses.122  The use of these unexplored enzymes with triazole 
anchored substrates has the potential to result in unique oxidation patterns not observed 
with PikC.   
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Chapter 5: Experimental Supporting Information 
 
5.1 General Protocols 
Unless otherwise noted, all reactions were conducted in flame‐dried or oven-dried 
glassware with magnetic stirring under an atmosphere of dry nitrogen.  Solvents were 
purified under nitrogen using a solvent purification system (Innovative Technology, inc., 
Model #SPS‐400‐3 and PS‐400‐3). Unless otherwise noted, all other chemical reagents 
were obtained from commercial sources and used as received. Silanes were purified by 
passing through alumina. Ni(COD)2 (Strem Chemicals, Inc.), all N‐heterocyclic carbene 
salts (Aldrich), potassium tert-butoxide (Strem Chemicals, Inc.) were stored and weighed 
in an inert atmosphere glovebox. Reaction temperatures were controlled by a JKEM 
Scientific (Model 210) temperature modulator. Analytical thin layer chromatography (TLC) 
was performed on SilicaPlate TLC 60Å F-254 (250 μm silica gel) and compounds were 
visualized with phosphomolybdic acid, ceric ammonium molybdate, or aqueous KMnO4 
stain. Flash column chromatography was performed using SiliaFlash® P60 (230‐400 
mesh) silica gel. 
1 H-Nuclear Magnetic Resonance (1 H-NMR) and 13 C Nuclear Magnetic 
Resonance (13 C-NMR) spectra were recorded on Varian MR 400, Vnmrs 500, INOVA 
500 and Vnmrs 700 MHz. NMR spectra were recorded in deuterated chloroform (CDCl3) 
at rt unless otherwise stated. The NMR data were presented as follows: chemical shift in 
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ppm with the proton signal of the residual of chloroform (δ 7.26 for 1 H-NMR) and (δ = 
77.0 ppm for 13 C-NMR) as internal standards, multiplicity (s = singlet; d = doublet; t = 
triplet; q = quartet; m = multiplet, dd = doublet of doublets; ddd = doublet of doublets of 
doublets; dddd = doublet of doublets of doublets of doublets; tt = triplet of triplets; dq = 
doublet of quartets), coupling constant (J/Hz), integration. In many instances, the 
quaternary triazole carbon could not be observed directly due to signal broadening.  
Whenever possible, this peak was assigned indirectly by HMBC and is noted as such in 
the compound characterization.  High resolution mass spectra were recorded on a VG 
70-250-s spectrometer manufactured by Micromass Corp. (Manchester UK) at the 
University of Michigan Mass Spectrometry Laboratory.  IPrCl free carbene was prepared 
from commercially available IPr free carbene following a previously reported 
procedure.123 Imidazole-1-sulfonyl azide was prepared according to established protocols 
and purified by chromatography (50% EtOAc/hex) prior to use.124  Fe(S,S-PDP) was 
purchased from Aldrich and handled in a nitrogen-filled glovebox.   
 
5.2 Chapter 2 Experimental 
5.2.1 Starting Material Characterization 
 
(1R,2S,5R)-2-isopropyl-5-methylcyclohexyl dimethylglycinate, ((–)-1):  
A flame-dried round-bottom flask was charged with (0.42 g) N,N-dimethylamino 
glycine•HCl (1.5 equiv), 0.62 g DCC (1.5 equiv), and 0.37 g DMAP (1.5 equiv). The 
contents of the flask were suspended in 20 mL of CH2Cl2 and allowed to stir for ~5 min. 
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0.47 mL of distilled triethylamine (1.7 equiv) was added dropwise and the reaction was 
stirred for an additional 5 min before 0.31 g of (–)-menthol (1.0 equiv) was added. The 
reaction was stirred for 7 d and was then filtered through a cotton plug. The solvent was 
removed by under reduced pressure, and 1 M HCl was added to the resulting yellow 
residue until the pH was between 2 and 3. The aqueous solution was extracted 3x with 
25 mL of 30% EtOAc/hexanes, and the remaining aqueous layer was adjusted to pH 8-9 
with a saturated aqueous sodium bicarbonate solution. The solution was extracted 3x 
with 30 mL of CH2Cl2. The resulting organic layers were combined, dried over sodium 
sulfate, and filtered. The solvent was removed under reduced pressure to afford the crude 
material, which was purified by column chromatography (the column was packed with 5% 
EtOAc, 5% triethylamine, and 90% hexanes and run on a gradient of 30% EtOAc/hexanes 
to 7:2:1 EtOAc: MeCN: MeOH) to yield 0.28 g (57%) of the title compound as a clear oil. 
1H NMR (500 MHz, CDCl3) δ 4.77 (td, J = 10.9, 4.4 Hz, 1H), 3.14 (s, 2H), 2.34 (s, 6H), 
2.04 – 1.94 (m, 1H), 1.92 – 1.78 (m, 1H), 1.76 – 1.61 (m, 2H), 1.58 – 1.44 (m, 1H), 1.43 
– 1.34 (m, 1H), 1.12 – 0.95 (m, 2H), 0.93 – 0.81 (m, 7H), 0.76 (d, J = 6.9 Hz, 3H)  
13C NMR (126 MHz, CDCl3) δ 170.2, 74.4, 60.8, 46.9, 45.3, 40.9, 34.2, 31.4, 26.3, 23.3, 
22.0, 20.7, 16.2 
HRMS (ESI) m/z calculated for [M+H]+ 242.2115, found 242.2112. 
 
(1R,2S,5R)-2-isopropyl-5-methylcyclohexyl 3-(dimethylamino)propanoate ((–)-2): 
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Following the procedure used to synthesize (1R,2S,5R)-2-isopropyl-5-
methylcyclohexyl dimethylglycinate, (–)-menthol (0.31 g), 3-(N,N-
dimethylamino)propionic acid•HCl (0.46 g), DCC (0.62 g), DMAP (0.37 g), and 
triethylamine (0.47 mL) was employed to give 0.096 g (19%) of the title compound as a 
clear oil after purification by column chromatography (silica gel, packed with 5% EtOAc, 
5% triethylamine, and 90% hexanes and run on a gradient of 30% EtOAc/hexanes to 
7:2:1 EtOAc: MeCN: MeOH).  
1H NMR (401 MHz, CDCl3) δ 4.69 (td, J = 10.9, 4.4 Hz, 1H), 2.83 – 2.70 (m, 2H), 2.67 – 
2.51 (m, 2H), 2.36 (s, 6H), 2.03 – 1.92 (m, 1H), 1.92 – 1.78 (m, 1H), 1.75 – 1.61 (m, 2H), 
1.56 – 1.42 (m, 1H), 1.42 – 1.30 (m, 1H), 1.13 – 0.93 (m, 2H), 0.93 – 0.79 (m, 8H), 0.75 
(d, J = 7.0 Hz, 3H)  
13C NMR (126 MHz, CDCl3) δ 172.1, 74.2, 54.8, 47.0, 45.2, 40.9, 34.3, 33.3, 31.4, 26.2, 
23.4, 22.0, 20.8, 16.3 
HRMS (ESI) m/z calculated for [M+H]+ 256.2271, found 256.2274. 
 
(1R,2S,5R)-2-isopropyl-5-methylcyclohexyl 4-(dimethylamino)butanoate ((–)-3): 
(–)-(1R,2S,5R)-menthol (200 mg, 1.28 mmol), 3-N,N-dimethylaminobutyric acid 
hydrochloride (325 mg, 1.92 mmol), triethylamine (304 µL, 2.18 mmol), DCC (400 mg, 
1.92 mmol) and DMAP (237 mg, 1.92 mmol) were dissolved in 12.5 mL of CH2Cl2 and 
stirred at rt for 4 d, then the reaction mixture was filtered through cotton and evaporated 
to dryness in vacuo. The crude residue was transferred to a separatory funnel by washing 
the flask with 0.1 M HCl and 30% EtOAc in hexanes. The acidified aqueous phase was 
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extracted three times with 30% EtOAc in hexanes. Then, the aqueous layer was basified 
with saturated aqueous NaHCO3 solution until it reached a pH of approximately 8-9, 
measured by pH paper. The aqueous layer was extracted three times with EtOAc. The 
EtOAc layers were combined, dried over anhydrous sodium sulfate, filtered, and 
evaporated to dryness in vacuo. The crude residue was chromatographed over silica gel 
(gradient from 30% EtOAc in hexanes to 20% MeCN, 10% MeOH in EtOAc) to yield 168 
mg (49% yield) of the desired ester derivative as a colorless oil.  
1H NMR (400 MHz, CDCl3) δ 4.67 (ddd, J = 10.8, 10.8, 4.4 Hz, 2H), 2.35 – 2.24 (m, 4H), 
2.22 (s, 6H), 2.06 – 1.93 (m, 1H), 1.91 – 1.74 (m, 3H), 1.72 – 1.62 (m, 2H), 1.54 – 1.42 
(m, 1H), 1.41 – 1.31 (m, 1H), 1.11 – 0.80 (m, 9H), 0.75 (d, J = 6.8 Hz, 3H);  
13C NMR (175 MHz, CDCl3) δ 173.1, 74.0, 58.9, 47.0, 45.4, 40.9, 34.2, 32.4, 31.3, 26.2, 
23.4, 23.1, 22.0, 20.7, 16.3; IR (thin film, cm-1) 2925, 2865, 2812, 2764, 1728, 1456; 
HRMS (ESI) m/z calculated for [M+H]+ 270.2433, found 270.2431. 
 
(1R,2S,5R)-2-isopropyl-5-methylcyclohexyl 5-bromopentanoate ((-)-S1)): 
Following the procedure used to synthesize (1R,2S,5R)-2-isopropyl-5-
methylcyclohexyl 6- bromohexanoate, (–)-menthol (0.23 g), DCC (0.46 g), DMAP (0.027 
g), 5-bromovaleric acid (0.45 g), and CH2Cl2 (23 mL) were employed. 0.48 g of the title 
compound was obtained after purification by column chromatography (Silica gel, 5% 
EtOAc/hexanes to 10% EtOAc/hexanes).  
1H NMR (400 MHz, CDCl3) δ 4.68 (td, J = 10.9, 4.4 Hz, 1H), 3.42 (t, J = 6.6 Hz, 2H), 2.32 
(t, J = 7.2 Hz, 2H), 2.02 – 1.94 (m, 1H), 1.94 – 1.73 (m, 4H), 1.72 – 1.63 (m, 2H), 1.56 – 
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1.42 (m, 1H), 1.41 – 1.32 (m, 1H), 1.12 – 0.93 (m, 2H), 0.93 – 0.80 (m, 7H), 0.75 (d, J = 
6.9 Hz, 3H);  
13C NMR (126 MHz, CDCl3) δ 172.6, 74.2, 47.0, 40.9, 34.2, 33.7, 33.0, 32.0, 31.4, 26.3, 
23.6, 23.5, 23.4, 22.0, 20.7, 16.3.  
HRMS (ESI) m/z calculated for [M+Na]+ 341.1087, found 341.1082. 
 
(1R,2S,5R)-2-isopropyl-5-methylcyclohexyl 5-(dimethylamino)pentanoate, ((–)-4): 
Following the procedure to synthesize (1R,2S,5R)-2-isopropyl-5-methylcyclohexyl 
6- (dimethylamino)hexanoate, (1R,2S,5R)-2-isopropyl-5-methylcyclohexyl 5-
bromopentanoate (0.16 g), 40% w/w aqueous dimethylamine (0.32 mL) and DMF (2.2 
mL) was employed to give 0.12 g (88%) of the desired product after purification by column 
chromatography (Silica gel, 30% EtOAc/hexanes to 98%CH2Cl2, 2%, Et3N).  
1H NMR (400 MHz, CDCl3) δ 4.68 (td, J = 10.9, 4.4 Hz, 1H), 2.36 – 2.16 (m, 10H), 2.03 – 
1.93 (m, 1H), 1.93 – 1.78 (m, 1H), 1.75 – 1.57 (m, 4H), 1.56 – 1.41 (m, 3H), 1.41 – 1.30 
(m, 1H), 1.13 – 0.92 (m, 2H), 0.92 – 0.78 (m, 7H), 0.75 (d, J = 7.0 Hz, 3H);  
13C NMR (126 MHz, CDCl3) δ 173.1, 73.9, 59.4, 47.0, 45.5, 41.0, 34.6, 34.3, 31.4, 27.2, 
26.3, 23.4, 23.0, 22.0, 20.8, 16.3. 
HRMS (ESI) m/z calculated for [M+H]+ 284.2584, found 284.2595. 
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(1R,2S,5R)-2-isopropyl-5-methylcyclohexyl 6-bromohexanoate (-)-S2: 
A flame-dried round-bottom flask was charged with 0.62 g of 
dicyclohexylcarbodiimide (DCC) (3.0 mmol), 0.037 g 4-dimethylaminopyridine (DMAP) 
(0.30 mmol), and 0.58 g of 6-bromohexanoic acid (3.0 equiv). The contents of the flask 
were suspended in 21 mL of CH2Cl2, and allowed to stir for 10 min. Then, 0.31 g of (–)-
menthol (2.0 mmol) was added and the reaction was stirred until all the (–)-menthol was 
consumed as judged by TLC. The reaction mixture was filtered through a cotton plug and 
the solvent was removed under reduced pressure to afford a white residue. The crude 
material was purified by column chromatography (silica gel, gradient 5% EtOAc/hexanes 
to 10% EtOAc/hexanes) to yield 0.66 g (99%) of the title compound as a clear oil.  
1H NMR (401 MHz, CDCl3) δ 4.68 (td, J = 10.9, 4.4 Hz, 1H), 3.40 (t, J = 6.8 Hz, 2H), 2.30 
(t, J = 7.4 Hz, 2H), 2.02 – 1.93 (m, 1H), 1.93 – 1.78 (m, 3H), 1.75 – 1.59 (m, 4H), 1.55 – 
1.42 (m, 3H), 1.41 – 1.31 (m, 1H), 1.12 – 0.93 (m, 2H), 0.93 – 0.79 (m, 6H), 0.75 (d, J = 
6.9 Hz, 3H) 
13C NMR (126 MHz, CDCl3) δ 173.0, 74.0, 47.0, 40.9, 34.4, 34.2, 33.5, 32.4, 31.4, 27.6, 
26.3, 24.2, 23.4, 22.0, 20.8, 16.3  
HRMS (ESI) m/z calculated for [M+Na]+ 355.1243, found 355.1240. 
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(1R,2S,5R)-2-isopropyl-5-methylcyclohexyl 6-(dimethylamino)hexanoate, ((–)-5):  
A flame-dried round-bottom flask was charged with 0.16 g of (1R,2S,5R)-2-
isopropyl-5- methylcyclohexyl 6-bromohexanoate (0.47 mmol). (1R,2S,5R)-2-isopropyl-
5-methylcyclohexyl 6- bromohexanoate was suspended in 2.2 mL DMF and allowed to 
stir for ~5 min, followed by addition of 0.31 mL of 40% w/w aqueous dimethylamine (2.5 
mmol). The mixture was stirred until all the starting material was consumed as monitored 
by TLC analysis. The reaction was quenched with 6 mL of saturated sodium bicarbonate 
solution and extracted with EtOAc (3 x 15 mL). The resulting organic layers were 
combined, dried with sodium sulfate, filtered and concentrated under reduced pressure. 
The resulting clear oil was chromatographed (Silica gel, 30% EtOAc/Hex to 99% CH2Cl2, 
1% Et3N) to yield 0.13 g (90%) of the title compound as a clear oil.  
1H NMR (401 MHz, CDCl3) δ 4.67 (td, J = 10.9, 4.4 Hz, 1H), 2.34 – 2.15 (m, 10H), 2.02 – 
1.93 (m, 1H), 1.93 – 1.77 (m, 1H), 1.75 – 1.58 (m, 4H), 1.48 (quint, J = 7.8 Hz, 3H), 1.41 
– 1.26 (m, 3H), 1.15 – 0.93 (m, 2H), 0.93 – 0.79 (m, 7H), 0.75 (d, J = 6.9 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 173.3, 73.9, 59.6, 47.0, 45.5, 40.9, 34.7, 34.3, 31.4, 27.4, 
27.0, 26.2, 23.4, 22.0, 20.8, 16.3.  
HRMS (ESI) m/z calculated for [M+H]+ 298.2741, found 298.2747. 
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(1R,2S,5R)-2-isopropyl-5-methylcyclohexyl 4-((dimethylamino)methyl)benzoate, 
((–)-6):  
Following the procedure used to synthesize (1R,2S,5R)-2-isopropyl-5-
methylcyclohexyl dimethylglycinate, (-)-(1R,2S,5R)-menthol (100 mg, 0.640 mmol), 172 
mg of 4- ((dimethylamino)methyl)benzoic acid (0.960 mmol, 1.50 equiv), 200 mg of 
dicyclohexylcarbodiimide (0.960 mmol, 1.5 equiv) and 118 mg 4-dimethylaminopyridine 
(0.960 mmol, 1.5 equiv) were employed to yield 166 mg (82%) of the desired ester 
derivative as a colorless oil after chromatography over silica gel (gradient from 30% 
EtOAc in hexanes to 100% EtOAc).  
1H NMR (700 MHz, CDCl3) δ 7.99 (d, J = 8.4 Hz, 2H), 7.38 (d, J = 8.4 Hz, 2H), 4.93 (ddd, 
J = 11.2, 11.2, 4.2 Hz, 1H), 3.47 (s, 2H), 2.25 (s, 6H), 2.12 (d, J = 11.9 Hz, 1H), 1.96 
(sept-d, J = 7.0, 2.8 Hz, 1H), 1.75 – 1.70 (m, 2H), 1.61 – 1.53 (m, 2H), 1.14 (td, J = 13.7, 
3.2 Hz, 1H), 1.09 (t, J = 12.0 Hz, 1H), 0.97 – 0.88 (m, 7H), 0.79 (d, J = 7.0 Hz, 3H) 
13C NMR (125 MHz, CDCl3) δ 166.0, 144.1, 129.6, 129.5, 128.8, 74.7, 64.0, 47.2, 45.3, 
41.0, 34.3, 31.4, 26.5, 23.6, 22.0, 20.8, 16.5.  
IR (thin film, cm-1) 2923, 2856, 2767, 1712, 1611, 1454. 
HRMS (ESI) m/z calculated for [M+H]+ 318.2433, found 318.2420. 
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(1R,2S,5R)-2-isopropyl-5-methylcyclohexyl 3-((dimethylamino)methyl)benzoate, 
((–)-7): 
 Following the procedure used to synthesize (1R,2S,5R)-2-isopropyl-5-
methylcyclohexyl dimethylglycinate, (-)-(1R,2S,5R)-menthol (160 mg, 1.02 mmol), 154 
mg of 3- ((dimethylamino)methyl)benzoic acid (1.54 mmol, 1.50 equiv), 320 mg of 
dicyclohexylcarbodiimide (1.54 mmol, 1.50 equiv) and 190 mg 4-dimethylaminopyridine 
(1.54 mmol, 1.50 equiv) to yield 105 mg (33%) of the desired ester derivative as a 
colorless oil after chromatography over silica gel (gradient from 30% EtOAc in hexanes 
to 100% EtOAc).  
1H NMR (400 MHz, CDCl3) δ 7.97 – 7.92 (m, 2H), 7.52 (d, J = 7.5 Hz, 1H), 7.40 (d, J = 
7.5 Hz, 2H), 4.94 (ddd, J = 11.0, 11.0, 4.5 Hz, 1H), 3.49 (d, J = 13.0 Hz, 1H), 3.45 (d, J = 
13.0 Hz, 1H), 2.25 (s, 6H), 2.11 (dtd, J = 11.5, 3.5, 2.0 Hz, 1H), 1.96 (sept-d, J = 7.0, 2.5 
Hz, 1H), 1.73 – 1.69 (m, 2H), 1.63 – 1.52 (m, 2H), 1.18 – 1.06 (m, 2H), 0.92 (t, J = 6.5 
Hz, 6H), 0.79 (d, J = 7.5 Hz, 3H). 
13C NMR (175 MHz, CDCl3) δ 166.0, 139.2, 133.3, 130.8, 130.0, 128.3, 128.2, 74.7, 63.9, 
47.1, 45.2, 40.9, 34.2, 31.4, 26.4, 23.6, 22.0, 20.7, 16.4. 
IR (thin film, cm-1) 2949, 2864, 2815, 2767, 1711, 1455, 1360.  
HRMS (ESI) m/z calculated for [M+H]+ 318.2433, found 318.2440. 
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(1R,2S,5R)-2-isopropyl-5-methylcyclohexyl 2-((dimethylamino)methyl)benzoate, 
((–)-8):  
2-((dimethylamino)methyl)benzoic acid (57 mg, 0.32 mmol) was dissolved in 1 mL 
CH2Cl2. To this mixture was added one drop of N,N-dimethylformamide followed by oxalyl 
chloride (33 µL, 0.38 mmol). The reaction was stirred at rt for 1.5 h before the solvent was 
evaporated and the crude acid chloride was resuspended in 1 mL CH2Cl2. The acyl 
chloride suspension was added dropwise to an ice cooled solution of (–)-(1R,2S,5R)-
menthol (100 mg, 0.64 mmol), DMAP (0.16 mmol, 20 mg) and triethylamine (180 µL, 1.3 
mmol) in 3.4 mL CH2Cl2. The reaction mixture was stirred as it was warmed to rt. After 12 
h, the reaction was quenched by the addition of saturated sodium bicarbonate solution. 
The aqueous phase was washed with EtOAc (3x), dried over sodium sulfate, filtered and 
concentrated. The crude residue was transferred to a separatory funnel by washing the 
flask with 0.1 M HCl and 30% EtOAc in hexanes. The acidified aqueous phase was 
extracted three times with 30% EtOAc in hexanes. Then, the aqueous layer was basified 
with saturated aqueous NaHCO3 solution until it reached a pH of approximately 8-9, 
measured by pH paper. The basic aqueous layer was extracted three times with EtOAc. 
The EtOAc organic layers were combined, dried over anhydrous sodium sulfate, filtered, 
and evaporated to dryness in vacuo. The crude residue was chromatographed over silica 
gel (gradient from 5% EtOAc in hexanes to 100% EtOAc) to yield 44 mg (44%) of the 
desired ester as a colorless oil. 
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1H NMR (500 MHz, CDCl3) δ 7.70 (d, J = 8.0 Hz, 1H), 7.48 (d, J = 7.5 Hz, 1H), 7.42 (t, J 
= 7.5 Hz, 1 H), 7.29 (t, J = 7.5 Hz, 1H), 4.91 (ddd, J = 11.0, 11.0, 4.5 Hz, 1 H), 3.80 (d, J 
= 14.0 Hz, 1H), 3.65 (d, J = 13.5 Hz, 1H), 2.22 (s, 6H), 2.17 (d, J = 11.5 Hz, 1H), 2.02 
(sept-d, J = 7.0, 2.5 Hz, 1H), 1.77 – 1.69 (m, 2H), 1.62 – 1.47 (m, 2H), 1.18 – 1.05 (m, 
2H), 0.98 – 0.86 (m, 7H), 0.82 (d, 6.5 Hz, 3H). 
13C NMR (175 MHz, CDCl3) δ 167.8, 139.9, 132.0, 130.8, 130.0, 129.3, 126.6, 76.8, 74.6, 
61.2, 47.2, 45.2, 40.9, 34.2, 31.4, 26.2, 23.4, 22.1, 20.8, 16.3. 
IR (thin film, cm-1) 2951, 2868, 2815, 2765, 1715, 1454, 1366;  
HRMS (ESI) m/z calculated for [M+H]+ 318.2433, found 318.2436. 
 
(3R,4S,6R)-4-(dimethylamino)-6-methyltetrahydro-2H-pyran-2,3-diyl diacetate, S3  
Following the literature procedure,100 7.0 g (9.5 mmol) of erythromycin was added 
to a round bottom flask followed by 50 mL of EtOH. 125 mL of a 6 N HCl solution was 
added, and the mixture was heated at reflux at 100 °C for 4 h. The reaction mixture was 
transferred to a separatory funnel and extracted with CHCl3 (3 x 50 mL). The organic layer 
was discarded, and the solvent was removed from the red/orange aqueous layer. After 
vacuum drying overnight, crude 4-(dimethylamino)-6- methyltetrahydro-2H-pyran-2,3-diol 
was obtained as a red/orange solid and was carried on to the next step without further 
purification. The crude compound was transferred to a round bottom flask and suspended 
in 50 mL Ac2O. 2 mL of concentrated sulfuric acid was added at 0 °C. The resulting 
mixture was stirred overnight at rt. The reaction mixture was poured into ice water and 
neutralized with solid sodium bicarbonate and extracted with EtOAc. The combined 
organic layers were concentrated and purified by column chromatography (80% EtOAc 
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20% Hexanes to 2% MeOH in EtOAc) to afford 4- (dimethylamino)-6-methyltetrahydro-
2H-pyran-2,3-diyl diacetate (1.5 g, 5.7 mmol, 60 % over 2 steps) as a yellow oil. Spectral 
data of the compound was identical with that previously reported.100 
 
(2R,3R,4S,6R)-4-(dimethylamino)-2-fluoro-6-methyltetrahydro-2H-pyran-3-yl 
acetate, S4  
To a stirring solution of HF pyridine (7.2 mL) in a dry polyethylene vial at 0 °C was 
added 1.2 g (4.4 mmol) of 4-(dimethylamino)-6-methyltetrahydro-2H-pyran-2,3-diyl 
diacetate as a solution in toluene (4.8 mL). The reaction was stirred at 0 °C for 2.5 h. The 
reaction mixture was diluted with 10 mL of a brine solution and quenched with a saturated 
sodium bicarbonate solution. The mixture was extracted with EtOAc and dried over 
Na2SO4, filtered, and concentrated. The crude material was chromatographed (100% 
EtOAc) to yield 0.48 g (2.2 mmol) of the α-anomer of 4-(dimethylamino)-2- fluoro-6-
methyltetrahydro-2H-pyran-3-yl acetate as a clear oil. Spectral data of the compound was 
identical with that previously reported.100 
 
(2S,3R,4S,6R)-4-(dimethylamino)-2-(((1R,2S,5R)-2-isopropyl-5-
methylcyclohexyl)oxy)-6- methyltetrahydro-2H-pyran-3-yl acetate, S5  
A suspension of (–)-menthol (0.038 g, 0.24 mmol), 4-(dimethylamino)-2-fluoro-6-
methyltetrahydro-2Hpyran-3-yl acetate (0.026 g, 0.12 mmol), and molecular sieves (4Å, 
0.15 g) in 2 mL CH2Cl2 was stirred for 30 min at rt under an N2 atmosphere. The 
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suspension was cooled to 0 °C and BF3•OEt2 0.060 mL (0.48 mmol, freshly distilled) was 
added. The reaction was stirred at 0 °C until the starting material was consumed as 
judged by TLC. The reaction was quenched with a solution of saturated sodium 
bicarbonate and extracted with EtOAc. The resulting organic layers were combined, dried 
over Na2SO4, filtered, concentrated, and purified by chromatography (5% MeOH in 
CH2Cl2) to yield 0.028 g (65%) of the title compound as a clear oil.  
1H NMR (401 MHz, CDCl3) δ 4.77 (dd, J = 10.5, 7.6 Hz, 1H), 4.32 (d, J = 7.6 Hz, 1H), 
3.63 – 3.42 (m, 1H), 3.32 (td, 1H), 2.77 (s, 1H), 2.41 – 2.18 (m, 7H), 2.06 (s, 3H), 2.01 – 
1.91 (m, 1H), 1.80 – 1.69 (m, 1H), 1.69 – 1.55 (m, 2H), 1.45 – 1.13 (m, 8H), 1.03 – 0.77 
(m, 9H), 0.74 (d, J = 6.9 Hz, 3H). 
 
(2S,3R,4S,6R)-4-(dimethylamino)-2-(((1R,2S,5R)-2-isopropyl-5-
methylcyclohexyl)oxy)-6- methyltetrahydro-2H-pyran-3-ol, (10):  
To a solution of 2-((1R,2S,5R)-(-)-menthol)-4-(dimethylamino)-6-methyltetrahydro-
2H-pyran-3-yl acetate 0.028 g (0.079 mmol) in 1.60 mL of MeOH was added 0.044 g of 
K2CO3 (0.32 mmol). The reaction was stirred at rt until all starting material was consumed 
as judged by TLC. The reaction was diluted with brine and extracted with EtOAc. The 
organic layers were combined, dried over Na2SO4, concentrated, and purified by 
chromatography (10% MeOH in CH2Cl2) to yield 0.023g (95%) of the title compound.  
1H NMR (401 MHz, CDCl3) δ 4.29 (d, J = 7.3 Hz, 1H), 3.59 – 3.39 (m, 2H), 3.27 (dd, J = 
10.2, 7.3 Hz, 1H), 2.63 (ddd, J = 12.3, 10.2, 4.1 Hz, 1H), 2.35 (s, 7H), 2.14 – 2.00 (m, 
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1H), 1.84 – 1.70 (m, 1H), 1.70 – 1.56 (m, 2H), 1.36 – 1.20 (m, 7H), 1.03 – 0.80 (m, 9H), 
0.76 (d, J = 6.9 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 101.0, 76.6, 69.6, 69.1, 65.3, 47.6, 40.7, 40.3, 34.3, 31.5, 
29.4, 24.9, 22.9, 22.1, 21.0, 20.9, 15.3.  
HRMS (ESI) m/z calculated for [M+H]+ 314.2690, found 314.2696.  
 
Synthesis of (+)-menthol derivatives: The parallel set of (+)-menthol substrates 
were synthesized in an analogous manner to yield products matching the characterization 
data for the (–)-menthol enantiomer. 
 
 
(R)-2-(4-methylcyclohex-3-en-1-yl)propan-2-yl 6-(dimethylamino)hexanoate, S6  
A flame-dried round bottom flask was charged with 0.771 g (5.00 mmol) of (+)-α-
terpineol, 1.545 g (7.50 mmol) of DCC, and 0.122 g (1.00 mmol) of DMAP. The contents 
of the flask were suspended in 25 mL of CH2Cl2 and allowed to stir for 5 minutes before 
1.460 g (7.50 mmol) of 6-bromohexanoic acid. Upon completion, the reaction was filtered 
through a plug of cotton and the solvent removed. The crude material was purified by 
chromatography to yield the ester. A round bottom flask was charged with 0.404 g (1.22 
mmol) of the ester. The contents of the flask were suspended in DMF and cooled to 0 °C. 
0.289 g (6.42 mmol) of dimethylamine solution (40 wt. % in H2O) was then added. Upon 
completion, the reaction was quenched with ethyl acetate and a solution of sat’d sodium 
bicarbonate. The organic layer was extracted twice with a solution of sat’d sodium 
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bicarbonate and once with a solution of brine. The solvent was removed from the organic 
layer and the resulting residue was suspended in 1 M HCl until pH ~2. The aqueous layer 
was extracted three times with diethyl ether and then basified to pH ~8 with a solution of 
sat’d sodium bicarbonate. The aqueous solution was extracted thrice with CH2Cl2, the 
organic layers combined, dried over sodium sulfate, and the solvent removed to yield 
0.292 g (81%) of the desired product. 
1H NMR (400 MHz, CDCl3): δ 5.38-5.32 (m, 1H), 2.29-2.16 (m, 11H), 2.07-1.92 (m, 4H), 
1.85-1.73 (m, 2H), 1.63-1.54 (m, 4H), 1.52-1.45 (m, 2H), 1.42 (s, 3H), 1.40 (s, 3H), 1.35-
1.25 (m, 3H).  
13C NMR (100 MHz, CDCl3): δ 173.0, 133.9, 120.283, 84.6, 59.6, 45.4 (2C), 42.7, 35.6, 
30.9, 27.3, 26.9, 26.3, 25.0, 23.8, 23.3, 23.3, 23.1. 
HRMS (ESI) m/z calculated for [M+H]+ 296.2584, found 296.2582. 
 
(1R,2S,5R)-5-methyl-2-(prop-1-en-2-yl)cyclohexyl-4-
((dimethylamino)methyl)benzoate, S7  
A flame-dried round bottom flask was charged with 0.462 g (3.00 mmol) of (-)-
Isopulegol, 0.927 g (4.50 mmol) of DCC, and 0.073 g (0.60 mmol) of DMAP. The contents 
of the flask were suspended in 15 mL of CH2Cl2 and allowed to stir for 5 minutes before 
0.675 g (4.50 mmol) of 4-formylbenzoic acid. Upon completion, the reaction was filtered 
through a plug of cotton and the solvent removed. The crude material was purified by 
chromatography to yield the ester. A flame-dried round bottom flask was charged with 
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0.772 g (2.70 mmol) of the ester and 0.284 g (3.51 mmol) of dimethylamine hydrochloride. 
The contents of the flask were suspended in CH2Cl2 and cooled to 0 °C. 0.859 g (4.05 
mmol) of sodium triacetoxyborohydride was then added over half an hour. Upon 
completion, the reaction was quenched with ethyl acetate and a solution of sat’d sodium 
bicarbonate. The organic layer was extracted twice with a solution of sat’d sodium 
bicarbonate and once with a solution of brine. The solvent was removed from the organic 
layer and the resulting residue was suspended in 1 M HCl until pH ~2. The aqueous layer 
was extracted three times with diethyl ether and then basified to pH ~8 with a solution of 
sat’d sodium bicarbonate. The aqueous solution was extracted thrice with CH2Cl2, the 
organic layers combined, dried over sodium sulfate, and the solvent removed to yield 
0.587 g (69%) of the desired product.  
1H NMR (400 MHz, CDCl3): δ 7.94 (d, J = 8.0 Hz, 2H), 7.36 (d, J = 8.0 Hz, 2H), 5.01 (td, 
J = 10.9, 4.4 Hz, 1H), 4.78-4.75 (m, 1H), 4.71-4.67 (m, 1H), 3.47 (s, 2H), 2.33-2.20 (m, 
7H), 2.19-2.11 (m, 1H), 1.90-1.55 (m, 6H), 1.53-1.40 (m, 1H), 1.13 (q, J = 11.8 Hz, 1H), 
1.07-0.97 (m, 1H), 0.95 (d, J = 6.5 Hz, 3H).  
13C NMR (100 MHz, CDCl3): δ 165.9, 146.1, 143.7, 129.7, 129.6, 128.8, 111.9, 74.2, 
64.0, 50.9, 45.4 (2C), 40.5, 34.2, 31.4, 30.5, 22.0, 19.5. 
HRMS (ESI) m/z calculated for [M+H]+ 316.2271, found 316.2276. 
 
(R)-1,2,3,4-tetrahydronaphthalen-1-yl 4-((dimethylamino)methyl)benzoate, S8  
A flame-dried round bottom flask was charged with 0.217 g (1.46 mmol) of (R)-
1,2,3,4- tetrahydronaphthalen-1-ol, 0.453 g (2.20 mmol) of DCC, and 0.036 g (0.29 mmol) 
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of DMAP. The contents of the flask were suspended in 10 mL of CH2Cl2 and allowed to 
stir for 5 minutes before 0.330 g (2.20 mmol) of 4-formylbenzoic acid. Upon completion, 
the reaction was filtered through a plug of cotton and the solvent removed. The crude 
material was purified by chromatography to yield the ester. A flame-dried round bottom 
flask was charged with 0.381 g (1.40 mmol) of the ester and 0.143 g (1.78 mmol) of 
dimethylamine hydrochloride. The contents of the flask were suspended in CH2Cl2 and 
cooled to 0 °C. 0.445 g (2.10 mmol) of sodium triacetoxyborohydride was then added 
over half an hour. Upon completion, the reaction was quenched with ethyl acetate and a 
solution of sat’d sodium bicarbonate. The organic layer was extracted twice with a solution 
of sat’d sodium bicarbonate and once with a solution of brine. The solvent was removed 
from the organic layer and the resulting residue was suspended in 1 M HCl until pH ~2. 
The aqueous layer was extracted three times with diethyl ether and then basified to pH 
~8 with a solution of sat’d sodium bicarbonate. The aqueous solution was extracted thrice 
with CH2Cl2, the organic layers combined, dried over sodium sulfate, and the solvent 
removed to yield 0.333 g (77%) of the desired product.  
1H NMR (400 MHz, CDCl3) δ 7.99 (d, J = 8.2 Hz, 2H), 7.40 – 7.31 (m, 3H), 7.29 – 7.20 
(m, 1H), 7.16 (m, 2H), 6.23 (t, J = 4.5 Hz, 1H), 3.45 (s, 2H), 2.96 – 2.86 (m, 1H), 2.85 – 
2.74 (m, 1H), 2.22 (s, 6H), 2.15 – 1.98 (m, 3H), 1.87 (m, 1H);  
13C NMR (100 MHz, CDCl3) δ 166.2, 144.1, 138.0, 134.7, 129.7, 129.5, 129.5, 129.0, 
128.8, 128.0, 126.0, 70.5, 64.0, 45.4, 29.2, 29.0, 19.1.  
HRMS (ESI) m/z calculated for [M+H]+ 310.1802, found 310.1808. 
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(S)-2,3-dihydro-1H-inden-1-yl 4-((dimethylamino)methyl)benzoate, S9  
A flame-dried round bottom flask was charged with 0.200 g (1.50 mmol) of (S)-2,3-
dihydro-1H-inden- 1-ol, 0.464 g (2.25 mmol) of DCC, and 0.027 g (0.225 mmol) of DMAP. 
The contents of the flask were suspended in 16 mL of CH2Cl2 and allowed to stir for 5 
minutes before 0.338 g (2.25 mmol) of 4-formylbenzoic acid. Upon completion, the 
reaction was filtered through a plug of cotton and the solvent removed. The crude material 
was purified by chromatography (Hexanes to 20% ethyl acetate in hexanes) to yield 0.323 
g (81%) of the desired product.  
1H NMR (700 MHz, CDCl3) δ 10.09 (s, 1H), 8.19 (d, J = 8.4 Hz, 2H), 7.93 (d, J = 8.4 Hz, 
2H), 7.50 (d, J = 7.5 Hz, 1H), 7.36 – 7.31 (m, 2H), 7.29 – 7.23 (m, 1H), 6.48 (dd, J = 7.1, 
3.8 Hz, 1H), 3.21 (ddd, J = 15.3, 8.4, 6.2 Hz, 1H), 2.97 (ddd, J = 16.0, 8.6, 4.9 Hz, 1H), 
2.69 – 2.61 (m, 1H), 2.31 – 2.23 (m, 1H).  
13C NMR (176 MHz, CDCl3) δ 191.6, 165.5, 144.5, 140.7, 139.1, 135.5, 130.3, 129.4, 
129.2, 126.8, 125.7, 124.9, 79.7, 32.4, 30.3;  
IR (thin film, cm-1) 2933, 2841, 1709, 1264.  
A flame-dried round bottom flask was charged with 0.283 g (1.06 mmol) of (S)-2,3-
dihydro-1H-inden- 1-yl 4-formylbenzoate and 0.112 g (1.38 mmol) of dimethylamine 
hydrochloride. The contents of the flask were suspended in DCM and cooled to 0 °C. 
0.337 g (1.59 mmol) of sodium triacetoxyborohydride was then added over half an hour. 
Upon completion, the reaction was quenched with ethyl acetate and a solution of sat’d 
sodium bicarbonate. The organic layer was extracted twice with a solution of sat’d sodium 
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bicarbonate and once with a solution of brine. The solvent was removed from the organic 
layer and the resulting residue was suspended in 1 M HCl until pH ~2. The aqueous layer 
was extracted three times with diethyl ether and then basified to pH ~8 with a solution of 
sat’d sodium bicarbonate. The aqueous solution was extracted thrice with CH2Cl2, the 
organic layers combined, dried over sodium sulfate, and the solvent removed to yield 
0.232 g (74%) of the desired product.  
1H NMR (500 MHz, CDCl3) δ 8.03 – 7.96 (m, 2H), 7.49 (d, J = 7.5 Hz, 1H), 7.36 (d, J = 
8.0 Hz, 2H), 7.33 – 7.30 (m, 2H), 7.28 – 7.21 (m, 1H), 6.45 (dd, J = 7.1, 4.1 Hz, 1H), 3.46 
(s, 2H), 3.18 (ddd, J = 15.9, 8.5, 5.9 Hz, 1H), 2.95 (ddd, J = 16.0, 8.6, 5.2 Hz, 1H), 2.68 
– 2.59 (m, 1H), 2.28 – 2.19 (m, 7H);  
13C NMR (176 MHz, CDCl3) δ 166.5, 144.4, 144.3, 141.2, 129.7, 129.3, 128.9, 128.8, 
126.7, 125.7, 124.8, 78.8, 64.0, 45.4, 32.5, 30.3. 
IR (thin film, cm-1) 2941, 2878, 2816, 2767, 1711, 1456, 1264.  
HRMS (ESI) m/z calculated for [M+H]+ 296.1645, found 296.1646. 
 
(1R,2R,4S)-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl-4-
((dimethylamino)methyl)benzoate, S10  
A flame-dried round bottom flask was charged with 1.000 g (6.50 mmol) of (+)-
fenchol, 2.060 g (10.0 mmol) of DCC, and 0.159 g (1.30 mmol) of DMAP. The contents 
of the flask were suspended in 30 mL of CH2Cl2 and allowed to stir for 5 minutes before 
1.500 g (10.00 mmol) of 4-formylbenzoic acid. Upon completion, the reaction was filtered 
through a plug of cotton and the solvent removed. The crude material was purified by 
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chromatography to yield the ester. A flame-dried round bottom flask was charged with 
0.530 g (1.85 mmol) of the ester and 0.195 g (2.41 mmol) of dimethylamine hydrochloride. 
The contents of the flask were suspended in CH2Cl2 and cooled to 0 °C. 0.588 g (2.78 
mmol) of sodium triacetoxyborohydride was then added over half an hour. Upon 
completion, the reaction was quenched with ethyl acetate and a solution of sat’d sodium 
bicarbonate. The organic layer was extracted twice with a solution of sat’d sodium 
bicarbonate and once with a solution of brine. The solvent was removed from the organic 
layer and the resulting residue was suspended in 1 M HCl until pH ~2. The aqueous layer 
was extracted three times with diethyl ether and then basified to pH ~8 with a solution of 
sat’d sodium bicarbonate. The aqueous solution was extracted thrice with CH2Cl2, the 
organic layers combined, dried over sodium sulfate, and the solvent removed to yield 
0.414 g (71%) of the desired product.  
1H NMR (400 MHz, CDCl3) δ 8.01 (d, J = 8.1 Hz, 2H), 7.40 (d, J = 8.1 Hz, 2H), 4.62 (s, 
1H), 3.48 (s, 2H), 2.26 (s, 6H), 1.99 – 1.88 (m, 1H), 1.77 (d, J = 9.0 Hz, 2H), 1.67 (d, J = 
11.7 Hz, 1H), 1.49 (s, 1H), 1.27 (s, 2H), 1.18 (s, 3H), 1.11 (s, 3H), 0.84 (s, 3H).  
13C NMR (126 MHz, CDCl3) δ 166.8, 129.5, 128.9, 86.6, 64.0, 48.6, 48.4, 45.4, 41.5, 39.8, 
29.8, 26.9, 25.9, 20.3, 19.5.  
HRMS (ESI) m/z calculated for [M+H]+ 316.2271, found 316.2268. 
 
5.2.2: Product Characterization 
General protocol for anchoring group cleavage  
A flame-dried round bottom flask was charged with lithium aluminium hydride (5.0 
eq). Under N2, the contents of the flask were suspended in 2 mL of THF and cooled to 0 
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°C. The solution of product from P450 oxidation in THF (1 mL) was then added dropwise 
via cannula. The reaction mixture was warmed to room temperature and stirred overnight, 
at which point H2O (0.1 mL), 15% NaOH in H2O (0.1 mL) and H2O (0.2 mL) were added 
sequentially to quench the reaction. The mixture was diluted with EtOAc (10 mL), filtered 
to remove aluminum salts and the filtrate was concentrated. The residue obtained was 
purified by column chromatography to yield the product. 
 
(1R,2S,4S,5S)-2-isopropyl-5-methylcyclohexane-1,4-diol (9)125: 
1H NMR (400 MHz, CDCl3): δ 3.47 (td, J = 10.5, 4.4 Hz, 1H), 3.19 (ddd, J = 10.9, 9.7, 4.3 
Hz, 1H), 2.19-2.10 (m, 1H), 1.96 (dt, J = 12.7, 4.1 Hz, 1H), 1.85 (ddd, J = 12.6, 4.3, 3.4 
Hz, 1H), 1.47-1.23 (m, 4H), 1.17-1.04 (m, 2H), 1.03 (d, J = 6.5 Hz, 3H), 0.94 (d, J = 7.0 
Hz, 3H), 0.83 (d, J = 6.9 Hz, 3H).  
13C NMR (176 MHz, CDCl3): δ 76.0, 70.7, 48.5, 42.5, 38.3, 32.3, 25.8, 21.0, 18.2, 15.9; 
IR (neat, cm-1): 3230.0, 2926.2, 1456.0, 1095.8, 1026.9. 
 
(R)-2-(4-(hydroxymethyl)cyclohex-3-en-1-yl)propan-2-ol, S11  
1H NMR (400 MHz, CDCl3): δ 5.72-5.66 (m, 1H), 4.01 (t, J = 2.6 Hz, 2H), 2.22-2.01 (m, 
3H), 2.00-1.93 (m, 1H), 1.92-1.80 (m, 1H), 1.60-1.50 (m, 1H), 1.35 – 1.25 (m, 3H), 1.20 
(s, 3H), 1.19 (s, 3H).  
13C NMR (100 MHz, CDCl3): δ 137.5, 122.4, 72.7, 67.1, 45.1, 27.4, 26.6, 26.5, 26.4, 23.6.  
HRMS (ESI) m/z calculated for [M+H]+ 171.1380, found 188.1645. 
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(1S,2S,4R,5S)-2-methyl-5-(prop-1-en-2-yl)cyclohexane-1,4-diol, S12  
1H NMR (400 MHz, CDCl3): δ 4.94-4.90 (m, 1H), 4.87-4.84 (m, 1H), 3.52 (td, J = 10.5, 
4.3 Hz, 1H), 3.31-3.21 (m, 1H), 2.13-2.00 (m, 2H), 1.92 (dt, J = 12.7, 3.9 Hz, 1H), 1.86-
1.80 (m, 1H), 1.74-1.69 (m, 3H), 1.54-1.37 (m, 3H), 1.19-1.09 (m, 1H), 1.06 (d, J = 6.5 
Hz, 3H). 
13C NMR (100 MHz, CDCl3): δ 145.2, 113.6, 75.3, 69.6, 52.5, 40.3, 38.2, 38.0, 19.0, 18.2. 
HRMS (ESI) m/z calculated for [M+H]+ 171.1380, found 188.1654. 
 
(1R,4R)-4-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl-4-
((dimethylamino)methyl)benzoate, (13):  
1H NMR (400 MHz, CDCl3) δ 7.98 (d, J = 8.2 Hz, 2H), 7.50 (d, J = 7.4 Hz, 1H), 7.41 – 
7.33 (m, 4H), 7.30 (t, J = 7.4 Hz, 1H), 6.26 (t, J = 4.8 Hz, 1H), 4.92 (t, J = 4.7 Hz, 1H), 
3.46 (s, 2H), 2.51 – 2.41 (m, 1H), 2.41 – 2.31 (m, 1H), 2.23 (s, 6H), 2.09 – 1.99 (m, 1H), 
1.99 – 1.92 (m, 1H).  
13C NMR (100 MHz, CDCl3) δ 166.1, 144.3, 139.4, 134.4, 129.7, 129.4, 129.2, 128.9, 
128.8, 128.6, 128.3, 70.0, 67.5, 64.0, 45.4, 28.4, 25.0;  
IR (thin film, cm-1) 3398, 2940, 2776, 1708, 1453, 1263. 
HRMS (ESI) m/z calculated for [M+H]+ 326.1751, found 326.1753. 
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(1S,3S)-3-hydroxy-2,3-dihydro-1H-inden-1-yl 4-((dimethylamino)methyl)benzoate, 
(14):  
1H NMR (500 MHz, CDCl3) δ 7.97 (d, J = 8.1 Hz, 2H), 7.53 (d, J = 7.5 Hz, 1H), 7.50 (d, J 
= 7.5 Hz, 1H), 7.43 (t, J = 7.4 Hz, 1H), 7.37 (m, 3H), 6.56 (dd, J = 6.7, 2.9 Hz, 1H), 5.56 
(t, J = 5.7 Hz, 1H), 3.48 (s, 2H), 2.74 – 2.64 (m, 1H), 2.53 – 2.42 (m, 1H), 2.25 (s, 6H); 
13C NMR (126 MHz, CDCl3) δ 166.4, 145.9, 140.6, 129.8, 129.0, 128.9, 126.2, 124.4, 
76.7, 74.4, 63.9, 45.3, 43.5.  
IR (thin film, cm-1) 3388, 2932, 1712, 1611, 1459, 1268, 1175. 
HRMS (ESI) m/z calculated for [M+H]+ 312.1594, found 312.1598. 
 
(1S,2R,4S,5R)-1,3,3-trimethylbicyclo[2.2.1]heptane-2,5-diol, S13  
1H NMR (500 MHz, CDCl3) δ 4.17 – 4.13 (m, 1H), 3.23 (d, J = 1.6 Hz, 1H), 2.18 (ddd, J 
= 13.8, 6.7, 2.5 Hz, 1H), 1.70 (s, 1H), 1.56 (dd, J = 10.6, 1.6 Hz, 1H), 1.37 (d, J = 10.6 
Hz, 1H), 1.20 (d, J = 6.2 Hz, 1H), 1.12 (s, 3H), 1.03 (s, 3H), 0.84 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 83.5, 71.5, 55.6, 48.5, 38.8, 38.1, 36.5, 30.6, 19.5, 18.9; 
IR (thin film, cm-1) 3341, 2944, 1277, 1071. 
 LRMS (EI) m/z calculated for [M] 170.1, found 170.0. 
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5.3 Chapter 3 Experimental 
5.3.1 Macrocycle Synthesis 
 
Methyl (R)-3-((tert-butyldiphenylsilyl)oxy)-2-methylpropanoate (26): 
To an oven-dried flask equipped with stir bar was added 5.055 g (42.79 mmol) of methyl 
(R)-3-hydroxy-2-methylpropanoate, 120 mL of DMF, and 12.938 g (47.071 mmol) of 
TBDPSCl sequentially.  The contents were stirred for ~5 min before the addition of 7.283 
g (106.98 mmol) of imidazole.  The reaction was stirred overnight.  The following day, the 
reaction was quenched by transferring to a separatory funnel with H2O and hexanes.  The 
organic layer was washed four times with H2O and once with brine.  The organic layer 
was dried over MgSO4, filtered, and concentrated. The spectra matched that of previous 
reports and the crude material was carried on without further purification.126   
 
Methyl (R)-3-((tert-butyldiphenylsilyl)oxy)-2-methylpropanoate (27): 
An oven-dried flask equipped with stir bar was charged with 12.0 g  (33.66 mmol) of 26 
and 166 mL of hexanes.  The contents were cooled to -78 °C and 50.490 mL of a 1M 
solution of DIBAL-H in hexanes was added by syringe drive over 30 min.  Upon complete 
addition the reaction was stirred for an additional 45 min.  The reaction was quenched 
with the addition of 25 mL of MeOH at -78 °C and allowed to stir for 10 min.  The reaction 
was transferred cold to a flask containing stirring sat’d aqueous Rochelle’s salt and Et2O.  
The solution was stirred vigorously until a biphasic mixture formed (~1 hour).   Once 
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complete, the contents were transferred to a separatory funnel and the aqueous layer 
was extracted three times with Et2O.  The organic layers were combined, dried over 
MgSO4, filtered, and concentrated to yield the title compound, which matched previously 
reported spectra and was carried on directly to the next reaction.126   
 
Ethyl (S,4E)-7-((tert-butyldiphenylsilyl)oxy)-6-methylhepta-2,4-dienoate (28): 
To a solution of 13.50 mL (103 mmol) of diisopropylamine in THF (173 mL) cooled to -78 
°C under a nitrogen atmosphere was added 27.46 mL (68.66 mmol) of n-BuLi dropwise.  
The solution was warmed to rt and stir for 20 min before being cooled to -78 °C.  20.15 
mL (85.50 mmol) of ethyl 4-(diethoxyphosphoryl)but-2-enoate was then added dropwise 
and the solution allowed to warm to 0 °C and stir for 20 min before being cooled to -78 
°C.  33.66 mmol of (R)-3-((tert-butyldiphenylsilyl)oxy)-2-methylpropanal (27) was then 
added dropwise as a solution in 30 mL of THF.  The reaction was stirred at -78 °C for 15 
min before warming to -15 °C and stirring for 2 hours.  The reaction was quenched by the 
addition of sat’d aqueous NH4Cl and transferred to a separatory funnel.  The aqueous 
phase was extracted 3x with EtOAc/hexanes (1:1), and the organic layers were 
combined, dried over Na2SO4, filtered, and concentrated.  The resulting residue was 
purified by column chromatography (6% EtOAc/hexanes) to yield the desired diene as a 
mixture of E/Z isomers, which was carried on directly to the hydrogenation.   
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Ethyl (S)-7-((tert-butyldiphenylsilyl)oxy)-6-methylheptanoate (29): 
28 was transferred with 4:1 MeOH/EtOAc to a flask containing a suspension of 1.682 
mmol of 10% w/w Pd/C in 4:1 MeOH/EtOAc.  The contents were shaken overnight in a 
Parr reactor at 40 psi.  Upon completion, the reaction was quenched by removing the 
solvent until ~10 mL of solvent remained, and the resulting suspension was filtered 
through a plug of silica gel with ethyl acetate.  The solvent was removed to yield 11.014 
g (77% over four steps) of the title compound the spectra of which matched previous 
reports13.   
 
(S)-7-((tert-Butyldiphenylsilyl)oxy)-6-methylheptanoic acid (30): 
A flask equipped with stir bar was charged with 11.014 g (25.813 mmol) of 29, 153 mL of 
MeOH, and 100 mL of THF.  The contents were cooled to 0 °C and 51.6 mL of 2M 
aqueous NaOH was added dropwise.  Upon complete addition, the reaction stirred for 1h 
at 0 °C before warming to rt and stirring for an additional 1h.  Additional aqueous 2M 
NaOH was added if starting material remained and stirring was continued.  Upon 
complete consumption 29 as judged by TLC, the reaction was quenched with an aqueous 
potassium bisulfate solution until pH ~1-2.  The aqueous layer was extracted three times 
with EtOAc, the organic layers combined, dried over MgSO4, filtered, and concentrated 
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to yield the desired compound, which was carried on to the next step without further 
purification.115   
 
But-3-yn-1-yl (S)-7-((tert-butyldiphenylsilyl)oxy)-6-methylheptanoate (31): 
An oven-dried flask equipped with stir bar was charged with 25.813 mmol of the crude 
30, 7.237 g (103.25 mmol) of but-3-yn-1-ol, and 210 mL of CH2Cl2.  After stirring for 5min, 
7.456 g (36.138 mmol) of DCC and 3.154 g (25.813 mmol) of DMAP were added 
sequentially.  The reaction was stirred overnight before being quenched by dilution with 
hexanes, filtration, and removal of the solvent.  The remaining residue was purified by 
chromatography (5% EtOAc/hexanes) to give 10.541 g (91% over two steps) of the title 
compound, whose spectra matched previous reports.115   
 
But-3-yn-1-yl (S)-7-hydroxy-6-methylheptanoate (32): 
An oven-dried flask equipped with stir bar was charged with 10.541 g (23.389 mmol) of 
31 and 54 mL of THF.  The contents were cooled to 0 °C whereupon 52.86 mL of a 1M 
solution of n-Bu4NF was added dropwise.  The reaction was stirred for 1h at 0 °C before 
warming to rt.  Upon consumption 31 as judged by TLC, the reaction was quenched with 
a sat’d solution of NH4Cl and transferred to a separatory funnel.  The aqueous layer was 
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extracted three times with Et2O, the organic layers were combined, dried over MgSO4, 
filtered, and concentrated.  Purification of the crude material by chromatography (30% 
EtOAc/hexanes) afforded 4.419 g (89%) of the title compound as a clear oil whose spectra 
matched that of previous reports13.115   
 
But-3-yn-1-yl (S)-6-methyl-7-oxoheptanoate (33): 
To an oven dried vial equipped with stir bar was added 0.071g (0.333 mmol) of S7, 3.40 
mL of CH2Cl2, and 0.145 mL (1.782 mmol) of pyridine.  The contents were cooled to 0 °C 
and 0.378 g (0.891 mmol) of Dess-Martin periodinane was added in a single portion.  After 
stirring at 0 °C for 10 min, the reaction was warmed to rt and stirred for 1 h.  A 1:1 solution 
of sat’d aqueous sodium bicarbonate and sat’d aqueous sodium thiosulfate was added 
and the mixture stirred for 30 min.  The aqueous layer was extracted three times with 
Et2O, the organic layers were combined, dried over MgSO4, filtered and concentrated.  
Purification by chromatography (15% EtOAc/hexanes) afforded 0.057 g (90%) of the title 
compound as a clear oil whose spectra matched previous reports.115   
 
But-3-yn-1-yl (R)-6-methyl-7-oxoheptanoate (R-33) was prepared in the same manner 
with matching 1H spectra starting from methyl (S)-3-hydroxy-2-methylpropanoate.   
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(7S,8S)-7-Methyl-9-methylene-8-((triisopropylsilyl)oxy)oxacycloundecan-2-one 
(34A): 
In a glovebox, an oven-dried flask equipped with stir bar was charged with 0.019 g (0.069 
mmol) of Ni(COD)2 and 0.029 g (0.063 mmol) of IPrCl.  The flask was capped with a 
septum, removed from the glovebox, and attached to a nitrogen line.  The contents of the 
flask were suspended in toluene (6.3 mL) and allowed to stir for 20 min.  The contents 
were diluted with an additional 31.4 mL of toluene and heated to 60 °C in an oil bath for 
20 min.  Triisopropylsilane (0.214 mL, 1.05 mmol) was then added in a single portion.  
Ynal 33 (0.044 g, 0.209 mmol) was then added by syringe drive over 1 hour as a 4.15 mL 
solution in toluene.  The reaction was stirred overnight at 60 °C.  The reaction was cooled 
to rt and the volatiles removed under vacuum.  The crude residue was filtered through a 
plug of silica with EtOAc/Hexanes (1:1) and then purified by column chromatography (2% 
EtOAc/Hexanes) to yield 0.044 g (60%) of the title compound as a colorless oil.115   
 
(7S,8S)-8-Hydroxy-7-methyl-9-methyleneoxacycloundecan-2-one (34B):  
An oven-dried flask equipped with stir bar was charged with 0.047 g (0.127 mmol) of 
(7S,8S)-7-methyl-9-methylene-8-((triisopropylsilyl)oxy)oxacycloundecan-2-one and THF 
(5.11 mL).  The contents of the flask were cooled to 0 °C and 0.015 mL (0.225 mmol) of 
acetic acid and 1.53 mL of a 1M solution of TBAF were added sequentially.  The reaction 
was warmed to rt and stir until all the starting material was consumed as judged by TLC.  
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Upon completion, the reaction was quenched with sat’d aqueous NH4Cl and transferred 
to a separatory funnel.  The aqueous layer was extracted three times with Et2O, and the 
organic layers were combined, dried over MgSO4, filtered, and concentrated.  The crude 
residue was purified by column chromatography (30% EtOAc/Hexanes) to yield the 
desired product as a white solid.   
1H NMR (700 MHz, CDCl3) δ 5.29 – 5.26 (m, 1H), 5.20 (s, 1H), 4.91 (ddd, J = 13.3, 10.9, 
2.5 Hz, 1H), 3.99 (s, 1H), 3.95 (ddd, J = 10.9, 4.1, 2.4 Hz, 1H), 2.49 (ddd, J = 16.0, 7.6, 
1.8 Hz, 1H), 2.40 – 2.34 (m, 1H), 2.17 (dddd, J = 15.2, 13.0, 4.1, 2.0 Hz, 1H), 2.10 (ddd, 
J = 16.0, 11.9, 1.8 Hz, 1H), 2.07 – 2.00 (m, 1H), 1.91 – 1.83 (m, 1H), 1.67 – 1.59 (m, 1H), 
1.59 – 1.53 (m, 1H), 1.48 (d, J = 4.6 Hz, 1H), 1.46 – 1.40 (m, 1H), 1.39 – 1.33 (m, 1H), 
1.05 (d, J = 6.9 Hz, 3H), 1.03 – 0.98 (m, 1H). 
13C NMR (176 MHz, CDCl3) δ 173.79, 148.01, 110.98, 79.70, 64.12, 35.24, 30.87, 29.18, 
25.79, 23.41, 20.12, 16.92. 
HRMS (ESI) m/z calculated for [M+H]+ 213.1485, found 213.1475.   
 
(7S,8S,E)-7-Methyl-8-((triethylsilyl)oxy)oxacyclododec-9-en-2-one (35A):   
In a glovebox, an oven-dried flask equipped with stir bar was charged with 0.019 g (0.069 
mmol) of Ni(COD)2, 0.023 g (0.069 mmol) of IMes•HCl, and 0.008 g (0.069 mmol) of 
potassium tert-butoxide.  The flask was sealed with a septum, removed from the 
glovebox, and attached to a nitrogen line.  The contents of the flask were suspended in 
THF (16.60 mL) and stirred for 20 min at rt.  Triethylsilane (0.073 mL, 0.456 mmol) was 
then added in a single portion.  Ynal 33 (0.048 g, 0.228 mmol) was suspended in 16.6 
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mL of THF and added to the reaction by syringe drive over 3 h and was stirred overnight.  
The volatiles were removed under vacuum, the crude residue was filtered through a plug 
of silica with EtOAc/Hexanes (1:1), and the volatiles were removed under vacuum.  The 
resulting residue was purified by column chromatography (4% EtOAc/Hexanes) to yield 
0.051 g (69%) of the desired product as a clear oil.   
1H NMR (500 MHz, CDCl3) δ 5.53 (dd, J = 20.0, 14.0 Hz, 1H), 5.39 (dt, J = 14.8, 7.1 Hz, 
1H), 4.71 (dt, J = 11.0, 7.3 Hz, 1H), 4.13 (dd, J = 8.1, 4.7 Hz, 1H), 3.91 (dt, J = 11.0, 4.3 
Hz, 1H), 2.42 – 2.36 (m, 2H), 2.33 – 2.28 (m, 2H), 1.92 – 1.83 (m, 1H), 1.75 – 1.66 (m, 
1H), 1.49 – 1.38 (m, 1H), 1.35 – 1.27 (m, 3H), 0.97 – 0.88 (m, 13H), 0.60 – 0.52 (m, 6H). 
13C NMR (176 MHz, CDCl3) δ 173.78, 133.70, 127.67, 74.99, 61.10, 37.57, 33.21, 32.41, 
30.94, 24.25, 23.40, 16.08, 6.88, 4.98. 
HRMS (ESI) m/z calculated for [M+NH4]+ 344.2615, found 344.2609.   
 
(7S,8S,E)-8-Hydroxy-7-methyloxacyclododec-9-en-2-one (35B):  
To an oven-dried flask equipped with stir bar was added 0.051 g (0.156 mmol) of 
(7S,8S,E)-7-methyl-8-((triethylsilyl)oxy)oxacyclododec-9-en-2-one and THF (6.30 mL).  
The contents of the flask were cooled to 0 °C and 0.018 mL (0.312 mmol) of acetic acid 
and 1.87 mL of a 1M solution of n-Bu4NF were added sequentially.  The reaction was 
warmed to rt and stir until all the starting material was consumed as judged by TLC.  The 
reaction was quenched by the addition of sat’d aqueous NH4Cl.  The contents of the flask 
were transferred to a separatory funnel, the aqueous phase was extracted three times 
with Et2O, and the organic layers were combined, dried over MgSO4, filtered, and 
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concentrated.  The crude residue was purified by column chromatography (30% 
EtOAc/Hexanes) to yield 0.031 g (94%) of the desired product as a white solid.    
1H NMR (500 MHz, CDCl3) δ 5.58 (dd, J = 15.3, 7.2 Hz, 1H), 5.55 – 5.47 (m, 1H), 4.63 
(ddd, J = 11.0, 7.9, 5.5 Hz, 1H), 4.18 (dd, J = 7.2, 4.3 Hz, 1H), 3.98 (dt, J = 11.0, 4.7 Hz, 
1H), 2.43 – 2.38 (m, 2H), 2.33 – 2.29 (m, 2H), 1.89 – 1.77 (m, 2H), 1.51 – 1.41 (m, 1H), 
1.38 – 1.24 (m, 3H), 1.20 – 1.09 (m, 1H), 0.99 (d, J = 6.9 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 173.65, 133.51, 128.18, 74.70, 61.14, 36.33, 33.14, 32.60, 
30.79, 24.19, 23.66, 16.08. 
HRMS (ESI) m/z calculated for [M+Na]+ 235.1305, found 235.1301.   
 
(6S,7S,E)-7-Methyl-12-oxooxacyclododec-4-en-6-yl (R)-3,3,3-trifluoro-2-methoxy-2-
phenylpropanoate ((R)-MTPA-35B): 
An oven-dried vial equipped with stir bar was charged with 0.005 g (0.024 mmol) of 35B, 
0.017 g (0.071 mmol) of (R)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoic acid, 0.015 g 
(0.071 mmol) of DCC, 0.003 g (0.024 mmol) of DMAP and 0.50 mL of CH2Cl2 sequentially.  
Upon consumption of the starting material as judged by TLC, the reaction was filtered 
through a plug of cotton and the solvent removed.  Purification by column chromatography 
(10% EtOAc/hex) of the resulting residue afforded 0.010 g (97%) of the desired product 
as a clear oil.   
1H NMR (500 MHz, CDCl3) δ 7.54 – 7.46 (m, 2H), 7.44 – 7.35 (m, 3H), 5.61 (ddd, J = 
14.6, 9.3, 5.1 Hz, 1H), 5.52 (dd, J = 8.5, 4.5 Hz, 1H), 5.46 (ddd, J = 15.1, 8.3, 1.3 Hz, 1H), 
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4.70 (td, J = 10.7, 4.0 Hz, 1H), 3.89 (dt, J = 11.0, 4.2 Hz, 1H), 3.52 (d, J = 1.3 Hz, 3H), 
2.47 – 2.24 (m, 4H), 2.03 – 1.94 (m, 1H), 1.94 – 1.83 (m, 1H), 1.46 (dtt, J = 12.6, 8.0, 4.3 
Hz, 1H), 1.42 – 1.28 (m, 3H), 1.24 – 1.12 (m, 1H), 0.96 (d, J = 6.9 Hz, 3H). 
 
(6S,7S,E)-7-Methyl-12-oxooxacyclododec-4-en-6-yl (S)-3,3,3-trifluoro-2-methoxy-2-
phenylpropanoate ((S)-MTPA-35B): 
Following the same procedure used to synthesize (6S,7S,E)-7-methyl-12-
oxooxacyclododec-4-en-6-yl (R)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoate, 0.005 g 
(0.024 mmol) of 35B, 0.017 g (0.071 mmol) of (S)-3,3,3-trifluoro-2-methoxy-2-
phenylpropanoic acid, 0.015 g (0.071 mmol) of DCC, and 0.003 g (0.024 mmol) of DMAP 
were employed to give 0.010 g of the title compound.   
1H NMR (500 MHz, CDCl3) δ 7.56 – 7.46 (m, 2H), 7.45 – 7.34 (m, 3H), 5.73 – 5.61 (m, 
1H), 5.61 – 5.49 (m, 2H), 4.74 (ddd, J = 10.9, 9.0, 5.5 Hz, 1H), 3.89 (dt, J = 11.0, 4.1 Hz, 
1H), 3.54 (s, 3H), 2.48 – 2.38 (m, 2H), 2.38 – 2.25 (m, 2H), 2.01 – 1.83 (m, 2H), 1.46 
(ddq, J = 13.6, 8.8, 4.5 Hz, 1H), 1.35 (tq, J = 10.4, 4.9 Hz, 3H), 1.16 (td, J = 11.9, 11.4, 
4.5 Hz, 1H), 0.85 (d, J = 6.9 Hz, 3H). 
See Figure 5.1 for the stereochemical determination of the secondary allylic alcohol via 
1H NMR.   
The products of the nickel-catalyzed macrocyclization of but-3-yn-1-yl (R)-6-methyl-7-
oxoheptanoate (R-33) and subsequent deprotection yielded (R,R)-34A and (R,R)-34B 
macrocycles whose spectra matched those of (34A) and (34B).   
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5.3.2: Triazole Anchor Assembly 
 
4-Azidobenzoic acid 
A flask equipped with stir bar was charged with 5.0 g (36.46 mmol) of 4-aminobenzoic 
acid and suspended in 150 mL of 5% aqueous HCl.  The flask was placed in the dark and 
cooled to 0 °C followed by the addition of 2.64 g (38.28 mmol) of NaNO2 as a solution in 
10 mL of H2O over 10 min.  The reaction was stirred for 20 min before the addition of 2.61 
g (40.10 mmol) of NaN3 as a solution in 10 mL of H2O over 30 min.  Stirring was continued 
for an additional 15 min before the reaction was quenched with the addition of 200 mL of 
Et2O.  The contents were transferred to a separatory funnel and the organic layer was 
extracted four times with H2O and once with brine.  The organic layer was dried over 
MgSO4, filtered, and concentrated to yield 4.358 g (73%) of the title compound as a yellow 
powder that was used without further purification.  1H spectra matched that of previously 
reported compound.127   
 
3-Azidobenzoic acid 
The title compound was prepared in a method analogous to 4-azidobenzoic acid 
employing 5.0 g (36.46 mmol) of 3-aminobenzoic acid, 2.64 g (38.28 mmol) of NaNO2, 
and 2.61 g (40.10 mmol) of NaN3 to give 4.50 g (76%) of the desired compound as a 
yellow solid.  1H spectra matched that of previously reported compounds.128   
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2-Azidobenzoic acid 
The title compound was prepared in a method analogous to 4-azidobenzoic acid 
employing 5.0 g (36.46 mmol) of 2-aminobenzoic acid, 2.64 g (38.28 mmol) of NaNO2, 
and 2.61 g (40.10 mmol) of NaN3 to give 1.40 g (24%) of the desired compound as a 
yellow solid.  1H spectra matched that of previously reported compounds.128   
 
4-Azido-3,5-difluorobenzoic acid 
The title compound was synthesized from commercially available 4-amino-3,5-
difluorobenzonitrile according to previously reported procedures.129,130  
 
(R)-2-Azidopropanoic acid 
The title compound was prepared according to literature precedent from D-Alanine.  (S)-
2-Azidopropanoic acid was prepared in an analogous method starting from L-Alanine.131   
 
General Procedure for the attachment of PikC anchoring groups 
Esterification: An oven-dried flask equipped with stir bar was charged with macrocycle, 
DCC, DMAP and CH2Cl2.  The contents were stirred for 5 min before the addition of azido-
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acid in a single portion.   The contents were stirred until all starting material was consumed 
as judged by TLC.  The reaction was filtered through a plug of cotton and the solvent 
removed under vacuum.  The crude material was purified by column chromatography and 
carried on directly to either copper-catalyzed (CuAAC) or ruthenium-catalyzed (RuAAC) 
azide-alkyne cycloaddition reactions.   
 
CuAAC: A flask equipped with stir bar was charged with azido-ester, H2O/t-BuOH (1:1), 
and alkyne.  The solution was stirred for 5 min before sequential addition of 10 mol % 
sodium ascorbate in 0.050 mL of H2O and 1 mol% CuSO4•5H2O in 0.050 mL of H2O.  The 
reaction was stirred until the starting material was consumed as judged by TLC.  Upon 
completion, the reaction was diluted with EtOAc and transferred to a separatory funnel 
containing sat’d aqueous sodium bicarbonate.  The aqueous layer was extracted 3x with 
EtOAc, the organic layers combined, dried over NaSO4, filtered, and concentrated.  The 
crude residue was purified by column chromatography to yield the desired substrate.119   
 
RuAAC: An oven-dried flask equipped with stir bar was charged with Cp*RuCl(PPh3)2 in 
a glovebox. The flask was sealed with a septum, removed from the glovebox, and placed 
on a nitrogen line.  Dioxane was then added and the solution stirred for 5 min.  A solution 
of azido-ester and alkyne in dioxane was then added in a single portion.  The reaction 
was then heated to 60 °C and allowed to stir until the starting material was consumed as 
judged by TLC.  Upon completion, reaction was cooled to rt and the volatiles removed 
under vacuum.  The crude residue was purified by column chromatography to yield the 
desired substrate.120     
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Several substrates could not be separated from trace triphenylphosphine oxide, in 
which case they were prepared using the following protocol:  
An oven-dried flask equipped with stir bar was charged with Cp*RuCl(COD) in a glovebox. 
The flask was sealed with a septum, removed from the glovebox, and placed on a nitrogen 
line.  Toluene was then added, and the solution was stirred for ~5 min.  A solution of 
azido-ester and alkyne in toluene was then added in a single portion and reaction stirred 
until all the starting material was consumed as judged by TLC.  Upon completion, the 
solvent was removed, and the crude residue was purified by column chromatography to 
yield the desired substrate.120   
 
(5S,6S)-6-Methyl-4-methylene-11-oxooxacycloundecan-5-yl 2-azidoacetate (S14): 
Following the general esterification procedure, the reaction of 0.035 g (0.165 mmol) of 
(7S,8S)-8-hydroxy-7-methyl-9-methyleneoxacycloundecan-2-one, 0.029 g (0.283 mmol) 
of 2-azidoacetic acid, 0.058 g (0.283 mmol) of DCC, 0.003 g (0.028 mmol) of DMAP, and 
3.0 mL of CH2Cl2 afforded 0.045g (92%) of the desired ester after purification by column 
chromatography (15% EtOAc/Hexanes), which was carried on directly to the CuAAC 
reaction.   
1H NMR (500 MHz, CDCl3) δ 5.24 (s, 1H), 5.18 (s, 1H), 5.03 (d, J = 2.0 Hz, 1H), 4.93 
(ddd, J = 13.2, 10.9, 2.6 Hz, 1H), 3.99 – 3.86 (m, 3H), 2.58 – 2.42 (m, 2H), 2.30 – 2.08 
(m, 3H), 1.94 – 1.79 (m, 1H), 1.70 – 1.39 (m, 4H), 1.08 (ddt, J = 14.4, 11.7, 3.8 Hz, 1H), 
0.96 (d, J = 6.8 Hz, 3H). 
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13C NMR (100 MHz, CDCl3) δ 173.60, 167.70, 142.66, 112.22, 82.40, 63.88, 50.45, 35.21, 
30.93, 28.70, 25.64, 24.64, 19.92, 16.46. 
HRMS (ESI) m/z calculated for [M+Na]+ 318.1424, found 318.1425.   
 
(5S,6S)-6-Methyl-4-methylene-11-oxooxacycloundecan-5-yl-2-(5-
((dimethylamino)methyl)-1H-1,2,3-triazol-1-yl)acetate (38a): 
Following one of the general RuAAC procedures, the reaction of 0.010 g (0.034 mmol) of 
(5S,6S)-6-methyl-4-methylene-11-oxooxacycloundecan-5-yl 2-azidoacetate, 0.005 mL 
(0.034 mmol) of N,N-dimethylprop-2-yn-1-amine, and 6.8x10-4 mmol of Cp*RuCl(COD) in 
0.60 mL of toluene afforded 0.008 g (62%) of the title compound as a clear oil after 
purification by column chromatography (50% EtOAc/Hexanes to EtOAc).   
1H NMR (700 MHz, CDCl3) δ 7.55 (s, 1H), 5.39 (s, 2H), 5.19 (s, 1H), 5.18 – 5.16 (m, 1H), 
5.03 – 5.00 (m, 1H), 4.91 (ddd, J = 13.3, 10.9, 2.5 Hz, 1H), 3.92 (ddd, J = 10.9, 4.1, 2.3 
Hz, 1H), 3.52 – 3.44 (m, 2H), 2.51 (ddd, J = 16.1, 7.5, 1.9 Hz, 1H), 2.46 – 2.40 (m, 1H), 
2.26 – 2.06 (m, 9H), 1.91 – 1.80 (m, 1H), 1.67 – 1.52 (m, 3H), 1.51 – 1.36 (m, 2H), 0.99 
– 0.79 (m, 4H). 
13C NMR (176 MHz, CDCl3) δ 173.59, 166.12, 142.65, 134.68, 133.95, 112.12, 82.45, 
63.85, 52.04, 49.43, 45.26, 35.21, 30.89, 28.68, 25.62, 24.52, 19.90, 16.44. 
HRMS (ESI) m/z calculated for [M+H]+ 379.234, found 379.2334.   
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(5S,6S)-6-Methyl-4-methylene-11-oxooxacycloundecan-5-yl-2-(5-
((diethylamino)methyl)-1H-1,2,3-triazol-1-yl)acetate (38b): 
Following one of the general RuAAC procedures, the reaction of 0.010 g (0.034 mmol) of 
(5S,6S)-6-methyl-4-methylene-11-oxooxacycloundecan-5-yl 2-azidoacetate, 0.005 mL 
(0.034 mmol) of N,N-diethylprop-2-yn-1-amine, and 6.8x10-4 mmol of Cp*RuCl(COD) in 
0.60 mL of toluene afforded 0.008 g (57%) of the title compound as a clear oil after 
purification by column chromatography (50% EtOAc/Hexanes to EtOAc).   
1H NMR (500 MHz, CDCl3) δ 7.55 (s, 1H), 5.47 (s, 2H), 5.19 (s, 1H), 5.16 (s, 1H), 5.01 – 
4.96 (m, 1H), 4.91 (ddd, J = 13.3, 10.9, 2.6 Hz, 1H), 3.92 (dt, J = 10.8, 3.2 Hz, 1H), 3.63 
(s, 2H), 2.51 (dd, J = 16.0, 7.2 Hz, 1H), 2.44 (q, J = 7.2 Hz, 4H), 2.25 – 2.06 (m, 3H), 1.92 
– 1.78 (m, 1H), 1.67 – 1.51 (m, 2H), 1.51 – 1.37 (m, 2H), 0.97 (t, J = 7.1 Hz, 6H), 0.94 – 
0.86 (m, 4H). 
13C NMR (176 MHz, CDCl3) δ 173.59, 166.26, 142.56, 135.18, 134.11, 112.25, 82.45, 
63.83, 49.30, 46.61, 46.10, 35.20, 30.91, 28.70, 25.60, 24.51, 19.91, 16.48, 11.29. 
HRMS (ESI) m/z calculated for [M+H]+ 407.2653, found 407.2653.   
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(5S,6S)-6-methyl-4-methylene-11-oxooxacycloundecan-5-yl (S)-2-azidopropanoate 
(S15): 
An oven-dried vial equipped with stir bar was charged with 0.015 g (0.071 mmol) of 
(7S,8S)-8-Hydroxy-7-methyl-9-methyleneoxacycloundecan-2-one (34B), 0.024 g (0.212 
mmol) of (S)-2-azidopropanoic acid, and 0.001 g (0.011 mmol) of DMAP.  The contents 
were suspended in 1.5 mL of CH2Cl2 and allowed to stir before the addition of 0.041 g 
(0.212 mmol) of EDC.  Upon completion as judged by TLC, the reaction was transferred 
to a separatory funnel with EtOAc.  The organic layer was extracted twice with 1M 
aqueous HCl, once with a sat’d solution of sodium bicarbonate, and once with brine.  The 
organic layer was dried over Na2SO4, filtered, and concentrated.  Purification of the crude 
residue by column chromatography (gradient of hexanes to 40% EtOAc/hexanes) 
afforded 0.021 g (95%) of the title compound.   
1H NMR (500 MHz, CDCl3) δ 5.20 (s, 1H), 5.18 (s, 1H), 5.05 (q, J = 1.9 Hz, 1H), 4.93 
(ddd, J = 13.3, 10.9, 2.6 Hz, 1H), 4.01 – 3.91 (m, 2H), 2.52 (ddd, J = 16.1, 7.5, 1.9 Hz, 
1H), 2.49 – 2.43 (m, 1H), 2.28 – 2.09 (m, 3H), 1.93 – 1.82 (m, 1H), 1.69 – 1.41 (m, 7H), 
1.10 (ddt, J = 14.6, 11.7, 3.7 Hz, 1H), 0.96 (d, J = 6.8 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 173.62, 170.33, 142.72, 112.11, 82.19, 63.88, 57.61, 35.22, 
30.95, 28.75, 25.66, 24.70, 19.93, 16.83, 16.42. 
HRMS (ESI) m/z calculated for [M+Na]+ 332.1581, found 332.1586.   
 
127 
 
 
(5S,6S)-6-methyl-4-methylene-11-oxooxacycloundecan-5-yl (R)-2-azidopropanoate 
(S16): 
An oven-dried vial equipped with stir bar was charged with 0.017 g (0.080 mmol) of 
(7S,8S)-8-Hydroxy-7-methyl-9-methyleneoxacycloundecan-2-one, 0.028 g (0.240 mmol) 
of (R)-2-azidopropanoic acid, and 0.001 g (0.011 mmol) of DMAP.  The contents were 
suspended in 1.5 mL of CH2Cl2 and allowed to stir before the addition of 0.046 g (0.240 
mmol) of EDC.  Upon completion as judged by TLC, the reaction was transferred to a 
separatory funnel with EtOAc.  The organic layer was extracted twice with 1M aqueous 
HCl, once with a sat’d solution of sodium bicarbonate, and once with brine.  The organic 
layer was dried over Na2SO4, filtered, and concentrated.  Purification of the crude residue 
by column chromatography (gradient of hexanes to 40% EtOAc/hexanes) afforded 0.023 
g (92%) of the title compound.   
1H NMR (500 MHz, CDCl3) δ 5.19 (s, 1H), 5.17 (s, 1H), 5.04 (s, 1H), 4.93 (ddd, J = 13.1, 
11.1, 2.5 Hz, 1H), 4.01 – 3.89 (m, 2H), 2.56 – 2.41 (m, 2H), 2.28 – 2.07 (m, 3H), 1.87 (q, 
J = 12.8 Hz, 1H), 1.69 – 1.39 (m, 7H), 1.14 – 1.04 (m, 1H), 0.95 (t, J = 5.5 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 173.62, 170.35, 142.67, 112.15, 82.16, 63.90, 57.64, 35.22, 
30.92, 28.70, 25.66, 24.70, 19.91, 16.92, 16.45. 
HRMS (ESI) m/z calculated for [M+Na]+ 332.1581, found 332.1584.   
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(5S,6S)-6-methyl-4-methylene-11-oxooxacycloundecan-5-yl-(S)-2-(5-
((dimethylamino)methyl)-1H-1,2,3-triazol-1-yl)propanoate (38c): 
Following the general RuAAC procedure, the reaction of 0.018 g (0.058 mmol) of (5S,6S)-
6-methyl-4-methylene-11-oxooxacycloundecan-5-yl (S)-2-azidopropanoate, 0.012 mL 
(0.102 mmol) of N,N-dimethylprop-2-yn-1-amine, and 1.1 mg (3.0x10-3 mmol) of 
Cp*RuCl(COD) in 1.2 mL of toluene afforded 0.017 g (74%) of the title compound as a 
4:1 inseparable mixture of diastereomers at the α-triazole stereocenter.  The NMR data 
of the major diastereomer is reported.   
1H NMR (500 MHz, CDCl3) δ 7.54 (s, 1H), 5.69 (q, J = 7.3 Hz, 1H), 5.16 – 5.10 (m, 2H), 
4.96 – 4.85 (m, 2H), 3.89 (ddd, J = 11.0, 4.1, 2.3 Hz, 1H), 3.54 (d, J = 13.8 Hz, 1H), 3.42 
(d, J = 14.0 Hz, 1H), 2.48 (ddd, J = 15.9, 7.6, 1.9 Hz, 1H), 2.42 (dq, J = 15.3, 2.0 Hz, 1H), 
2.24 – 2.03 (m, 9H), 1.96 (d, J = 7.3 Hz, 3H), 1.89 – 1.76 (m, 1H), 1.60 – 1.29 (m, 4H), 
0.81 (d, J = 6.8 Hz, 3H), 0.71 – 0.62 (m, 1H). 
13C NMR (126 MHz, CDCl3) δ 173.60, 168.55, 142.82, 134.25, 133.68, 111.88, 82.22, 
63.79, 56.06, 51.93, 45.26, 35.21, 30.92, 28.67, 25.59, 24.38, 19.85, 16.92, 16.21. 
HRMS (ESI) m/z calculated for [M+H]+ 393.2496, found 393.2502.   
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(5S,6S)-6-methyl-4-methylene-11-oxooxacycloundecan-5-yl-(R)-2-(5-
((dimethylamino)methyl)-1H-1,2,3-triazol-1-yl)propanoate (38d): 
Following the general RuAAC procedure, the reaction of 0.020 g (0.065 mmol) of (5S,6S)-
6-methyl-4-methylene-11-oxooxacycloundecan-5-yl (R)-2-azidopropanoate, 0.013 mL 
(0.113 mmol) of N,N-dimethylprop-2-yn-1-amine, and 1.2 mg (3.25x10-3 mmol) of 
Cp*RuCl(COD) in 1.2 mL of toluene afforded 0.021 g (81%) of the title compound as an 
inseparable 9:1 mixture of diastereomers at the α-triazole stereocenter.  The NMR data 
of the major diastereomer is reported.   
1H NMR (500 MHz, CDCl3) δ 7.54 (s, 1H), 5.67 (q, J = 7.4 Hz, 1H), 5.14 (s, 1H), 5.12 (s, 
1H), 4.93 – 4.84 (m, 2H), 3.91 (ddd, J = 10.9, 4.1, 2.3 Hz, 1H), 3.52 (d, J = 13.7 Hz, 1H), 
3.40 (d, J = 13.9 Hz, 1H), 2.50 (dd, J = 16.0, 7.3 Hz, 1H), 2.41 (d, J = 15.4 Hz, 1H), 2.23 
– 2.06 (m, 9H), 2.00 (d, J = 7.4 Hz, 3H), 1.89 – 1.78 (m, 1H), 1.66 – 1.50 (m, 2H), 1.49 – 
1.35 (m, 2H), 0.93 – 0.80 (m, 4H). 
13C NMR (126 MHz, CDCl3) δ 173.53, 168.70, 142.40, 134.29, 133.78, 112.20, 82.18, 
63.86, 56.20, 51.91, 45.22, 35.16, 30.84, 28.67, 25.61, 24.62, 19.87, 16.91, 16.49. 
HRMS (ESI) m/z calculated for [M+H]+ 393.2496, found 393.2502.   
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(5S,6S)-6-Methyl-4-methylene-11-oxooxacycloundecan-5-yl-2-(4-
((dimethylamino)methyl)-1H-1,2,3-triazol-1-yl)acetate (38e): 
Following the general CuAAC reaction procedure, the reaction of 0.010 g (0.034 mmol) 
of (5S,6S)-6-methyl-4-methylene-11-oxooxacycloundecan-5-yl 2-azidoacetate, 0.004 mL 
(0.034 mmol) N,N-dimethylprop-2-yn-1-amine, 3.40x10-4 mmol CuSO4•5H2O, and 
3.40x10-3 mmol of sodium ascorbate in 0.50 ml of H2O/t-BuOH (1:1) afforded 0.013 g 
(99%) of the title compound as a clear oil after purification by column chromatography 
(gradient CH2Cl2 to 10% MeOH/CH2Cl2). 
1H NMR (700 MHz, CDCl3) δ 7.66 (s, 1H), 5.25 – 5.17 (m, 3H), 5.16 – 5.13 (m, 1H), 3.91 
(ddd, J = 10.9, 4.1, 2.4 Hz, 1H), 3.70 (s, 2H), 2.49 (ddd, J = 16.0, 7.6, 1.9 Hz, 1H), 2.45 
– 2.39 (m, 1H), 2.31 (s, 6H), 2.23 – 2.05 (m, 3H), 1.88 – 1.78 (m, 1H), 1.63 – 1.51 (m, 
2H), 1.46 – 1.34 (m, 2H), 0.96 – 0.80 (m, 4H). 
13C NMR (176 MHz, CDCl3) δ 173.53, 165.49, 144.93, 142.34, 124.12, 112.28, 82.81, 
63.79, 54.10, 50.86, 44.79, 35.15, 30.85, 28.70, 25.54, 24.44, 19.86, 16.45. 
HRMS (ESI) m/z calculated for [M+H]+ 379.2340, found 379.2332.   
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(5S,6S)-6-Methyl-4-methylene-11-oxooxacycloundecan-5-yl-2-(4-
((diethylamino)methyl)-1H-1,2,3-triazol-1-yl)acetate (38f): 
Following the general CuAAC reaction procedure, the reaction of 0.010 g (0.034 mmol) 
of (5S,6S)-6-methyl-4-methylene-11-oxooxacycloundecan-5-yl 2-azidoacetate, 0.005 mL 
(0.034 mmol) N,N-diethylprop-2-yn-1-amine, 3.40x10-4 mmol CuSO4•5H2O, and 3.40x10-
3 mmol of sodium ascorbate in 0.50 ml of H2O/t-BuOH (1:1) afforded 0.013 g (93%) of the 
title compound as a clear oil after purification by column chromatography (gradient CH2Cl2 
to 10% MeOH/CH2Cl2) 
1H NMR (700 MHz, CDCl3) δ 7.88 (s, 1H), 5.26 – 5.17 (m, 3H), 5.14 (t, J = 1.7 Hz, 1H), 
4.94 – 4.86 (m, 2H), 3.99 (s, 2H), 3.91 (ddd, J = 10.9, 4.2, 2.4 Hz, 1H), 2.72 (s, 4H), 2.49 
(ddd, J = 16.1, 7.6, 1.9 Hz, 1H), 2.45 – 2.39 (m, 1H), 2.23 – 2.05 (m, 3H), 1.88 – 1.78 (m, 
1H), 1.65 – 1.50 (m, 2H), 1.47 – 1.34 (m, 2H), 1.19 (t, J = 7.3 Hz, 6H), 0.94 – 0.82 (m, 
4H). 
13C NMR (176 MHz, CDCl3) δ 173.53, 165.43, 142.32, 125.33, 112.34, 82.85, 63.80, 
50.89, 47.26, 46.44, 35.17, 30.87, 28.73, 25.57, 24.45, 19.86, 16.48, 10.78. 
HRMS (ESI) m/z calculated for [M+H]+ 407.2653, found 407.2665.   
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(5S,6S)-6-Methyl-4-methylene-11-oxooxacycloundecan-5-yl-(S)-2-(4-
((dimethylamino)methyl)-1H-1,2,3-triazol-1-yl)propanoate (38g): 
Following the general CuAAC reaction procedure, the reaction of 0.051 g (0.164 mmol) 
of (5S,6S)-6-methyl-4-methylene-11-oxooxacycloundecan-5-yl (S)-2-azidopropanoate, 
0.014 g (0.164 mmol) of N,N-dimethylprop-2-yn-1-amine, 1.64x10-3 mmol of 
CuSO4•5H2O, and 1.64x10-2 mmol of sodium ascorbate in 2.0 ml of H2O/t-BuOH (1:1) 
afforded 0.061 g (95%) of the title compound as a clear oil after purification by column 
chromatography (gradient CH2Cl2 to 10% MeOH/CH2Cl2) 
1H NMR (500 MHz, CDCl3) δ 7.70 (s, 1H), 5.51 (q, J = 7.5 Hz, 1H), 5.18 – 5.08 (m, 2H), 
4.96 – 4.82 (m, 2H), 3.91 (ddd, J = 10.9, 4.2, 2.3 Hz, 1H), 3.67 (dd, J = 19.5, 14 Hz, 2H), 
2.50 (dd, J = 16, 7 Hz, 1H), 2.46 – 2.38 (m, 1H), 2.31 (s, 6H), 2.25 – 1.97 (m, 3H), 1.94 – 
1.69 (m, 4H), 1.69 – 1.49 (m, 2H), 1.48 – 1.27 (m, 2H), 0.96 – 0.76 (m, 4H). 
13C NMR (176 MHz, CDCl3) δ 173.55, 168.49, 145.45, 142.41, 121.46, 112.10, 82.50, 
63.78, 58.21, 54.43, 45.11, 35.15, 30.84, 28.67, 25.53, 24.40, 19.82, 18.00, 16.36. 
HRMS (ESI) m/z calculated for [M+H]+ 393.2496, found 393.2498.   
 
 
133 
 
 
(5S,6S)-6-Methyl-4-methylene-11-oxooxacycloundecan-5-yl-(R)-2-(4-
((dimethylamino)methyl)-1H-1,2,3-triazol-1-yl)propanoate (38h): 
Following the general esterification procedure, the reaction of 0.022 g (0.104 mmol) of 
(7S,8S)-8-hydroxy-7-methyl-9-methyleneoxacycloundecan-2-one, 0.018 g (0.155 mmol) 
of (R)-2-azidopropanoic acid, 0.032 g (0.283 mmol) of DCC, 0.002 g (0.016 mmol) of 
DMAP, and 1.75 mL of CH2Cl2 afforded the desired ester after purification by column 
chromatography (15% EtOAc/Hexanes), which was carried on directly to the CuAAC 
reaction.  Following the general CuAAC reaction procedure, the reaction of 0.104 mmol 
of (5S,6S)-6-methyl-4-methylene-11-oxooxacycloundecan-5-yl (R)-2-azidopropanoate, 
0.0012 mL (0.104 mmol) N,N-dimethylprop-2-yn-1-amine, 1.04x10-3 mmol CuSO4•5H2O, 
and 1.04x10-2 mmol of sodium ascorbate in 0.50 ml of H2O/t-BuOH (1:1) afforded 0.030 
g (75% over two steps) of the title compound after purification by column chromatography 
(gradient CH2Cl2 to 10% MeOH/CH2Cl2).   
1H NMR (500 MHz, CDCl3) δ 7.72 (s, 1H), 5.50 (q, J = 7 Hz, 1H), 5.18 – 5.08 (m, 2H), 
4.94 – 4.81 (m, 2H), 3.91 (ddd, J = 11.0, 4.2, 2.4 Hz, 1H), 3.78 – 3.66 (m, 2H), 2.50 (m, 
1H), 2.45 – 2.37 (m, 1H), 2.33 (s, 6H), 2.25 – 1.98 (m, 4H), 1.95 – 1.72 (m, 4H), 1.67 – 
1.49 (m, 2H), 1.48 – 1.34 (m, 2H), 0.96 – 0.79 (m, 3H). 
13C NMR (126 MHz, CDCl3) δ 173.53, 168.51, 145.02, 142.25, 121.66, 112.19, 82.50, 
63.81, 58.27, 54.30, 44.96, 35.13, 30.81, 28.69, 25.54, 24.44, 19.83, 17.98, 16.40. 
HRMS (ESI) m/z calculated for [M+H]+ 393.2496, found 393.2506.   
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(5S,6S)-6-Methyl-4-methylene-11-oxooxacycloundecan-5-yl-2-(4-(4-
((dimethylamino)methyl)phenyl)-1H-1,2,3-triazol-1-yl)acetate (38i): 
Following the general CuAAC reaction procedure, the reaction of 0.014 g (0.047 mmol) 
of (5S,6S)-6-methyl-4-methylene-11-oxooxacycloundecan-5-yl 2-azidoacetate, 0.007 g 
(0.047 mmol) of 1-(4-ethynylphenyl)-N,N-dimethylmethanamine, 4.70x10-4 mmol of 
CuSO4•5H2O, and 4.70x10-3 mmol of sodium ascorbate in 0.50 ml of H2O/t-BuOH (1:1) 
afforded 0.007 g (33%) of the title compound as a clear oil after purification by column 
chromatography (gradient CH2Cl2 to 10% MeOH/CH2Cl2) 
1H NMR (401 MHz, CDCl3) δ 7.90 (s, 1H), 7.81 (d, J = 7.9 Hz, 2H), 7.43 (d, J = 7.9 Hz, 
2H), 5.31 – 5.21 (m, 3H), 5.17 (s, 1H), 4.97 (s, 1H), 4.90 (t, J = 2.3 Hz, 1H), 3.93 (dt, J = 
10.8, 2.9 Hz, 1H), 3.60 (s, 2H), 2.56 – 2.29 (m, 8H), 2.28 – 2.04 (m, 3H), 1.92 – 1.75 (m, 
1H), 1.66 – 1.51 (m, 2H), 1.51 – 1.32 (m, 2H), 0.93 (d, J = 6.9 Hz, 4H). 
13C NMR (176 MHz, CDCl3) δ 173.58, 165.52, 147.96, 142.40, 133.89, 130.09, 125.99, 
120.94, 112.33, 82.95, 63.81, 63.30, 50.95, 44.56, 35.16, 30.90, 28.76, 25.55, 24.48, 
19.89, 16.52. 
HRMS (ESI) m/z calculated for [M+H]+ 455.2653, found 455.2637.   
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(5S,6S)-6-methyl-4-methylene-11-oxooxacycloundecan-5-yl-4-(4-
((dimethylamino)methyl)-1H-1,2,3-triazol-1-yl)benzoate (38j): 
Following the general esterification procedure, the reaction of 0.060 g (0.283 mmol) of 
(7S,8S)-8-hydroxy-7-methyl-9-methyleneoxacycloundecan-2-one, 0.231 g (1.413 mmol) 
of 4-azidobenzoic acid, 0.292 g (1.413 mmol) of DCC, 0.035 g (0.283 mmol) of DMAP, 
and 4.50 mL of CH2Cl2 afforded the desired azido ester, which was purified by column 
chromatography (15% EtOAc/hexanes) and carried on directly to the CuAAC reaction.   
Following the general CuAAC reaction procedure, the reaction of 0.092 g (0.257 mmol) 
of (5S,6S)-6-methyl-4-methylene-11-oxooxacycloundecan-5-yl 4-azidobenzoate, 0.028 
mL (0.257 mmol) N,N-dimethylprop-2-yn-1-amine, 2.57x10-3 mmol CuSO4•5H2O, and 
2.57x10-2 mmol of sodium ascorbate in 1 ml of H2O/t-BuOH (1:1) afforded 0.110 g (88% 
over two steps) of the title compound after purification by column chromatography 
(gradient CH2Cl2 to 10% MeOH/CH2Cl2) 
1H NMR (500 MHz, CDCl3) δ 8.23 (d, J = 8.5 Hz, 2H), 8.12 (s, 1H), 7.87 (d, J = 8.4 Hz, 
2H), 5.40 (s, 1H), 5.22 – 5.17 (m, 1H), 5.13 – 5.08 (m, 1H), 4.98 (ddd, J = 13.3, 10.9, 2.5 
Hz, 1H), 3.98 (ddd, J = 10.9, 4.1, 2.3 Hz, 1H), 3.81 (s, 2H), 2.60 – 2.48 (m, 2H), 2.48 – 
2.24 (m, 8H), 2.23 – 2.11 (m, 1H), 1.93 (q, J = 12.8 Hz, 1H), 1.77 – 1.45 (m, 4H), 1.36 – 
1.17 (m, 1H), 1.03 (d, J = 6.8 Hz, 3H). 
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13C NMR (126 MHz, CDCl3) δ 173.67, 164.58, 146.49, 143.07, 140.27, 131.31, 130.22, 
120.40, 119.87, 112.13, 81.73, 64.01, 54.37, 45.26, 35.30, 30.95, 29.01, 25.78, 24.99, 
19.99, 16.67. 
HRMS (ESI) m/z calculated for [M+H]+ 441.2496, found 441.2500.   
 
(5S,6S)-6-Methyl-4-methylene-11-oxooxacycloundecan-5-yl-3-(4-
((dimethylamino)methyl)-1H-1,2,3-triazol-1-yl)benzoate (38k): 
Following the general esterification procedure, the reaction of 0.007 g (0.033 mmol) of 
(7S,8S)-8-hydroxy-7-methyl-9-methyleneoxacycloundecan-2-one, 0.016 g (0.100 mmol) 
of 3-azidobenzoic acid, 0.021 g (0.100 mmol) of DCC, 0.001 g (0.008 mmol) of DMAP, 
and 0.50 mL of CH2Cl2 afforded 0.010 g (85%) the desired azido ester, after purification 
by column chromatography (15% EtOAc/Hexanes) and was carried on directly to the 
CuAAC reaction.   
 
1H NMR (700 MHz, CDCl3) δ 7.84 (d, J = 7.8 Hz, 1H), 7.71 (s, 1H), 7.45 (t, J = 7.9 Hz, 
1H), 7.23 (ddd, J = 8.0, 2.2, 1.1 Hz, 1H), 5.37 (s, 1H), 5.17 (s, 1H), 5.09 (d, J = 2.0 Hz, 
1H), 4.96 (ddd, J = 13.3, 10.9, 2.5 Hz, 1H), 3.97 (ddd, J = 11.0, 4.2, 2.4 Hz, 1H), 2.55 (dd, 
J = 15.8, 6.9 Hz, 1H), 2.50 (d, J = 15.3 Hz, 1H), 2.34 – 2.24 (m, 2H), 2.16 (ddd, J = 16.1, 
11.9, 1.9 Hz, 1H), 1.96 – 1.88 (m, 1H), 1.73 – 1.57 (m, 3H), 1.54 – 1.48 (m, 1H), 1.27 – 
1.20 (m, 1H), 1.00 (d, J = 6.8 Hz, 3H). 
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13C NMR (176 MHz, CDCl3) δ 173.64, 164.80, 143.01, 140.64, 132.03, 129.89, 125.86, 
123.38, 119.95, 112.07, 81.60, 63.98, 35.25, 30.91, 28.94, 25.74, 24.91, 19.96, 16.60. 
HRMS (ESI) m/z calculated for [M+Na]+ 380.1581, found 380.1582.   
 
Following the general CuAAC reaction procedure, the reaction of 0.010 g (0.028 mmol) 
of (5S,6S)-6-methyl-4-methylene-11-oxooxacycloundecan-5-yl 3-azidobenzoate, 0.003 
mL (0.028 mmol) N,N-dimethylprop-2-yn-1-amine, 2.80x10-4 mmol CuSO4•5H2O, and 
2.8x10-3 mmol of sodium ascorbate in 0.50 ml of H2O/t-BuOH (1:1) afforded 0.011 g (89%) 
of the title compound after purification by column chromatography (gradient CH2Cl2 to 
10% MeOH/CH2Cl2) 
1H NMR (700 MHz, CDCl3) δ 8.36 (s, 1H), 8.13 (d, J = 7.8 Hz, 1H), 8.07 (s, 1H), 8.05 – 
8.01 (m, 1H), 7.63 (t, J = 7.9 Hz, 1H), 5.41 (s, 1H), 5.18 (s, 1H), 5.13 – 5.09 (m, 1H), 4.96 
(ddd, J = 13.2, 11.0, 2.6 Hz, 1H), 3.98 (ddd, J = 11.0, 4.2, 2.3 Hz, 1H), 3.77 (s, 2H), 2.60 
– 2.47 (m, 2H), 2.39 (s, 6H), 2.36 – 2.25 (m, 2H), 2.17 (ddd, J = 16.2, 11.9, 1.9 Hz, 1H), 
1.97 – 1.87 (m, 1H), 1.74 – 1.65 (m, 2H), 1.61 (ddq, J = 13.2, 8.3, 3.6, 2.8 Hz, 1H), 1.52 
(tq, J = 13.3, 3.1 Hz, 1H), 1.26 (ddd, J = 13.5, 9.0, 3.0 Hz, 1H), 1.02 (d, J = 6.8 Hz, 3H). 
13C NMR (176 MHz, CDCl3) δ 173.7, 164.5, 145.7, 143.0, 137.4, 132.1, 130.1, 129.5, 
124.9, 121.1, 120.9, 112.2, 82.0, 64.0, 54.2, 45.0, 35.3, 31.0, 29.0, 25.8, 25.0, 20.0, 16.6. 
HRMS (ESI) m/z calculated for [M+H]+ 441.2496, found 441.2485.   
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 (5S,6S)-6-Methyl-4-methylene-11-oxooxacycloundecan-5-yl-2-(4-
((dimethylamino)methyl)-1H-1,2,3-triazol-1-yl)benzoate (38l): 
Following the general esterification procedure, the reaction of 0.040 g (0.188 mmol) of 
(7S,8S)-8-hydroxy-7-methyl-9-methyleneoxacycloundecan-2-one, 0.154 g (0.942 mmol) 
of 2-azidobenzoic acid, 0.194 g (0.942 mmol) of DCC, 0.023 g (0.188 mmol) of DMAP, 
and 4.0 mL of CH2Cl2 afforded the desired ester after purification by column 
chromatography (15% EtOAc/Hexanes), which was carried on directly to the CuAAC 
reaction.   
Following the general CuAAC reaction procedure, the reaction of 0.065 g (0.183 mmol) 
of (5S,6S)-6-methyl-4-methylene-11-oxooxacycloundecan-5-yl 2-azidobenzoate, 0.021 
mL (0.183 mmol) N,N-dimethylprop-2-yn-1-amine, 1.83x10-3 mmol CuSO4•5H2O, and 
1.83x10-2 mmol of sodium ascorbate in 3.0 ml of H2O/t-BuOH (1:1) afforded 0.065 g (78% 
over two steps) of the title compound after purification by column chromatography 
(gradient CH2Cl2 to 10% MeOH/CH2Cl2) 
1H NMR (400 MHz, CDCl3) δ 8.03 (dd, J = 7.8, 1.6 Hz, 1H), 7.79 (s, 1H), 7.68 (td, J = 7.7, 
1.6 Hz, 1H), 7.60 (td, J = 7.6, 1.4 Hz, 1H), 7.49 (dd, J = 7.8, 1.3 Hz, 1H), 5.24 (s, 1H), 
5.15 (s, 1H), 5.09 – 5.04 (m, 1H), 4.92 (ddd, J = 13.2, 10.9, 2.6 Hz, 1H), 3.93 (ddd, J = 
11.0, 4.1, 2.5 Hz, 1H), 3.72 (s, 2H), 2.51 (dd, J = 15.1, 5.2 1H), 2.43 (d, J = 15.4 Hz, 1H), 
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2.35 (s, 6H), 2.28 – 2.07 (m, 3H), 1.87 (q, J = 12.8 Hz, 1H), 1.70 – 1.52 (m, 3H), 1.52 – 
1.39 (m, 1H), 1.10 – 0.99 (m, 1H), 0.94 (d, J = 6.8 Hz, 3H). 
13C NMR (176 MHz, CDCl3) δ 173.63, 163.76, 143.22, 142.72, 136.49, 132.73, 130.76, 
129.94, 127.50, 127.40, 125.36, 112.24, 82.09, 63.96, 53.87, 44.61, 35.25, 30.95, 28.91, 
25.71, 24.76, 19.95, 16.50. 
The fully substituted triazole carbon was detected at 143.22 ppm by HMBC. 
HRMS (ESI) m/z calculated for [M+H]+ 441.2496, found 441.2513.   
 
(5S,6S)-6-methyl-4-methylene-11-oxooxacycloundecan-5-yl-4-(4-isobutyl-1H-1,2,3-
triazol-1-yl)benzoate (38m): 
Following the general CuAAC reaction procedure, the reaction of 8.5 mg g (0.024 mmol) 
of (5S,6S)-6-methyl-4methylene-11-oxooxacycloundecan-5-yl 4-azidobenzoate, 10.0 mg 
(0.120 mmol) 4-methylpent-1-yne, 1.19x10-3 mmol CuSO4•5H2O, and 1.19x10-2 mmol of 
sodium ascorbate in 1 ml of H2O/t-BuOH (1:1) afforded 9.0 mg (86%) of the title 
compound after purification by column chromatography (30% EtOAc/hex).   
1H NMR (700 MHz, CDCl3) δ 8.21 (d, J = 8.6 Hz, 2H), 7.85 (d, J = 8.6 Hz, 2H), 7.78 (s, 
1H), 5.39 (s, 1H), 5.20 – 5.17 (m, 1H), 5.11 (d, J = 2.0 Hz, 1H), 4.98 (ddd, J = 13.3, 10.9, 
2.5 Hz, 1H), 3.97 (ddd, J = 11.0, 4.1, 2.3 Hz, 1H), 2.69 (d, J = 7.0 Hz, 2H), 2.55 (ddd, J = 
16.2, 8.0, 1.8 Hz, 1H), 2.52 (d, J = 15.3 Hz, 1H), 2.36 – 2.26 (m, 2H), 2.17 (ddd, J = 16.2, 
11.9, 1.9 Hz, 1H), 2.10 – 2.01 (m, 1H), 1.93 (q, J = 13.2 Hz, 1H), 1.74 – 1.59 (m, 4H), 
1.55 – 1.49 (m, 1H), 1.32 – 1.26 (m, 1H), 1.02 (d, J = 6.8 Hz, 3H), 0.99 (d, J = 6.6 Hz, 
5H). 
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13C NMR (176 MHz, CDCl3) δ 173.70, 164.65, 148.38, 143.07, 140.38, 131.25, 129.93, 
119.76, 119.04, 112.12, 81.68, 64.01, 35.30, 34.67, 30.94, 28.97, 28.64, 25.77, 24.96, 
22.31, 19.96, 16.67. 
HRMS (ESI) m/z calculated for [M+H]+ 440.2544, found 440.2544. 
 
 
 
(5S,6S)-6-methyl-4-methylene-11-oxooxacycloundecan-5-yl 4-(4-((1H-imidazol-1-
yl)methyl)-1H-1,2,3-triazol-1-yl)benzoate (38n): 
Following the general CuAAC reaction procedure, the reaction of 8.5 mg g (0.024 mmol) 
of (5S,6S)-6-methyl-4methylene-11-oxooxacycloundecan-5-yl 4-azidobenzoate, 5.0 mg 
(0.048 mmol) 1-(prop-2-yn-1-yl)-1H-imidazole, 1.19x10-3 mmol CuSO4•5H2O, and 
1.19x10-2 mmol of sodium ascorbate in 1 ml of H2O/t-BuOH (1:1) afforded 6.0 mg (55%) 
of the title compound after purification by column chromatography (4% MeOH/CH2Cl2). 
1H NMR (700 MHz, CDCl3) δ 8.22 (d, J = 8.6 Hz, 2H), 7.86 (s, 1H), 7.81 (d, J = 8.6 Hz, 
2H), 7.65 (s, 1H), 7.12 (s, 1H), 7.07 (s, 1H), 5.39 (s, 1H), 5.37 (s, 2H), 5.18 (s, 1H), 5.09 
(d, J = 2.0 Hz, 1H), 4.98 (ddd, J = 13.2, 11.0, 2.5 Hz, 1H), 3.97 (ddd, J = 10.9, 4.2, 2.4 
Hz, 1H), 2.55 (ddd, J = 16.2, 7.6, 1.8 Hz, 1H), 2.51 (d, J = 15.8 Hz, 1H), 2.35 – 2.26 (m, 
2H), 2.16 (ddd, J = 16.2, 12.0, 1.9 Hz, 1H), 1.97 – 1.89 (m, 1H), 1.74 – 1.58 (m, 3H), 1.55 
– 1.48 (m, 1H), 1.30 – 1.22 (m, 1H), 1.02 (d, J = 6.8 Hz, 3H). 
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13C NMR (176 MHz, CDCl3) δ 173.68, 164.41, 144.85, 143.01, 139.77, 137.13, 131.37, 
130.73, 130.21, 120.08, 119.98, 119.04, 112.12, 81.84, 63.98, 42.32, 35.29, 30.93, 28.96, 
25.75, 24.95, 19.95, 16.67. 
HRMS (ESI) m/z calculated for [M+H]+ 464.2292, found 464.2294.   
 
(5S,6S)-6-Methyl-4-methylene-11-oxooxacycloundecan-5-yl-4-(4-
((dimethylamino)methyl)-1H-1,2,3-triazol-1-yl)-3,5-difluorobenzoate (38p): 
Following the general esterification procedure, the reaction of 0.010 g (0.047 mmol) of 
(7S,8S)-8-hydroxy-7-methyl-9-methyleneoxacycloundecan-2-one, 0.047 g (0.236 mmol) 
of 4-azido-3,5-difluorobenzoic acid, 0.049 g (0.236 mmol) of DCC, 0.006 g (0.047 mmol) 
of DMAP, and 3.00 mL of CH2Cl2 afforded the desired azido ester, which was purified by 
column chromatography (15% EtOAc/Hexanes) and carried on directly to the CuAAC 
reaction.   
Following the general CuAAC reaction procedure, the reaction of (0.047 mmol) of 
(5S,6S)-6-methyl-4-methylene-11-oxooxacycloundecan-5-yl 4-azido-3,5-
difluorobenzoate, 0.005 mL (0.047 mmol) N,N-dimethylprop-2-yn-1-amine, 4.70x10-4 
mmol CuSO4•5H2O, and 4.7x10-3 mmol of sodium ascorbate in 1 ml of H2O/t-BuOH (1:1) 
afforded 0.022 g (99% over two steps) of the title compound after purification by column 
chromatography (gradient CH2Cl2 to 10% MeOH/CH2Cl2) 
1H NMR (401 MHz, CDCl3) δ 7.87 – 7.77 (m, 3H), 5.39 (s, 1H), 5.20 (s, 1H), 5.06 (d, J = 
2.0 Hz, 1H), 4.97 (ddd, J = 13.3, 10.9, 2.7 Hz, 1H), 3.98 (ddd, J = 10.9, 4.1, 2.3 Hz, 1H), 
3.77 (s, 2H), 2.62 – 2.45 (m, 2H), 2.41 – 2.24 (m, 7H), 2.17 (ddd, J = 16.0, 11.8, 1.7 Hz, 
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1H), 2.00 – 1.85 (m, 1H), 1.77 – 1.46 (m, 4H), 1.34 – 1.16 (m, 2H), 1.02 (d, J = 6.8 Hz, 
3H). 
13C NMR (176 MHz, CDCl3) δ 173.60, 162.54, 156.31 (dd, J = 257.9, 2.4 Hz) 145.11, 
142.65, 133.14 (t, J = 8.5 Hz) 124.98, 118.97 (t, J = 15.8 Hz) 113.70 (dd, J = 21.8, 3.8 
Hz) 112.24, 82.82, 63.90, 54.06, 45.08, 35.23, 30.93, 29.00, 25.71, 24.93, 19.95, 16.66. 
HRMS (ESI) m/z calculated for [M+H]+ 477.2308, found 477.2319.   
 
 
(3R,12S,13S)-12-Methyl-7-oxo-1,6-dioxaspiro[2.10]tridecan-13-yl-4-(4-
((dimethylamino)methyl)-1H-1,2,3-triazol-1-yl)benzoate (43j): 
To an oven-dried flask equipped with stir bar was added 0.014 g (0.061 mmol) of 
(3R,12S,13S)-13-hydroxy-12-methyl-1,6-dioxaspiro[2.10]tridecan-7-one, 0.007 g (0.061 
mmol) of DMAP and 1 mL of CH2Cl2/Pyridine (1:1).  The contents were cooled to 0 °C 
and 0.033 g (0.183 mmol) of 4-azidobenzoyl chloride was added dropwise as a solution 
in 1 mL of CH2Cl2.  The reaction was warmed to rt and stir for 24 hours.  The reaction was 
quenched with the addition of sat’d aqueous sodium bicarbonate and EtOAc.  The 
aqueous layer was extracted 3x with EtOAc, the organic layers combined, dried over 
Na2SO4, filtered, and concentrated.  The crude residue was purified by column 
chromatography (30% EtOAc/Hexanes) to yield 0.010 g (43%) of the desired product that 
was directly carried on to the CuAAC reaction 
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Following the general CuAAC reaction procedure, the reaction of 0.010 g (0.027 mmol) 
of (5S,6S)-6-methyl-4-methylene-11-oxooxacycloundecan-5-yl 4-azidobenzoate, 0.003 
mL (0.027 mmol) N,N-dimethylprop-2-yn-1-amine, 2.73x10-4 mmol CuSO4•5H2O, and 
2.57x10-3 mmol of sodium ascorbate in 1 ml of H2O/t-BuOH (1:1) afforded 0.011 g (88%) 
of the title compound after purification by column chromatography (gradient CH2Cl2 to 
10% MeOH/CH2Cl2).   
1H NMR (500 MHz, CDCl3) δ 8.18 – 8.07 (m, 3H), 7.84 (d, J = 8.7 Hz, 2H), 5.41 (s, 1H), 
4.74 (td, J = 12.1, 2.4 Hz, 1H), 3.95 (dt, J = 11.8, 3.6 Hz, 1H), 3.81 (s, 2H), 2.97 (d, J = 
4.5 Hz, 1H), 2.91 (d, J = 4.5 Hz, 1H), 2.64 – 2.54 (m, 1H), 2.42 (s, 8H), 2.23 (ddd, J = 
15.6, 11.6, 2.0 Hz, 1H), 2.07 – 1.92 (m, 2H), 1.80 – 1.63 (m, 3H), 1.62 – 1.52 (m, 1H), 
1.42 – 1.31 (m, 1H), 1.01 (d, J = 6.8 Hz, 3H). 
13C NMR (176 MHz, CDCl3) δ 173.84, 164.59, 145.24, 140.09, 131.29, 130.15, 121.08, 
119.85, 76.74, 60.72, 57.25, 54.00, 48.23, 44.80, 35.29, 31.99, 29.75, 26.19, 25.63, 
20.25, 16.81. 
HRMS (ESI) m/z calculated for [M+H]+ 457.2445, found 457.2447.   
 
(6S,7S,E)-7-Methyl-12-oxooxacyclododec-4-en-6-yl-4-(4-((dimethylamino)methyl)-
1H-1,2,3-triazol-1-yl)benzoate (55j):  
Following the general esterification procedure, the reaction of 0.030 g (0.141 mmol) of 
(7S,8S,E)-8-hydroxy-7-methyloxacyclododec-9-en-2-one, 0.115 g (0.707 mmol) of 4-
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azidobenzoic acid, 0.146 g (0.707 mmol) of DCC, 0.034 g (0.282 mmol) of DMAP, and 
4.0 mL of CH2Cl2 afforded the desired ester after purification by column chromatography 
(15% EtOAc/Hexanes), which was carried on directly to the CuAAC reaction.   
Following the general CuAAC reaction procedure, the reaction of (0.141 mmol) of 
(6S,7S,E)-7-methyl-12-oxooxacyclododec-4-en-6-yl 4-azidobenzoate, 0.016 mL (0.141 
mmol) N,N-dimethylprop-2-yn-1-amine, 1.41x10-3 mmol CuSO4•5H2O, and 1.41x10-2 
mmol of sodium ascorbate in 2.0 ml of H2O/t-BuOH (1:1) afforded 0.055 g (89% over two 
steps) of the title compound after purification by column chromatography (gradient CH2Cl2 
to 10% MeOH/CH2Cl2). 
1H NMR (700 MHz, CDCl3) δ 8.19 (d, J  = 7 Hz, 2H), 8.11 (s, 1H), 7.85 (d, J  = 7 Hz, 2H), 
5.69 – 5.60 (m, 2H), 5.57 (dd, J = 6.9, 4.5 Hz, 1H), 4.64 (ddd, J = 11.0, 9.4, 4.2 Hz, 1H), 
4.01 (dt, J = 11.0, 4.5 Hz, 1H), 3.80 (s, 2H), 2.52 – 2.28 (m, 11H), 2.12 – 2.03 (m, 1H), 
1.94 – 1.85 (m, 1H), 1.59 – 1.38 (m, 5H), 1.35 – 1.26 (m, 2H), 1.07 (d, J = 6.9 Hz, 3H). 
13C NMR (176 MHz, CDCl3) δ 173.51, 164.56, 145.40, 140.00, 131.28, 131.26, 130.70, 
128.51, 120.95, 119.81, 77.66, 60.93, 54.08, 44.91, 34.92, 33.30, 32.39, 30.90, 24.15, 
23.25, 16.35. 
HRMS (ESI) m/z calculated for [M+H]+ 441.2496, found 441.2498.   
 
(6S,7S,E)-7-Methyl-12-oxooxacyclododec-4-en-6-yl-2-(4-((dimethylamino)methyl)-
1H-1,2,3-triazol-1-yl)benzoate (55l): 
145 
 
Following the general esterification procedure, the reaction of 0.030 g (0.141 mmol) of 
(7S,8S,E)-8-hydroxy-7-methyloxacyclododec-9-en-2-one, 0.115 g (0.707 mmol) of 2-
azidobenzoic acid, 0.146 g (0.707 mmol) of DCC, 0.034 g (0.282 mmol) of DMAP, and 
4.0 mL of CH2Cl2 afforded the desired ester after purification by column chromatography 
(15% EtOAc/Hexanes), which was carried on directly to the CuAAC reaction.   
Following the general CuAAC reaction procedure, the reaction of (0.141 mmol) of 
(6S,7S,E)-7-methyl-12-oxooxacyclododec-4-en-6-yl 2-azidobenzoate, 0.016 mL (0.141 
mmol) N,N-dimethylprop-2-yn-1-amine, 1.41x10-3 mmol CuSO4•5H2O, and 1.41x10-2 
mmol of sodium ascorbate in 2.0 ml of H2O/t-BuOH (1:1) afforded 0.050 g (80% over two 
steps) of the title compound after purification by column chromatography (gradient CH2Cl2 
to 10% MeOH/CH2Cl2). 
1H NMR (500 MHz, CDCl3) δ 7.96 (dd, J = 7.8, 1.6 Hz, 1H), 7.74 (s, 1H), 7.64 (td, J = 7.7, 
1.6 Hz, 1H), 7.58 (td, J = 7.7, 1.3 Hz, 1H), 7.48 (dd, J = 7.8, 1.3 Hz, 1H), 5.62 (ddd, J = 
14.5, 8.5, 5.9 Hz, 1H), 5.47 – 5.34 (m, 2H), 4.70 (ddd, J = 10.9, 9.1, 5.2 Hz, 1H), 3.91 (dt, 
J = 11.0, 4.2 Hz, 1H), 3.70 (s, 2H), 2.45 – 2.25 (m, 10H), 1.95 – 1.81 (m, 2H), 1.52 – 1.41 
(m, 1H), 1.40 – 1.24 (m, 3H), 1.18 – 1.08 (m, 1H), 0.84 (d, J = 6.8 Hz, 3H). 
13C NMR (176 MHz, CDCl3) δ 173.41, 164.33, 144.97, 136.17, 132.37, 132.33, 130.97, 
129.63, 128.03, 127.56, 126.77, 124.37, 78.18, 60.86, 54.38, 45.24, 34.54, 33.27, 32.17, 
30.96, 24.09, 23.01, 15.91. 
HRMS (ESI) m/z calculated for [M+H]+ 441.2496, found 441.2503.   
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(6S,7S,E)-7-Methyl-12-oxooxacyclododec-4-en-6-yl-(R)-2-(4-
((diethylamino)methyl)-1H-1,2,3-triazol-1-yl)propanoate (55o): 
Following the general esterification procedure, the reaction of 0.056 g (0.264 mmol) of 
(7S,8S,E)-8-hydroxy-7-methyloxacyclododec-9-en-2-one, 0.065 g (0.565 mmol) of (R)-2-
azidopropanoic acid, 0.117 g (0.565 mmol) of DCC, 0.017 g (0.142 mmol) of DMAP, and 
4.50 mL of CH2Cl2 afforded 0.077 g (94%) the desired ester after purification by column 
chromatography (15% EtOAc/Hexanes), which was carried on directly to the CuAAC 
reaction.   
Following the general CuAAC reaction procedure, the reaction of 0.077 g (0.249 mmol) 
of (6S,7S,E)-7-methyl-12-oxooxacyclododec-4-en-6-yl (R)-2-azidopropanoate, 0.035 mL 
(0.249 mmol) N,N-diethylprop-2-yn-1-amine, 2.49x10-3 mmol CuSO4•5H2O, and 2.49x10-
2 mmol of sodium ascorbate in 2.0 ml of H2O/t-BuOH (1:1) afforded 0.104 g (99%) of the 
title compound after purification by column chromatography (gradient CH2Cl2 to 10% 
MeOH/CH2Cl2). 
1H NMR (500 MHz, CDCl3) δ 7.71 (s, 1H), 5.53 (ddd, J = 14.5, 8.2, 5.9 Hz, 1H), 5.48 – 
5.38 (m, 2H), 5.32 (dd, J = 8.1, 4.5 Hz, 1H), 4.64 (ddd, J = 10.8, 8.9, 5.1 Hz, 1H), 3.98 – 
3.81 (m, 3H), 2.71 – 2.52 (m, 4H), 2.45 – 2.21 (m, 4H), 1.96 – 1.76 (m, 5H), 1.52 – 1.40 
(m, 1H), 1.37 – 1.21 (m, 3H), 1.20 – 1.06 (m, 7H), 0.87 (d, J = 6.9 Hz, 3H). 
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13C NMR (126 MHz, CDCl3) δ 173.34, 168.44, 144.25, 132.17, 127.39, 122.18, 78.74, 
60.79, 58.34, 47.49, 46.65, 34.60, 33.21, 32.15, 30.67, 23.97, 22.96, 18.07, 15.85, 11.46. 
HRMS (ESI) m/z calculated for [M+H]+ 421.2809, found 421.2806.   
 
Substrates 55j, 55k, 55h, 55l, and (R,R)-34a were synthesized following the same 
procedures used to make their corresponding enantiomers.  The 1H and 13C spectra of 
these compounds matched those of the enantiomeric series.   
 
 
 
 
5.3.3 PikC Oxidations 
Preparation of PikC-RhFRED mutants 
Using previously prepared pET28b_PikCD50N/D176Q/E246A-RhFRED as template, site-
directed mutagenesis was performed with the following primers: (E85A) 5’-
CTGACCGAGGCCGCGGCCGCGCTCAAC-3’ and (E94A) 5’-
CCACAACATGCTGGCATCCGACCCGCCGC-3’. 
 
Expression and purification of PikC-RhFRED 
The plasmid encoding PikCD50N/D176Q/E246A-RhFRED was transformed into E. coli 
BL21(DE3) cells, and an individual colony was selected for overnight growth (37 °C) in 
250 mL of LB containing kanamycin (50 μg/mL).105 12 x 1.5 L of LB (2.8 L baffled 
Fernbach flasks) supplemented with kanamycin (50 μg/mL), thiamine (1 mM), and FeCl3 
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(100 μM) were each inoculated with 15 mL of overnight seed culture and incubated at 37 
°C (160 rpm). When the OD600 reached 0.6-1.0, the cultures were cooled in an ice-water 
bath (15-20 min) before addition of IPTG (0.1 mM) and δ-aminolevulinic acid (1 mM). The 
cultures were grown at 18 °C for 18-20 h before the cells were harvested and stored at -
80 °C until used for protein purification. All subsequent steps were performed at 4 °C. The 
cells were thawed and resuspended in 180 mL of lysis buffer (50 mM NaH2PO4, 300 mM 
NaCl, 10 mM imidazole, 10% glycerol, 1 mM PMSF, pH 8) prior to lysis via sonication. 
The crude lysate was centrifuged at 50,000 x g for 30 min to remove cellular debris, and 
the clarified lysate was incubated with 20 mL of pre-equilibrated Ni-NTA resin on a 
nutating shaker for 1-2 h. The slurry was loaded onto an empty column, and the lysate 
was pushed through with gentle syringe pressure. The resin was washed with wash buffer 
(50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, 10% glycerol, pH 8) to remove bulk 
protein contaminants prior to elution of PikC-RhFRED with elution buffer (50 mM 
NaH2PO4, 300 mM NaCl, 300 mM imidazole, 10% glycerol, pH 8). The protein was 
subsequently concentrated using 30-50 kD MWCO centrifugal filters and desalted by 
loading onto PD-10 columns and eluting with storage buffer (50 mM NaH2PO4, 1 mM 
EDTA, 0.2 mM DTT, 10% glycerol, pH 7.3). The purified enzyme was typically used right 
away for large-scale reactions; any unused enzyme was aliquoted, flash frozen in liquid 
N2, and stored at -80 °C for subsequent use in analytical- and/or additional large-scale 
reactions. The yield of functional P450 (as assessed by obtaining CO difference spectra 
according to the established protocol was ~4-9 mg per 1 L of overexpression culture.132 
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Analytical-scale enzymatic reactions 
Analytical-scale enzymatic reactions were carried out under the following conditions: 5 
μM PikC-RhFRED, 1 mM substrate (5% DMSO, final concentration), 1 mM NADP+, 5 mM 
glucose-6-phosphate, and 1 U/mL glucose-6-phosphate dehydrogenase in storage buffer 
(50 mM NaH2PO4 (pH = 7.3), 1 mM EDTA, 0.2 mM DTT, 10% (v/v) glycerol). The total 
volume of each reaction was 100 μL (carried out in a 1.7 mL Eppendorf tube), and 
reactions were incubated at 30 °C (200 rpm) for 14-18 h prior to quenching via extraction 
with chloroform (2 x 100 μL). The combined organic layers were dried under a gentle 
stream of N2 and resuspended in methanol prior to LC-MS analysis.  The subsequent 
liquid chromatography mass spectrometry (LC-MS) analysis was performed on an Agilent 
Q-TOF HPLC-MS (Department of Chemistry, University of Michigan) equipped with an 
high resolution electrospray mass spectrometry (ESI-MS) source and a Beckmann 
Coulter reverse-phase HPLC system using an Waters XBridge C18 3.5 µm, 2.1x150 mm 
under the following conditions: mobile phase (A = deionized water + 0.1% formic acid, B 
= acetonitrile + 0.1% formic acid), 10% to 100% B over 15 min, 100% B for 4 min; flow 
rate, 0.2 mL/min. Reactions were scanned for [M+H] (starting material), [M+H+16] 
(monohydoxylation), [M+H+32] (dihydroxylation), [M+H-14] (demethylated starting 
material), and [M+H+2] (demethylated monohydroxylated product). In instances where a 
diethylamine was used instead of a dimethylamine, the scanned mass values were 
adjusted to observe deethylation.  The percent conversion was determined as outlined in 
Li et al.100 Briefly, the percent conversion was calculated with (AUCtotal 
products/(AUCtotal products + AUCunreacted substrate) by assuming ionization 
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efficiency of substrate and hydroxylated products are the same, because the ionization 
site of this series of compounds should be the dimethylamino group.100 
 
Preparative-scale enzymatic reactions 
To an Erlenmeyer flask containing reaction buffer (50 mM NaH2PO4, 1 mM EDTA, 0.2 
mM DTT, 10% (v/v) glycerol, pH 7.3) were added the following components sequentially: 
substrate (20 mM stock in DMSO, 1 mM final concentration), glucose-6-phosphate (100 
mM stock in reaction buffer, 5 mM final concentration), glucose-6-phosphate 
dehydrogenase (100 U/mL stock in water, 1 U/mL final concentration), PikC-RhFRED 
(varied stock concentrations, 5 µM final concentration), and NADP+ (20 mM stock in 
reaction buffer, 1 mM final concentration). The reaction mixture was capped with a milk 
filter and incubated at 30 °C overnight (14-16 h) with gentle shaking (100 rpm). Reactions 
were typically conducted on ~40-60 mg of each substrate (~90-130 mL total reaction 
volume) and performed in 500 mL Erlenmeyer flasks. After overnight incubation, the 
reaction was quenched by addition of acetone (2 x total reaction volume) and incubated 
at 4 °C for 2 h. The mixture was then filtered through celite, and the acetone was removed 
under reduced pressure. The remaining aqueous solution was saturated with NaCl, 
adjusted to pH 11, and extracted with ethyl acetate (3 x total reaction volume). The 
combined organic layers were dried over anhydrous Na2SO4 and evaporated under 
reduced pressure to afford a crude mixture of products and remaining starting material, 
which were purified by flash column chromatography. Mixtures that were recalcitrant to 
separation using standard column chromatographic techniques were further purified via 
semi-preparative HPLC using a Beckman Coulter System Gold HPLC equipped with a 
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Waters XBridge BEH C18 column (dimensions, 250 x 10 mm; particle size, 5 μm; pore 
size, 130 Å). The flow rate was maintained at 3 mL/min, and the mobile phase consisted 
of an acetonitrile/water mixture with formic acid (0.1%) included as a modifier. All crude 
material was dissolved in methanol and filtered through 0.20 μm PTFE filters (EMD 
Millipore) prior to manual HPLC injection. UV absorption was monitored at 240 nm and 
260 nm. 
 
Representative PikC preparative scale reaction 
Following the preparative-scale PikC reaction protocol, the oxidation of 38j was 
performed on 60 mg (1.36 mmol) of substrate.  Upon completion of the reaction and 
workup, an aliquot of the reaction was analyzed by LCMS to assess conversion and 
product ratios.  One quarter of the crude material (~45 mg) was purified by silica gel 
chromatography (CH2Cl2 to 10% MeOH/CH2Cl2) to give 3.1 mg (20% yield) of the oxidized 
product 39j.   
 
Explanation of Content for Tables S1, S2, and S3.   
In tables S1, S2, and S3 the product ratios from crude LCMS analysis are provided for all 
triazole linkers tested.  Entries that are reflected in manuscript Table 1 are depicted in 
bold in Tables S1, S2, and S3.  Cases where product structures were determined by 
authentic standard comparisons are described in detail below the supplementary tables.  
All compounds identified in manuscript Table 1 were fully characterized by NMR methods 
as described starting on page S41.   
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Entry Substrate Mutant Conversiona Ratiob,c Major product 
1 38j Triple 62 3(C):14(A):82(B):1 39j 
2 38j Triple+E85A 60 3(C):25(A):71(B):1 - 
3 38j Triple+E94A 41 70(A):6(B):24 - 
4 38j D50N 31 2(C):16(A):77(B):5 - 
5 38k Triple 55 1:22(A):73(B):4 39k 
6 38h Triple 39 6:94(A) 40c 
7 38h Triple+E85A 39 6:94(A):0 - 
8 38h Triple+E94A 26 7:86(A):7 - 
9 38h D50N 2 - - 
10 38l Triple 31 71(C):24(A):4:1 41l 
11 38l Triple+E85A 26 71(C):20(A):7:2 - 
12 38l Triple+E94A 33 81(C):15(A):2:2 - 
13 38e Triple 19 21:76:3 - 
14 38f Triple 29 14:76:10 - 
15 38a Triple 12 23:77 - 
16 38b Triple 27 18:82 - 
17 38g Triple 32 16:72:2:4:6 - 
18 38d Triple 25 15:80:2:3 - 
19 38c Triple 18 31:69 - 
20 38i Triple 28 8:42:46:4 - 
21 38p Triple 59 4:31:65(B) - 
22 38m Triple 0 - - 
23 38n Triple 0 - - 
aValues are percent conversion to M+H+16. 
bRatios for M+H+16 in order of elution from the LCMS. 
cKnown oxidation products shown in parentheses. 
 
Table 5.1: PikC analytical reactions with the 11-membered macrocycle 38.   
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Figure 5.1: Identification of PikC product 40j (Table 5.1, entry 1) with an authentic 
standard.  A. The LCMS reaction profile of 38j with PikC.  B. The LCMS trace overlay of 
the PikC oxidation of 38j (shown in black) and authentic standard (shown in red).  C. The 
co-injection of the PikC oxidation of 38j and authentic standard.   
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Figure 5.2: Identification of PikC product 40k (Table 5.1, entry 5) with an authentic 
standard.  A. The LCMS reaction profile of 38k with PikC.  B. The LCMS trace overlay of 
the PikC oxidation of 38k (shown in black) and authentic standard (shown in red).  C. The 
co-injection of the PikC oxidation of 38k and authentic standard.   
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Figure 5.3: Identification of PikC product 39k (Table 5.1, entry 5) with an authentic 
standard.  A. The LCMS reaction profile of 38k with PikC.  B. The LCMS trace overlay of 
the PikC oxidation of 38k (shown in black) and authentic standard (shown in red).  C. The 
co-injection of the PikC oxidation of 38k and authentic standard.   
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Figure 5.4: Identification of PikC product 40l (Table 5.1, entry 10) with an authentic 
standard.  A. The LCMS reaction profile of 38l with PikC.  B. The LCMS trace overlay of 
the PikC oxidation of 38l (shown in black) and authentic standard (shown in red).  C. The 
co-injection of the PikC oxidation of 4d and authentic standard.   
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Entry Substrate Mutant Conversiona Ratiob,c Major product 
1 52j Triple 65 30(A):61(B):9(C) 53j 
2 52j Triple+E94A 46 3(A):92(B):3(C):2 - 
3 52k Triple 56 16:83(B):1(C) 53k 
4 52k Triple+E94A 49 32:61(B):4(C):3 - 
5 52h Triple 37 59:41e 54h 
6 52l Triple 36 67(A):22:11(B) 54l 
7 52l Triple+E94A 45 86d(A):12(B):2 - 
8 52p Triple 57 38:53:8:1 - 
9 52p Triple+E94A 32 3:93:4:0  
aValues are percent conversion to M+H+16.  
bRatios for M+H+16 in order of elution from the LCMS.  
cKnown oxidation products shown in parentheses.  
dMultiple peaks overlap  
ePrepartive ratio differs from the analytical scale ratio  
 
 
Table 5.2: Analytical PikC reactions with the (R,R) 11-membered substrate 52. 
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Figure 5.5: Identification of PikC product 53j (Table 5.2, entry 1) with authentic standard 
40j.  A. The LCMS reaction profile of 52j with PikC.  B. The LCMS trace overlay of the 
PikC oxidation of 52j (shown in black) and authentic standard 40j (shown in red).  C. The 
co-injection of the PikC oxidation of 52j and 40j.  Experiments are run under the 
assumption that enantiomeric compounds have identical LCMS retention times.   
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Figure 5.6: Identification of PikC product (R,R,R)-39j (Table 5.2, entry 1) with authentic 
standard 39j.  A. The LCMS reaction profile of 52j with PikC.  B. The LCMS trace overlay 
of the PikC oxidation of 52j (shown in black) and authentic standard 39j (shown in red).  
C. The co-injection of the PikC oxidation of 52j and 39j.  Experiments are run under the 
assumption that enantiomeric compounds have identical LCMS retention times.   
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Figure 5.7: Identification of 41j and (R,R,R)-39j (Table 5.2, entry 1) by the comparison of 
the LCMS retention times of the PikC reactions of 38j and 52j.  Assignments are made 
under the assumption that enantiomeric compounds have identical retention times. A. 
The LCMS profile of the PikC oxidation of 38j (repeated from table 5.1, entry 1). B. The 
LCMS profile of the PikC oxidation of 52j. C. The overlay of LCMS profiles A and B.   
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Figure 5.8: Identification of PikC product 53k (Table 5.2, entry 3) with authentic standard 
40k.  A. The LCMS reaction profile of 52k with PikC.  B. The LCMS trace overlay of the 
PikC oxidation of 52k (shown in black) and authentic standard 40k (shown in red).  C. 
The co-injection of the PikC oxidation of 52k and 40k.  Experiments are run under the 
assumption that enantiomeric compounds have identical LCMS retention times. 
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Figure 5.9: Identification of PikC product (R,R,R)-39k (Table 5.2, entry 3) with authentic 
standard 39k.  A. The LCMS reaction profile of 52k with PikC.  B. The LCMS trace overlay 
of the PikC oxidation of 52k (shown in black) and authentic standard 39k (shown in red).  
C. The co-injection of the PikC oxidation of 52k and 39k.  Experiments are run under the 
assumption that enantiomeric compounds have identical LCMS retention times.   
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Figure 5.10: Identification of PikC product 53l (Table 5.2, entry 6) with authentic standard 
40l.  A. The LCMS reaction profile of 52l with PikC.  B. The LCMS trace overlay of the 
PikC oxidation of 52l (shown in black) and authentic standard 40l (shown in red).  C. The 
co-injection of the PikC oxidation of 52l and 40l.  Experiments are run under the 
assumption that enantiomeric compounds have identical LCMS retention times.   
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Figure 5.11: Identification of 54l (Table 5.2, entry 6) by comparison of LCMS retention 
times of the PikC oxidation of 38l and 52l.  Assignments are made under the assumption 
that enantiomeric compounds have identical retention times. A. The LCMS profile of the 
PikC oxidation of 38l (Table 5.1, entry 10 repeated for comparison). B. The LCMS profile 
of the PikC oxidation of 52l. C. The overlay of LCMS profiles A and B.   
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Entry Substrate Mutant Conversiona Ratiob,c Major product 
1 55l Triple 25 73(B):25(A):2 57j 
2 55o Triple 62 15:85(A) 56o 
3 55o Triple+E85A 66 14:86(A) 56o 
4 55o Triple+E94A 42 29:71(A) 56o 
5 55j Triple 57 31:69(A) 56j 
aValues are percent conversion to M+H+16.     
bRatios for M+H+16 in order of elution from the LCMS.    
cKnown oxidation products shown in parentheses.    
 
 
 
Table 5.3: Analytical scale PikC reactions performed with the 12-membered 
macrolactone 55.   
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5.3.4 Compounds Isolated from PikC Scale up Reactions 
 
(3S,5S,6S)-3-Hydroxy-6-methyl-4-methylene-11-oxooxacycloundecan-5-yl-4-(4-
((dimethylamino)methyl)-1H-1,2,3-triazol-1-yl)benzoate (39j): 
The title compound was prepared following the preparative-scale enzymatic reaction 
protocol and isolated via benchtop chromatography (CH2Cl2 to 10% MeOH/CH2Cl2).   
1H NMR (700 MHz, CDCl3) δ: 8.20 (d, J = 8.7 Hz, 2H), 8.14 (s, 1H), 7.87 (d, J = 8.6 Hz, 
2H), 5.60 (d, J = 1.4 Hz, 1H), 5.54 (s, 1H), 5.25 (s, 1H), 4.85 (t, J = 10.6 Hz, 1H), 4.34 
(dd, J = 10.6, 4.7, 1H), 4.01 (dd, J = 10.3, 4.7 Hz, 1H), 3.82 (s, 2H), 2.56 (ddd, J = 16.0, 
7.5, 1.9 Hz, 1H), 2.43 (s, 7H), 2.17 (ddd, J = 16.2, 12.2, 1.9 Hz, 1H), 2.11 – 2.04 (m, 1H), 
1.94 – 1.85 (m, 1H), 1.72 – 1.66 (m, 1H), 1.65 – 1.58 (m, 2H), 1.51 (td, J = 13.8, 13.2, 3.7 
Hz, 1H), 1.30 – 1.23 (m, 1H), 1.05 (d, J = 6.8 Hz, 3H) 
13C NMR (176 MHz, CDCl3) δ 172.70, 164.54, 149.02, 145.4, 140.24, 131.32, 130.07, 
121.38, 120.01, 113.82, 80.63, 66.99, 65.69, 53.93, 44.70, 34.94, 30.14, 25.65, 24.51, 
19.99, 16.61. 
The fully substituted triazole carbon was detected at 145.4 ppm by HMBC.   
HRMS (ESI) m/z calculated for [M+H]+ 457.2445, found 457.2443.   
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(3S,7S,8S)-3-((tert-Butyldimethylsilyl)oxy)-8-hydroxy-7-methyl-9-
methyleneoxacycloundecan-2-one (S17): 
Compound 40h was prepared following the preparative-scale enzymatic reaction 
protocol using substrate 38h.  Prior to TBS protection and anchor methanolysis, most of 
the impurities from the crude PikC reaction were removed via column chromatography 
(CH2Cl2 to 10% MeOH/CH2Cl2).   
An oven-dried vial equipped with stir bar was charged with the residue from the 
PikC oxidation reaction and 1.5 mL of DMF.  TBSCl (40 eq.) and imidazole (60 eq.) were 
added sequentially and the contents stirred until the starting material was consumed as 
judged by TLC.  Upon completion, the reaction was quenched by diluting with H2O and 
EtOAc.  The organic layer was extracted four times with H2O and once with brine.  Then, 
the organic layer was dried over Na2SO4, filtered, and concentrated.  The resulting 
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residue with loaded onto a pad of silica gel and washed with CH2Cl2, then eluted with 
10% MeOH/CH2Cl2.  Removal of the solvent furnished the TBS protected compound, 
which was carried on directly to the methanolysis.   
A vial containing the crude TBS protected product and a stir bar was suspended 
in 1.5 mL of MeOH/CHCl3 (4:1) and allowed to stir for 5 min before the addition of K2CO3 
(5.0 eq.).  The contents were stirred until all of the starting material was consumed as 
judged by TLC.  Upon completion, the reaction was quenched with pH 7 buffer and the 
aqueous layer extracted three times with EtOAc.  The organic layers were combined, 
dried over Na2SO4, filtered, and concentrated.  Purification of the crude residue by column 
chromatography (30% EtOAc/hexanes) afforded the title compound.   
1H NMR (500 MHz, CDCl3) δ 5.28 (s, 1H), 5.21 (d, J = 1.9 Hz, 1H), 4.81 (ddd, J = 12.9, 
10.7, 2.5 Hz, 1H), 4.15 (dt, J = 10.8, 3.4 Hz, 1H), 4.04 (dd, J = 9.9, 2.4 Hz, 1H), 3.99 (s, 
1H), 2.39 (dd, J = 15.5, 3.3 Hz, 1H), 2.26 – 2.16 (m, 1H), 2.09 – 1.92 (m, 1H), 1.70 – 
1.57 (m, 2H), 1.41 (s, 1H), 1.36 – 1.27 (m, 2H), 1.09 – 0.94 (m, 4H), 0.88 (s, 10H), 0.07 
(s, 3H), 0.06 (s, 3H). 
13C NMR (176 MHz, CDCl3) δ 173.19, 148.18, 111.14, 79.33, 73.89, 64.73, 31.96, 
30.95, 30.06, 25.70, 24.25, 21.05, 18.24, 17.00, -5.02, -5.17. 
 
(5S,6S,9R)-9-Hydroxy-6-methyl-4-methylene-11-oxooxacycloundecan-5-yl 2-(4-
((dimethylamino)methyl)-1H-1,2,3-triazol-1-yl)benzoate (41l): 
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The title compound was prepared following the preparative-scale enzymatic reaction 
protocol using substrate 38l and isolated via preparative HPLC. 
1H NMR (700 MHz, CDCl3) δ: 8.09 (s, 1H), 8.06 (d, J = 7.8 Hz, 1H), 7.71 (t, J = 7.7 Hz, 
1H), 7.64 (t, J = 7.7 Hz, 1H), 7.51 (d, J = 7.9 Hz, 1H), 5.20 (s, 1H), 5.17 (s, 1H), 5.07 (s, 
1H), 4.97 (ddd, J = 13.3, 11.2, 2.1 Hz, 1H), 4.28 – 4.21 (m, 1H), 4.05 (s, 2H), 3.95 (d, J = 
11.2, 4.2, 2.1 Hz, 1H), 2.76 (d, J = 15.2 Hz, 1H), 2.58 (s, 6H), 2.46 – 2.37 (m, 2H), 2.23 – 
2.14 (m, 1H), 2.13 – 2.06 (m, 1H), 1.92 – 1.84 (m, 1H), 1.66 – 1.59 (m, 1H), 1.57 – 1.51 
(m, 1H), 1.20 – 1.12 (m, 1H), 1.02 (d, J = 6.8 Hz, 3H) 
13C NMR (176 MHz, CDCl3) δ 170.29, 163.54, 142.25, 136.36, 132.96, 130.85, 130.22, 
127.56, 127.33, 126.61, 112.57, 81.60, 66.03, 64.07, 53.81, 44.14, 43.57, 35.37, 30.73, 
30.00, 23.90, 16.73 
HRMS (ESI) m/z calculated for [M+H]+ 457.2445, found 457.2442.   
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(3R,8S,12S,13S)-8-Hydroxy-12-methyl-7-oxo-1,6-dioxaspiro[2.10]tridecan-13-yl-4-
(4-((dimethylamino)methyl)-1H-1,2,3-triazol-1-yl)benzoate (44j): 
The title compound was prepared following the preparative-scale enzymatic 
reaction protocol using substrate 43j and isolated via preparative HPLC. 
1H NMR (700 MHz, CDCl3) δ 8.13 (d, J = 8.7 Hz, 2H), 8.01 (s, 1H), 7.85 (d, J = 8.7 Hz, 
2H), 5.42 (s, 1H), 4.58 (dt, J = 11.6, 3.9 Hz, 1H), 4.24 – 4.18 (m, 1H), 4.15 (dd, J = 8.9, 
2.1 Hz, 1H), 3.71 (s, 2H), 2.98 (d, J = 4.5 Hz, 1H), 2.92 (d, J = 4.6 Hz, 1H), 2.40 – 2.32 
(m, 7H), 2.16 – 2.10 (m, 1H), 2.09 – 1.99 (m, 2H), 1.90 – 1.81 (m, 2H), 1.79 – 1.72 (m, 
2H), 1.40 (ddt, J = 14.9, 10.3, 5.1 Hz, 1H), 1.01 (d, J = 6.8 Hz, 3H). 
13C NMR (176 MHz, CDCl3) δ 174.91, 164.54, 146.60, 140.25, 131.31, 129.90, 120.35, 
119.79, 75.96, 71.72, 62.30, 57.05, 54.37, 48.55, 45.29, 31.89, 31.20, 31.00, 27.41, 
21.68, 17.06. 
HRMS (ESI) m/z calculated for [M+H]+ 473.2395, found 473.2396.   
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(5R,6R,9S)-9-Hydroxy-6-methyl-4-methylene-11-oxooxacycloundecan-5-yl 4-(4-
((dimethylamino)methyl)-1H-1,2,3-triazol-1-yl)benzoate (54j): 
Compound 54j was prepared following the preparative-scale enzymatic reaction 
protocol using substrate 52j and was purified by preparative HPLC. 
1H NMR (700 MHz, CDCl3) δ: 8.22 (d, J = 8.7 Hz, 2H), 8.18 (s, 1H), 7.88 (d, J = 8.7 Hz, 
2H), 5.37 (s, 1H), 5.20 (s, 1H), 5.12 (d, J = 2.0 Hz, 1H), 5.02 (ddd, J = 13.4, 11.0, 2.6 Hz, 
1H), 4.30 (tt, J = 10.5, 2.9 Hz, 1H), 4.00 (ddd, J = 11.0, 4.2, 2.3 Hz, 1H), 3.88 (s, 2H), 
2.81 (d, J = 15.4 Hz, 1H), 2.58 – 2.40 (m, 8H), 2.28 (dddd, J = 15.1, 13.0, 4.3, 1.9 Hz, 
1H), 2.23 – 2.15 (m, 1H), 1.99 – 1.92 (m, 1H), 1.72 – 1.64 (m, 2H), 1.41 – 1.33 (m, 1H), 
1.10 (d, J = 6.8 Hz, 3H) 
13C NMR (176 MHz, CDCl3) δ 170.27, 164.46, 142.89, 142.57, 140.19, 131.33, 130.21, 
121.45, 120.00, 112.42, 81.24, 66.05, 64.11, 53.48, 44.33, 44.25, 35.45, 30.72, 29.87, 
24.13, 16.83. 
The fully substituted triazole carbon was detected at 142.89 ppm by HMBC.   
HRMS (ESI) m/z calculated for [M+H]+ 457.2445, found 457.2448.   
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(4S,7R,8R)-4-((tert-butyldimethylsilyl)oxy)-8-hydroxy-7-methyl-9-
methyleneoxacycloundecan-2-one (S18): 
Compound 54h was prepared following the preparative-scale enzymatic reaction 
protocol using substrate 52h.  Prior to TBS protection and anchor methanolysis, 13c was 
purified by preparative HPLC.   
An oven-dried vial equipped with stir bar was charged with the residue from the 
PikC oxidation reaction and 1.5 mL of DMF.  TBSCl (40 eq.) and imidazole (60 eq.) were 
added sequentially and the contents stirred until the starting material was consumed as 
judged by TLC.  Upon completion, the reaction was quenched by diluting with H2O and 
EtOAc.  The organic layer was extracted four times with H2O and once with brine.  Then, 
the organic layer was dried over Na2SO4, filtered, and concentrated.  The resulting 
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residue with loaded onto a pad of silica gel and washed with CH2Cl2, then eluted with 
10% MeOH/CH2Cl2.  Removal of the solvent furnished the TBS protected compound, 
which was carried on directly to the methanolysis.   
A vial containing the crude TBS protected product and a stir bar was suspended 
in 1.5 mL of MeOH/CHCl3 (4:1) and allowed to stir for 5 min before the addition of K2CO3 
(5.0 eq.).  The contents were stirred until all the starting material was consumed as judged 
by TLC.  Upon completion, the reaction was quenched with pH 7 buffer and the aqueous 
layer extracted three times with EtOAc.  The organic layers were combined, dried over 
Na2SO4, filtered, and concentrated.  Purification of the crude residue by column 
chromatography (30% EtOAc/hexanes) afforded the title compound.   
1H NMR (700 MHz, CDCl3) δ 5.28 (d, J = 2.1 Hz, 1H), 5.21 (s, 1H), 4.93 (ddd, J = 13.4, 
10.9, 2.7 Hz, 1H), 4.19 (tt, J = 10.6, 2.9 Hz, 1H), 3.99 (ddd, J = 10.9, 4.3, 2.2 Hz, 1H), 
3.96 (s, 1H), 2.62 (d, J = 15.5 Hz, 1H), 2.40 (dd, J = 15.5, 10.3 Hz, 1H), 2.36 (d, J = 15.6 
Hz, 1H), 2.16 (dddd, J = 15.2, 13.2, 4.3, 2.0 Hz, 1H), 1.95 – 1.88 (m, 1H), 1.82 – 1.76 (m, 
1H), 1.56 (ddt, J = 14.2, 10.9, 4.2 Hz, 1H), 1.40 (s, 1H), 1.35 – 1.29 (m, 1H), 0.89 (s, 9H), 
0.09 (s, 6H). 
13C NMR (176 MHz, CDCl3) δ 170.71, 147.53, 111.12, 79.42, 66.77, 64.02, 45.00, 35.85, 
30.60, 29.89, 25.80, 22.61, 18.06, 17.14, -4.69, -4.88. 
HRMS (ESI) m/z calculated for [M+Na]+ 365.2119, found 365.2121.   
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(3R,6S,7S,E)-3-Hydroxy-7-methyl-12-oxooxacyclododec-4-en-6-yl-4-(4-
((dimethylamino)methyl)-1H-1,2,3-triazol-1-yl)benzoate (56j): 
Compound 56j was prepared following the preparative-scale enzymatic reaction protocol 
using substrate 55j and was purified by preparative HPLC. 
1H NMR (700 MHz, CDCl3) δ 8.20 (d, J = 8.7 Hz, 2H), 8.02 (s, 1H), 7.87 (d, J = 8.6 Hz, 
2H), 5.90 (ddd, J = 15.5, 5.7, 1.3 Hz, 1H), 5.66 (td, J = 3.9, 1.8 Hz, 1H), 5.63 (ddd, J = 
15.5, 5.6, 1.4 Hz, 1H), 4.45 – 4.42 (m, 1H), 4.36 (dd, J = 11.4, 3.9 Hz, 1H), 4.33 (dd, J = 
11.4, 5.5 Hz, 1H), 3.71 (s, 2H), 2.43 (ddd, J = 14.6, 7.6, 4.1 Hz, 1H), 2.38 – 2.32 (m, 7H), 
2.08 – 2.01 (m, 1H), 1.85 – 1.78 (m, 1H), 1.70 – 1.63 (m, 1H), 1.55 – 1.42 (m, 3H), 1.41 
– 1.35 (m, 1H), 1.07 (d, J = 7.0 Hz, 3H). 
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13C NMR (176 MHz, CDCl3) δ 173.78, 164.60, 146.58, 140.23, 131.33, 130.75, 130.17, 
129.11, 120.35, 119.85, 77.26, 70.92, 65.37, 54.36, 45.29, 35.22, 32.59, 29.89, 24.03, 
23.75, 17.07. 
HRMS (ESI) m/z calculated for [M+H]+ 457.2445, found 457.2444.   
The stereochemistry of 56j was determined by Mosher ester derivatization (see 
the stereochemical determination and chemical correlation section for the comparison of 
the two ester 1H NMRs and subsequent assignment).   
 
(7S,8S,11R,E)-11-((tert-Butyldimethylsilyl)oxy)-8-hydroxy-7-methyloxacyclododec-
9-en-2-one (S19): 
Compound 56o was prepared following the preparative-scale enzymatic reaction 
protocol using substrate 55o.  Prior to TBS protection and anchor methanolysis, 56o was 
purified by column chromatography (CH2Cl2 to 10% MeOH/CH2Cl2).   
An oven-dried vial equipped with stir bar was charged with the residue from the 
PikC oxidation reaction and 1.5 mL of DMF.  TBSCl (40 eq.) and imidazole (60 eq.) were 
added sequentially and the contents stirred until the starting material was consumed as 
judged by TLC.  Upon completion, the reaction was quenched by diluting with H2O and 
EtOAc.  The organic layer was extracted four times with H2O and once with brine.  Then, 
the organic layer was dried over Na2SO4, filtered, and concentrated.  The resulting 
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residue with loaded onto a pad of silica gel and washed with CH2Cl2, then eluted with 
10% MeOH/CH2Cl2.  Removal of the solvent furnished the TBS protected compound, 
which was carried on directly to the hydrolysis.   
A vial containing the crude TBS protected product and a stir bar was suspended 
in 1.5 mL of MeOH/CHCl3 (4:1) and allowed to stir for 5 min before the addition of K2CO3 
(5.0 eq.).  The contents were stirred until all the starting material was consumed as judged 
by TLC.  Upon completion, the reaction was quenched with pH 7 buffer and the aqueous 
layer extracted three times with EtOAc.  The organic layers were combined, dried over 
Na2SO4, filtered, and concentrated.  Purification of the crude residue by column 
chromatography (30% EtOAc/hexanes) afforded the title compound.   
1H NMR (700 MHz, CDCl3) δ: 5.72 (dd, J = 15.4, 8.1 Hz, 1H), 5.50 (dd, J = 15.4, 8.0 Hz, 
1H), 4.41 (dd, J = 10.6, 8.7 Hz, 1H), 4.33 (td, J = 8.3, 4.8 Hz, 1H), 4.22 (s, 1H), 3.89 (dd, 
J = 10.6, 4.8 Hz, 1H), 2.33 (dt, J = 14.4, 4.8 Hz, 1H), 2.27 (ddd, J = 14.7, 11.8, 3.8 Hz, 
1H), 1.91 – 1.82 (m, 2H), 1.51 – 1.44 (m, 1H), 1.41 (s, 1H), 1.36 – 1.26 (m, 3H), 1.19 – 
1.11 (m, 1H), 0.99 (d, J = 6.9 Hz, 3H), 0.89 (s, 9H), 0.08 (s, 3H), 0.06 (s, 3H) 
13C NMR (176 MHz, CDCl3) δ 173.24, 133.05, 132.48, 75.21, 74.53, 71.87, 64.74, 36.34, 
32.23, 30.50, 25.76, 24.12, 23.37, 18.14, 15.68, -4.28, -4.81. 
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Scheme 5.1: Stereochemical assignment of S19 by conversion to 56j.   
 
Stereochemical determination of S19 by chemical synthesis.  
An oven-dried vial equipped with stir bar was charged with 3 mg (0.009 mmol) of 
S19 and suspended in 1 mL of CH2Cl2.  Then, 7 mg (0.045 mmol) of 4-azidobenzoic acid, 
2 mg (0.018 mmol) of DMAP, and 7 mg (0.045 mmol) of EDC were added sequentially.  
The contents were stirred until all the starting material was consumed as judged by TLC.  
Upon completion, the reaction was quenched with a 1 M aqueous HCl solution and 
EtOAc.  The organic layer was extracted twice with a 1 M aqueous HCl solution, once 
with sat’d aqueous sodium bicarbonate, and once with brine.  The organic layer was dried 
over Na2SO4, filtered, concentrated, and carried on to the next step without further 
purification.   
To an oven-dried vial equipped with stir bar was added the crude material from the 
EDC esterification and 0.50 mL of THF.  The contents were cooled to 0 °C, whereupon 1 
μL of AcOH and 0.108 μL of a 1 M solution of TBAF in THF where added sequentially. 
The reaction was warmed to rt and stir until all of the starting material was consumed as 
judged by TLC.  Upon completion, the reaction was quenched with sat’d NH4Cl and Et2O.  
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The aqueous layer was extracted thrice with Et2O, the organic layers combined, filtered, 
and concentrated to give the free alcohol.  The crude material was carried on to the 
CuAAC cyclization without further purification.   
Following the general CuAAC reaction procedure, the reaction of the crude 
material obtained from the deprotection, 0.005 mL (0.045 mmol) N,N-dimethylprop-2-yn-
1-amine, 4.5x10-4 mmol CuSO4•5H2O, and 4.5x10-3 mmol of sodium ascorbate in 1.0 ml 
of H2O/t-BuOH (1:1) afforded the desired adduct.  After following the standard workup, 
the crude material was washed through a plug of silica with CH2Cl2 and then eluted with 
10% MeOH/CH2Cl2 to afford the triazole, the 1H NMR spectrum of which matched that of 
S25 obtained through PikC oxidation (see the stereochemical determination and chemical 
correlation section for stacked 1H NMRs).   
 
(6S,7S,10R,E)-10-hydroxy-7-methyl-12-oxooxacyclododec-4-en-6-yl-2-(4-
((dimethylamino)methyl)-1H-1,2,3-triazol-1-yl)benzoate (57l): 
Compound 57l was prepared following the preparative-scale enzymatic reaction protocol 
using substrate 55l and was purified by preparative HPLC. 
1H NMR (700 MHz, CDCl3) δ 8.10 (s, 1H), 8.04 (d, J = 7.8 Hz, 1H), 7.70 (t, J = 7.7 Hz, 
1H), 7.64 (t, J = 7.7 Hz, 1H), 7.50 (d, J = 7.8 Hz, 1H), 5.53 – 5.44 (m, 2H), 5.38 (t, J = 
5.1 Hz, 1H), 4.43 – 4.36 (m, 1H), 4.27 – 4.19 (m, 3H), 4.14 – 4.07 (m, 1H), 2.68 (s, 6H), 
2.62 (dd, J = 14.1, 4.3 Hz, 1H), 2.52 (dd, J = 14.2, 8.8 Hz, 1H), 2.45 – 2.39 (m, 2H), 
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1.99 – 1.93 (m, 1H), 1.65 – 1.56 (m, 2H), 1.53 – 1.47 (m, 1H), 1.33 – 1.27 (m, 1H), 0.94 
(d, J = 7.0 Hz, 3H). 
13C NMR (176 MHz, CDCl3) δ 171.28, 164.28, 144.88, 136.31, 132.53, 130.93, 130.15, 
129.80, 128.75, 127.86, 126.88, 124.45, 77.80, 68.37, 61.08, 54.37, 45.22, 40.24, 
34.36, 33.31, 30.74, 26.09, 15.74. 
HRMS (ESI) m/z calculated for [M+H]+ 457.2445, found 457.2445.   
The stereochemistry of 57l was determined by Mosher ester derivatization (see 
the stereochemical determination and chemical correlation section for the comparison of 
the two ester 1H NMR and subsequent assignment).   
 
(6S,7S,E)-3-hydroxy-7-methyl-12-oxooxacyclododec-4-en-6-yl-2-(4-
((dimethylamino)methyl)-1H-1,2,3-triazol-1-yl)benzoate (56l): 
The title compound was isolated by preparative HPLC from the same product 
mixture as 57l as the minor product.   
1H NMR (700 MHz, CDCl3) δ 7.83 (dd, J = 7.7, 1.5 Hz, 1H), 7.73 (s, 1H), 7.64 (td, J = 7.7, 
1.5 Hz, 1H), 7.57 (td, J = 7.6, 1.2 Hz, 1H), 7.48 (dd, J = 7.9, 1.2 Hz, 1H), 5.67 (dd, J = 
14.1, 8.9 Hz, 1H), 5.51 – 5.44 (m, 2H), 4.63 (t, J = 10.1 Hz, 1H), 4.26 (td, J = 9.3, 5.1 Hz, 
1H), 3.93 (dd, J = 10.5, 5.1 Hz, 1H), 3.68 (q, J = 13.5 Hz, 2H), 2.34 (s, 6H), 2.33 – 2.30 
(m, 2H), 2.09 – 2.03 (m, 1H), 1.97 – 1.89 (m, 1H), 1.45 – 1.39 (m, 1H), 1.37 – 1.30 (m, 
2H), 1.29 – 1.22 (m, 2H), 1.21 – 1.16 (m, 1H), 0.93 (d, J = 6.9 Hz, 3H). 
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13C NMR (126 MHz, CDCl3) δ 172.98, 165.09, 144.47, 137.77, 135.50, 131.97, 129.94, 
129.61, 128.93, 126.51, 125.49, 124.11, 77.53, 71.20, 64.27, 54.21, 45.18, 33.72, 
31.58, 31.17, 24.09, 22.46, 15.48. 
HRMS (ESI) m/z calculated for [M+H]+ 457.2445, found 457.2447. 
The stereochemistry of 56l was determined by Mosher ester derivatization (see 
the stereochemical determination and chemical correlation section for the comparison of 
the two ester 1H NMR and subsequent assignment).   
 
5.3.5: Authentic Standard Synthesis 
Synthesis of Diol Standard 45 
 
(3S,7S,8S)-3-Hydroxy-7-methyl-9-methylene-8-
((triisopropylsilyl)oxy)oxacycloundecan-2-one (45): 
To an oven-dried flask equipped with stir bar was added 0.171 g (0.464 mmol) of 
(7S,8S)-7-methyl-9-methylene-8-((triisopropylsilyl)oxy)oxacycloundecan-2-one and 9 mL 
of THF.  The contents were cooled to -78 °C whereupon 0.696 mL of a 1M solution of 
KHMDS in THF was added dropwise.  The reaction was stirred for 20 min before the 
addition of 0.182 g (0.696 mmol) of 3-phenyl-2-(phenylsulfonyl)-1,2-oxaziridine dropwise 
as a solution in 6 mL of THF.  The reaction was stirred for an additional 20 mins at -78 °C 
before being quenched with sat’d aqueous NH4Cl and transferred to a separatory funnel.  
The aqueous layer was extracted 3x with Et2O, the organic layers combined, dried over 
MgSO4, filtered, and concentrated under vacuum.  The crude residue was purified by 
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column chromatography (CH2Cl2 to 1% MeOH/CH2Cl2) to give 0.120 g (67%) of the title 
compound as a clear oil.   
1H NMR (700 MHz, CDCl3) δ 5.36 (s, 1H), 5.17 – 5.13 (m, 1H), 4.55 (ddd, J = 10.8, 4.4, 
2.9 Hz, 1H), 4.40 (ddd, J = 12.3, 10.7, 3.1 Hz, 1H), 4.16 (t, J = 1.5 Hz, 1H), 4.05 – 3.99 
(m, 1H), 2.59 (d, J = 5.7 Hz, 1H), 2.43 – 2.34 (m, 1H), 2.22 – 2.13 (m, 1H), 1.97 – 1.89 
(m, 1H), 1.79 – 1.72 (m, 1H), 1.70 – 1.48 (m, 4H), 1.10 – 1.03 (m, 22H), 0.99 (d, J = 6.8 
Hz, 3H). 
13C NMR (176 MHz, CDCl3) δ 175.25, 147.25, 111.73, 80.58, 71.93, 65.49, 32.14, 32.05, 
30.24, 25.18, 21.71, 18.31, 18.22, 17.65, 13.20. 
HRMS (ESI) m/z calculated for [M+Na]+ 407.2588, found 407.2585.   
The stereochemistry of 45 was determined by Mosher ester analysis (see the 
stereochemical determination and chemical correlation section for the comparison of the 
two ester 1H NMR and subsequent assignment).   
  
(3S,7S,8S)-3,8-Dihydroxy-7-methyl-9-methyleneoxacycloundecan-2-one (46):  
To an oven-dried flask equipped with stir bar was added 0.023 g (0.060 mmol) of 
(3S,7S,8S)-3-hydroxy-7-methyl-9-methylene-8-((triisopropylsilyl)oxy)oxacycloundecan-
2-one and 2.40 mL of THF.  The contents were cooled to 0 °C and 0.007 mL (0.120 mmol) 
of acetic acid and 0.718 mL of a 1 M solution of TBAF in THF were added sequentially.  
The reaction was warmed to rt until all the starting material was consumed as judged by 
TLC.  Upon completion, the reaction was quenched with sat’d aqueous NH4Cl and 
transferred to a separatory funnel.  The aqueous layer was extracted three times with 
Et2O, the organic layers combined, dried over MgSO4, filtered and the solvent removed.  
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The crude residue was purified by column chromatography (50% EtOAc/Hexanes) to 
yield 0.012 g (88%) of the title compound as a white solid.   
1H NMR (500 MHz, CDCl3) δ 5.33 (d, J = 1.8 Hz, 1H), 5.18 (s, 1H), 4.62 (ddd, J = 10.7, 
4.4, 2.4 Hz, 1H), 4.31 (ddd, J = 12.8, 10.7, 3.1 Hz, 1H), 4.05 – 3.95 (m, 2H), 2.68 (s, 1H), 
2.47 – 2.34 (m, 1H), 2.22 (dddd, J = 15.1, 12.8, 4.5, 1.8 Hz, 1H), 2.01 – 1.90 (m, 1H), 
1.77 (dqd, J = 13.9, 4.9, 4.4, 2.5 Hz, 2H), 1.73 – 1.56 (m, 2H), 1.52 (dddd, J = 13.8, 11.3, 
4.5, 2.5 Hz, 2H), 1.12 – 1.00 (m, 4H). 
13C NMR (126 MHz, CDCl3) δ 175.39, 147.78, 110.58, 79.19, 71.83, 65.89, 31.90, 
30.45, 30.06, 24.55, 21.96, 17.12. 
HRMS (ESI) m/z calculated for [M+H]+ 251.1254, found 251.1250.   
 
Synthesis of THP Monoprotected Diol Intermediate 47  
 
(3S,7S,8S)-8-Hydroxy-7-methyl-9-methylene-3-((tetrahydro-2H-pyran-2-
yl)oxy)oxacycloundecan-2-one (47): 
To an oven-dried vial equipped with stir bar was added 0.038 g (0.099 mmol) of 
(3S,7S,8S)-3-hydroxy-7-methyl-9-methylene-8-((triisopropylsilyl)oxy)oxacycloundecan-
2-one and 2.0 mL of CH2Cl2.  The contents were stirred for ~5 min before the sequential 
addition of 0.014 mL (0.148 mmol) of 3,4-dihydro-2H-pyran and 0.002 g (0.010 mmol) of 
PPTS.  The reaction was stirred until all the starting material was consumed as judged by 
TLC.  Upon completion, the reaction was quenched by diluting with a solution of sat’d 
aqueous sodium bicarbonate.  The aqueous layer was extracted three times with EtOAc, 
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the organic layers combined, dried over Na2SO4, filtered and concentrated.  The crude 
residue was carried on to the TIPS deprotection without further purification.   
To a vial containing the THP protected diol was added 1.70 mL of THF.  The 
contents were cooled to 0 °C and 0.010 mL (0.179 mmol) of acetic acid and 1.075 mL of 
a 1M solution of TBAF in THF were added sequentially.  The reaction was warmed to rt 
and stir until all the starting material was consumed as judged by TLC.  Upon completion, 
the reaction was quenched by diluting with a solution of sat’d aqueous NH4Cl.  The 
aqueous layer was extracted thrice with Et2O, the organic layers combined, dried over 
MgSO4, filtered and concentrated.  The resulting residue was purified by column 
chromatography (30% EtOAc/Hexanes) to give 0.027 g (88% over two steps) of 1:1 
mixtures of diastereomers at the THP chiral center.   
1H NMR (500 MHz, CDCl3) δ 5.28 (s, 1H), 5.20 (s, 0.5H), 5.18 (s, 1H), 4.73 (ddd, J = 
13.1, 10.8, 2.7 Hz, 0.5H), 4.67 (t, J = 3.7 Hz, 0.5H), 4.65 – 4.58 (m, 1H), 4.32 (dt, J = 
10.8, 3.4 Hz, 1H), 4.25 (dt, J = 10.9, 3.4 Hz, 1H), 4.11 (dd, J = 10.1, 2.5 Hz, 0.5H), 3.98 
(s, 1H), 3.89 (dd, J = 10.5, 2.7 Hz, 1H), 3.86 – 3.77 (m, 1H), 3.50 (dt, J = 10.7, 4.9 Hz, 
1H), 3.43 (dt, J = 10.8, 4.7 Hz, 1H), 2.42 – 2.30 (m, 1H), 2.29 – 2.15 (m, 1H), 2.08 – 1.87 
(m, 2H), 1.86 – 1.66 (m, 3H), 1.66 – 1.46 (m, 6H), 1.46 – 1.35 (m, 1H), 1.07 – 0.94 (m, 
4H) 
13C NMR (126 MHz, CDCl3) δ 172.67, 172.57, 147.99, 147.92, 110.97, 110.85, 98.64, 
97.17, 79.25, 79.21, 78.41, 75.51, 64.77, 64.64, 62.55, 62.33, 30.58, 30.51, 30.48, 30.37, 
29.67, 29.46, 29.26, 28.39, 25.27, 25.16, 24.03, 23.83, 21.90, 21.63, 19.23, 19.14, 16.92, 
16.80. 
HRMS (ESI) m/z calculated for [M+H]+ 313.2010, found 313.2007.   
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Synthesis of Authentic Standard 40j 
 
(5S,6S,10S)-10-Hydroxy-6-methyl-4-methylene-11-oxooxacycloundecan-5-yl 4-
azidobenzoate (48A):  
An oven-dried vial equipped with stir bar was charged with 0.008 g (0.026 mmol) 
of (3S,7S,8S)-8-hydroxy-7-methyl-9-methylene-3-((tetrahydro-2H-pyran-2-
yl)oxy)oxacycloundecan-2-one, 0.021 g (0.128 mmol) of 4-azidobenzoic acid, 0.025 g 
(0.128 mmol) of EDC, and 0.008 g (0.0.064 mmol) of DMAP.  The contents were 
suspended in 2.0 mL of CH2Cl2 and allowed to stir until all the starting material was 
consumed as judged by TLC.  Upon completion, the reaction was filtered through a plug 
of silica gel and the solvent removed.  The crude material was carried on to the THP 
deprotection without further purification.   
An oven-dried vial equipped with stir bar was charged with the crude material from 
the above reaction and suspended in 3.0 mL of EtOH.  0.013 g (0.052 mmol) of PPTS 
was then added, the reaction heated to 60 °C and allowed to stir until all the starting 
material was consumed as judged by TLC.  The reaction was quenched by diluting with 
a solution of sat’d aqueous sodium bicarbonate and EtOAc.  The aqueous layer was 
extracted three times with EtOAc, the organic layers combined, dried over Na2SO4, 
filtered, and concentrated.  The crude residue was purified by chromatography (10% 
EtOAc/Hexanes to 30% EtOAc/Hexanes) to yield 8.4 mg (87% over two steps) of the title 
compound as a clear oil.   
1H NMR (500 MHz, CDCl3) δ 8.07 (d, J = 8.6 Hz, 2H), 7.09 (d, J = 8.7 Hz, 2H), 5.35 (s, 
1H), 5.16 – 5.09 (m, 2H), 4.63 (ddd, J = 10.8, 4.5, 2.5 Hz, 1H), 4.35 (ddd, J = 12.6, 10.8, 
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3.1 Hz, 1H), 4.10 – 4.03 (m, 1H), 2.67 (s, 1H), 2.51 (d, J = 15.5 Hz, 1H), 2.40 – 2.30 (m, 
1H), 2.08 – 1.92 (m, 2H), 1.89 – 1.60 (m, 3H), 1.32 – 1.27 (m, 1H), 0.99 (d, J = 6.7 Hz, 
3H). 
13C NMR (126 MHz, CDCl3) δ 175.21, 164.88, 144.95, 143.04, 131.40, 126.67, 118.95, 
111.65, 80.71, 71.83, 65.79, 31.72, 30.26, 30.24, 26.11, 21.97, 16.84. 
 
(5S,6S,10S)-10-Hydroxy-6-methyl-4-methylene-11-oxooxacycloundecan-5-yl4-(4-
((dimethylamino)methyl)-1H-1,2,3-triazol-1-yl)benzoate (40j): 
Following the general CuAAC reaction procedure, the reaction of 0.006 g (0.016 
mmol) of (5S,6S,10S)-10-hydroxy-6-methyl-4-methylene-11-oxooxacycloundecan-5-yl 4-
azidobenzoate, 0.006 mL (0.048 mmol) N,N-dimethylprop-2-yn-1-amine, 1.60x10-4 mmol 
CuSO4•5H2O, and 1.60x10-3 mmol of sodium ascorbate in 1.0 ml of H2O/t-BuOH (1:1) 
afforded 0.007 g (95%) of the title compound after purification by column chromatography 
(gradient CH2Cl2 to 10% MeOH/CH2Cl2).   
1H NMR (500 MHz, CDCl3) δ 8.23 (d, J = 8.6 Hz, 2H), 8.17 (s, 1H), 7.88 (d, J = 8.6 Hz, 
2H), 5.40 (s, 1H), 5.19 – 5.10 (m, 2H), 4.63 (ddd, J = 10.8, 4.5, 2.5 Hz, 1H), 4.37 (ddd, J 
= 13.4, 11.0, 3.1 Hz, 1H), 4.08 (dd, J = 9.0, 2.0 Hz, 1H), 3.85 (s, 2H), 2.59 – 2.50 (m, 1H), 
2.45 (s, 6H), 2.41 – 2.32 (m, 1H), 2.09 – 1.94 (m, 2H), 1.90 – 1.59 (m, 4H), 1.37 – 1.22 
(m, 2H), 1.01 (d, J = 6.8 Hz, 3H) 
13C NMR (176 MHz, CDCl3) δ 175.19, 164.50, 145.1, 142.89, 140.19, 131.34, 130.23, 
121.21, 119.98, 111.75, 81.16, 71.83, 65.74, 54.00, 44.80, 31.71, 30.28, 30.27, 26.12, 
21.95, 16.86. 
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The fully substituted triazole carbon was detected at 145.1 ppm by HMBC.   
HRMS (ESI) m/z calculated for [M+H]+ 457.2445, found 457.2449.   
 
Synthesis of Authentic Standard 40l 
 
(5S,6S,10S)-10-Hydroxy-6-methyl-4-methylene-11-oxooxacycloundecan-5-yl 2-
azidobenzoate (48C):  
An oven-dried vial equipped with stir bar was charged with 0.008 g (0.026 mmol) 
of (3S,7S,8S)-8-hydroxy-7-methyl-9-methylene-3-((tetrahydro-2H-pyran-2-
yl)oxy)oxacycloundecan-2-one, 0.042 g (0.260 mmol) of 2-azidobenzoic acid, 0.054 g 
(0.260 mmol) of DCC, and 0.016 g (0.130 mmol) of DMAP.  The contents were suspended 
in 2.0 mL of CH2Cl2 and allowed to stir until all the starting material was consumed as 
judged by TLC.  Upon completion, the reaction was filtered through a plug of silica gel 
and the solvent removed.  The crude material was carried on to the THP deprotection 
without further purification.   
An oven-dried vial equipped with stir bar was charged with the crude material from 
the above reaction and suspended in 3.0 mL of EtOH.  0.013 g (0.052 mmol) of PPTS 
was then added, the reaction heated to 60 °C and allowed to stir until all the starting 
material was consumed as judged by TLC.  The reaction was quenched by diluting with 
a solution of sat’d aqueous sodium bicarbonate and EtOAc.  The aqueous layer was 
extracted three times with EtOAc, the organic layers combined, dried over Na2SO4, 
filtered, and concentrated.  The crude residue was purified by chromatography (10% 
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EtOAc/Hexanes to 30% EtOAc/Hexanes) to yield 9.3 mg (96% over two steps) of the title 
compound as a clear oil.   
 
(5S,6S,10S)-10-Hydroxy-6-methyl-4-methylene-11-oxooxacycloundecan-5-yl-2-(4-
((dimethylamino)methyl)-1H-1,2,3-triazol-1-yl)benzoate (40l): 
Following the general CuAAC reaction procedure, the reaction of 0.004 g (0.011 
mmol) of (5S,6S,10S)-10-hydroxy-6-methyl-4-methylene-11-oxooxacycloundecan-5-yl 2-
azidobenzoate, 0.006 mL (0.048 mmol) N,N-dimethylprop-2-yn-1-amine, 1.11x10-4 mmol 
CuSO4•5H2O, and 1.11x10-3 mmol of sodium ascorbate in 1.0 ml of H2O/t-BuOH (1:1) 
afforded 4.1 mg (84%) of the title compound after purification by column chromatography 
(gradient CH2Cl2 to 10% MeOH/CH2Cl2).   
1H NMR (500 MHz, CDCl3) δ 8.13 – 8.03 (m, 2H), 7.70 (t, J = 7.7 Hz, 1H), 7.64 (t, J = 7.7 
Hz, 1H), 7.52 (d, J = 7.8 Hz, 1H), 5.22 (s, 1H), 5.17 – 5.09 (m, 2H), 4.57 (ddd, J = 10.8, 
4.4, 2.8 Hz, 1H), 4.33 (ddd, J = 13.8, 11.0, 3.1 Hz, 1H), 4.11 – 4.02 (m, 3H), 2.62 (s, 6H), 
2.51 – 2.42 (m, 1H), 2.33 – 2.20 (m, 1H), 2.00 – 1.88 (m, 2H), 1.85 – 1.75 (m, 1H), 1.73 
– 1.56 (m, 3H), 1.18 – 1.08 (m, 1H), 0.95 (d, J = 6.8 Hz, 3H) 
13C NMR (176 MHz, CDCl3) δ 175.11, 163.45, 142.45, 136.36, 132.99, 130.84, 130.26, 
127.56, 127.28, 126.77, 112.06, 81.38, 71.74, 65.67, 53.21, 43.75, 31.74, 30.45, 30.40, 
26.19, 21.83, 16.77. 
HRMS (ESI) m/z calculated for [M+H]+ 457.2445, found 457.2447.   
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Synthesis of Authentic Standard 40k 
 
(5S,6S,10S)-10-Hydroxy-6-methyl-4-methylene-11-oxooxacycloundecan-5-yl 3-
azidobenzoate (48B): 
An oven-dried vial equipped with stir bar was charged with 0.008 g (0.026 mmol) of 
(3S,7S,8S)-8-hydroxy-7-methyl-9-methylene-3-((tetrahydro-2H-pyran-2-
yl)oxy)oxacycloundecan-2-one, 0.042 g (0.260 mmol) of 3-azidobenzoic acid, 0.054 g 
(0.260 mmol) of DCC, and 0.016 g (0.130 mmol) of DMAP.  The contents were suspended 
in 2.0 mL of CH2Cl2 and allowed to stir until all the starting material was consumed as 
judged by TLC.  Upon completion, the reaction was filtered through a plug of silica gel 
and the solvent removed.  The crude material was carried on to the THP deprotection 
without further purification.   
An oven-dried vial equipped with stir bar was charged with the crude material from the 
above reaction and suspended in 3.0 mL of EtOH.  0.013 g (0.052 mmol) of PPTS was 
then added, the reaction heated to 60 C and allowed to stir until all of the starting material 
was consumed as judged by TLC.  The reaction was quenched by diluting with a solution 
of sat’d aqueous sodium bicarbonate and EtOAc.  The aqueous layer was extracted thrice 
with EtOAc, the organic layers combined, dried over Na2SO4, filtered, and concentrated.  
The crude residue was purified by chromatography (10% EtOAc/Hexanes to 30% 
EtOAc/Hexanes) to yield 8.2 mg (85% over two steps) of the title compound as a clear 
oil.   
1H NMR (500 MHz, CDCl3) δ 7.85 (d, J = 7.8 Hz, 1H), 7.72 (t, J = 1.9 Hz, 1H), 7.46 (t, J 
= 7.9 Hz, 1H), 7.26 – 7.23 (m, 1H), 5.37 (s, 1H), 5.15 (s, 1H), 5.13 (d, J = 1.7 Hz, 1H), 
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4.63 (ddd, J = 10.8, 4.5, 2.5 Hz, 1H), 4.35 (ddd, J = 12.5, 10.8, 3.1 Hz, 1H), 4.08 (d, J = 
8.9 Hz, 1H), 2.64 (d, J = 4.7 Hz, 1H), 2.53 (d, J = 15.6 Hz, 1H), 2.35 (dddd, J = 14.9, 
12.7, 4.5, 1.7 Hz, 1H), 2.06 – 1.94 (m, 2H), 1.87 – 1.62 (m, 4H), 1.34 – 1.23 (m, 1H), 
0.99 (d, J = 6.8 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 175.22, 164.80, 142.89, 140.71, 131.95, 129.95, 125.91, 
123.47, 120.00, 111.75, 81.05, 71.82, 65.78, 31.73, 30.29, 30.25, 26.11, 21.95, 16.84. 
HRMS (ESI) m/z calculated for [M+Na]+ 396.1530, found 396.1525.   
 
(5S,6S,10S)-10-Hydroxy-6-methyl-4-methylene-11-oxooxacycloundecan-5-yl-3-(4-
((dimethylamino)methyl)-1H-1,2,3-triazol-1-yl)benzoate (40k): 
Following the general CuAAC reaction procedure, the reaction of (0.141 mmol) of 
(6S,7S,E)-7-methyl-12-oxooxacyclododec-4-en-6-yl 2-azidobenzoate, 0.016 mL (0.141 
mmol) N,N-dimethylprop-2-yn-1-amine, 1.41x10-3 mmol CuSO4•5H2O, and 1.41x10-2 
mmol of sodium ascorbate in 2.0 ml of H2O/t-BuOH (1:1) afforded 0.050 g (80% over two 
steps) of the title compound after purification by column chromatography (gradient CH2Cl2 
to 10% MeOH/CH2Cl2). 
1H NMR (500 MHz, CDCl3) δ: 8.39 (s, 1H), 8.20 – 8.09 (m, 2H) 8.03 (d, J = 8.1 Hz, 1H), 
7.65 (t, J = 7.9 Hz, 1H), 5.42 (s, 1H), 5.21 – 5.09 (m, 2H), 4.63 (ddd, J = 10.9, 4.5, 2.6 
Hz, 1H), 4.36 (ddd, J = 13.4, 10.9, 3.1 Hz, 1H), 4.08 (dd, J = 9.0, 2.1 Hz, 1H), 3.83 (s, 
2H), 2.61 – 2.32 (m, 8H), 2.10 – 1.94 (m, 2H), 1.89 – 1.61 (m, 4H), 1.38 – 1.19 (m, 2H), 
1.01 (d, J = 6.8 Hz, 3H) 
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13C NMR (176 MHz, CDCl3) δ 175.21, 164.41, 145.8, 142.83, 137.33, 132.00, 130.15, 
129.60, 124.90, 121.31, 121.18, 111.85, 81.36, 71.81, 65.76, 54.03, 44.83, 31.73, 30.36, 
30.29, 26.15, 21.96, 16.87. 
The fully substituted triazole carbon was detected at 145.8 ppm by HMBC.   
HRMS (ESI) m/z calculated for [M+H]+ 457.2445, found 457.2448.   
 
(5S,6S)-6-Methyl-4-methylene-11-oxooxacycloundecan-5-yl acetate (34C):  
An oven dried flask equipped with stir bar was charged with 0.050 g (0.236) of 
(7S,8S)-8-hydroxy-7-methyl-9-methyleneoxacycloundecan-2-one, 0.003 g (0.024 mmol) 
of DMAP, and 1.67 mL of acetonitrile. The contents were stirred for ~5 min before the 
sequential addition of 0.029 mL (0.353 mmol) of pyridine and 0.033 mL (0.353 mmol) of 
acetic anhydride.  The reaction was stirred until all of the starting material was consumed 
as judged by TLC.  Upon completion, the reaction was quenched by diluting with Et2O 
and transferred to a separatory funnel.  The organic layer was extracted once with sat’d 
aqueous sodium bicarbonate, once with H2O, and once with brine.  The organic layer was 
dried over MgSO4, filtered and the solvent removed.  The crude residue was purified by 
column chromatography (20% EtOAc/Hexanes) to yield 0.056 g (93%) of the title 
compound as a clear oil.   
1H NMR (700 MHz, CDCl3) δ 5.13 (s, 1H), 5.11 (s, 1H), 5.03 (s, 1H), 4.91 (ddd, J = 13.2, 
10.9, 2.6 Hz, 1H), 3.93 (ddd, J = 10.9, 4.1, 2.5 Hz, 1H), 2.50 (dd, J = 16.0, 6.5 Hz, 1H), 
2.46 – 2.40 (m, 1H), 2.22 (dddd, J = 15.2, 13.0, 4.1, 2.0 Hz, 1H), 2.16 – 2.08 (m, 5H), 
1.92 – 1.83 (m, 1H), 1.67 – 1.59 (m, 1H), 1.59 – 1.53 (m, 1H), 1.52 – 1.46 (m, 1H), 1.46 
– 1.39 (m, 1H), 1.06 (ddt, J = 15.0, 11.7, 3.9 Hz, 1H), 0.93 (d, J = 6.8 Hz, 3H). 
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13C NMR (176 MHz, CDCl3) δ 173.67, 170.38, 143.36, 111.74, 80.62, 64.03, 35.26, 30.92, 
28.55, 25.70, 24.61, 20.86, 19.96, 16.42. 
HRMS (ESI) m/z calculated for [M+Na]+ 277.1410, found 277.1407.   
 
(3R,12S,13S)-12-Methyl-7-oxo-1,6-dioxaspiro[2.10]tridecan-13-yl acetate (42): 
To a vial equipped with stir bar was added 0.014 g (0.055 mmol) of (5S,6S)-6-
methyl-4-methylene-11-oxooxacycloundecan-5-yl acetate.  0.0026 g (2.75x10-3 mmol) of 
Fe(S,S-PDP) and 0.0016 mL (0.0275 mmol) of acetic acid in 0.10 mL of acetonitrile was 
added .  The solution was stirred vigorously and 0.004 mL of a 50% w/w solution of 
hydrogen peroxide diluted to 0.50 mL in acetonitrile was added dropwise over ~2 min.  
The reaction was stirred for 10 min.  A second addition of 0.0026 g (2.75x10-3 mmol) of 
Fe(S,S-PDP) and 0.0016 mL of acetic acid in 0.10 mL of acetonitrile was added followed 
by a solution of 0.004 mL of a 50% w/w solution of hydrogen peroxide diluted to 0.50 mL 
in acetonitrile over ~2 min.  After stirring for 10 min, this process was repeated for a third 
time for a total of 15 mol% Fe(S,S-PDP), 1.5 equivalents of acetic acid, and 3.6 
equivalents of hydrogen peroxide and a total reaction time of 30 min.  The reaction was 
immediately quenched by diluting with sat’d aqueous sodium bicarbonate and the 
aqueous layer extracted three times with Et2O.  The combined organic layers were dried 
over MgSO4, filtered and concentrated.  The crude residue was purified by column 
chromatography (10% EtOAc/Hexanes to 20% EtOAc/Hexanes) to 8.5 mg (57%) of the 
title compound as a clear oil.   
1H NMR (700 MHz, C6D6) δ: 5.25 (s, 1H), 4.40 (td, J = 12.0, 2.4 Hz, 1H), 3.32 (dt, J = 
11.6, 3.7 Hz, 1H), 2.65 (d, J = 4.9 Hz, 1H), 2.63 (d, J = 4.9 Hz, 1H), 2.11 (ddd, J = 15.3, 
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7.5, 2.1 Hz, 1H), 2.01 – 1.94 (m, 1H), 1.89 (ddd, J = 15.4, 11.7, 2.2 Hz, 1H), 1.76 (ddd, J 
= 16.2, 12.4, 3.9 Hz, 1H), 1.66 (s, 3H), 1.65 – 1.56 (m, 1H), 1.50 – 1.40 (m, 2H), 1.40 – 
1.32 (m, 1H), 1.18 – 1.10 (m, 2H), 1.00 (ddt, J = 13.6, 11.2, 4.1 Hz, 1H), 0.78 (d, J = 6.8 
Hz, 3H) 
13C NMR (126 MHz, C6D6) δ 172.83, 169.44, 75.43, 60.41, 56.79, 47.64, 35.27, 32.08, 
29.70, 26.24, 25.79, 20.44, 20.21, 16.70. 
HRMS (ESI) m/z calculated for [M+H]+ 271.1540, found 271.1540.   
 
 
(3R,12S,13S)-13-Hydroxy-12-methyl-1,6-dioxaspiro[2.10]tridecan-7-one (43): 
To an oven-dried flask equipped with stir bar was added 0.089 g (0.419 mmol) of 
(7S,8S)-8-hydroxy-7-methyl-9-methyleneoxacycloundecan-2-one and CH2Cl2 (10 mL).  
The reaction was stirred for 5 min before the addition of 0.165 g (0.671 mmol) of 70% w/w 
mCPBA.  The reaction was stirred overnight.  The following day, the reaction was 
quenched by diluting with 1M NaOH and transferred to a separatory funnel.  The aqueous 
layer was extracted thrice with CH2Cl2, the organic layers combined, dried over Na2SO4, 
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filtered, and concentrated.  The crude residue was purified by column chromatography 
(30% EtOAc/Hexanes) to yield 0.094 g (99%) of the desired product as a clear oil.   
1H NMR (401 MHz, CDCl3) δ 4.72 (ddd, J = 12.7, 11.6, 2.5 Hz, 1H), 3.92 (ddd, J = 11.7, 
4.1, 2.8 Hz, 1H), 3.75 (s, 1H), 3.06 – 2.97 (m, 2H), 2.53 (ddd, J = 15.4, 7.7, 2.1 Hz, 1H), 
2.30 (ddd, J = 16.5, 12.8, 4.1 Hz, 1H), 2.17 (ddd, J = 15.4, 11.6, 2.0 Hz, 1H), 2.12 – 2.02 
(m, 1H), 2.00 (s, 1H), 1.98 – 1.79 (m, 2H), 1.73 – 1.57 (m, 2H), 1.53 – 1.41 (m, 1H), 1.39 
– 1.17 (m, 2H), 1.06 (d, J = 6.9 Hz, 3H). 
13C NMR (176 MHz, CDCl3) δ 174.00, 75.37, 60.68, 59.75, 48.40, 35.26, 31.72, 29.47, 
25.68, 24.96, 20.30, 17.14. 
HRMS (ESI) m/z calculated for [M+Na]+ 251.1254, found 251.1253.  
 
Stereochemical Determination of (3R,12S,13S)-13-hydroxy-12-methyl-1,6-
dioxaspiro[2.10]tridecan-7-one (43): 
To an oven-dried vial equipped with stir bar was added 0.006 g (0.026 mmol) of 
(3R,12S,13S)-13-hydroxy-12-methyl-1,6-dioxaspiro[2.10]tridecan-7-one, 0.002 g (0.016 
mmol) of DMAP and 1.0 mL of acetonitrile. The contents were stirred for for ~5 min before 
the sequential addition of 0.010 mL (0.130 mmol) of pyridine and 0.008 mL (0.078 mmol) 
of acetic anhydride.  The reaction was stirred until all the starting material was consumed 
as judged by GCMS.  Upon completion, the reaction was quenched with a solution of 
sat’d aqueous sodium bicarbonate.  The aqueous layer was extracted thrice with CH2Cl2, 
the organic layers combined, dried over Na2SO4, filtered, and the solvent removed.  The 
crude residue was purified by column chromatography (20% EtOAc/Hexanes) to give 5.8 
mg (83%) of the acetylated product whose 1H NMR matched that of the product obtained 
from the Fe(S,S-PDP) oxidation.  See part 6 for the comparison of the 1H NMRs.   
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(3S,5S,6S)-3-Hydroxy-6-methyl-4-methylene-11-oxooxacycloundecan-5-yl-3-
azidobenzoate (50): 
An oven-dried vial equipped with stir bar was charged with 0.060 g (0.168 mmol) 
of (5S,6S)-6-methyl-4-methylene-11-oxooxacycloundecan-5-yl 3-azidobenzoate and 
0.022 g (0.201 mmol) of selenium dioxide.  The contents were suspended in 3.0 mL of 
dioxane and allowed to stir for 5 min before the addition of 0.064 g (0.671 mmol) of 
pyridine N-oxide.  The vial was sealed, heated to 90 °C, and allowed to stir until all the 
starting material was consumed as judged by TLC.  Upon completion, the reaction was 
quenched with a sat’d solution of sodium bicarbonate and the aqueous layer extracted 
three times with EtOAc.  The organic layers were combined, dried over Na2SO4, filtered, 
and concentrated.  The resulting residue was purified by chromatography (gradient 10% 
EtOAc/hexanes to 45% EtOAc/hexanes) to yield 0.030g (48%) of the desired compound.   
1H NMR (500 MHz, CDCl3) δ 7.82 (dt, J = 7.7, 1.2 Hz, 1H), 7.71 – 7.68 (m, 1H), 7.45 (t, 
J = 7.9 Hz, 1H), 7.24 (ddd, J = 8.1, 2.4, 1.0 Hz, 1H), 5.58 (d, J = 1.5 Hz, 1H), 5.50 (s, 1H), 
5.23 (s, 1H), 4.84 (t, J = 10.6 Hz, 1H), 4.33 (dd, J = 10.8, 4.4 Hz, 1H), 3.99 (dd, J = 10.3, 
4.7 Hz, 1H), 2.55 (ddd, J = 16.1, 7.5, 1.9 Hz, 1H), 2.27 (s, 1H), 2.15 (ddd, J = 16.1, 12.0, 
1.8 Hz, 1H), 2.11 – 2.01 (m, 1H), 1.95 – 1.82 (m, 1H), 1.79 – 1.44 (m, 4H), 1.28 – 1.18 
(m, 1H), 1.03 (d, J = 6.8 Hz, 3H). 
 
13C NMR (126 MHz, CDCl3) δ 172.70, 164.90, 148.87, 140.76, 131.79, 129.98, 125.88, 
123.58, 119.99, 113.84, 80.61, 66.96, 65.67, 34.94, 30.09, 25.65, 24.46, 19.97, 16.57. 
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HRMS (ESI) m/z calculated for [M+NH4]+ 391.1976, found 391.1977.   
 
(3S,5S,6S)-3-Hydroxy-6-methyl-4-methylene-11-oxooxacycloundecan-5-yl 3-(4-
((dimethylamino)methyl)-1H-1,2,3-triazol-1-yl)benzoate (39k): 
Following the general CuAAC reaction procedure, the reaction of 0.005 g (0.013 
mmol) of (3S,5S,6S)-3-Hydroxy-6-methyl-4-methylene-11-oxooxacycloundecan-5-yl 3-
azidobenzoate, 0.003 mL (0.027 mmol) N,N-dimethylprop-2-yn-1-amine, 1.3x10-4 mmol 
CuSO4•5H2O, and 1.3x10-3 mmol of sodium ascorbate in 1.0 ml of H2O/t-BuOH (1:1) 
afforded 0.005 g (85%) of the title compound after purification by column chromatography 
(gradient CH2Cl2 to 10% MeOH/CH2Cl2). 
1H NMR (500 MHz, CDCl3) δ: 8.37 (s, 1H), 8.19 (s, 1H), 8.11 (d, J = 7.8 Hz, 1H), 8.02 (d, 
J = 8.0 Hz, 1H), 7.63 (t, J = 7.9 Hz, 1H), 5.60 (s, 1H), 5.54 (s, 1H), 5.25 (s, 1H), 4.84 (t, J 
= 10.6 Hz, 1H), 4.34 (dd, J = 10.9, 4.6 Hz, 1H), 4.00 (dd, J = 10.3, 4.6 Hz, 1H), 3.88 (s, 
2H), 2.55 (dd, J = 15.9, 6.8 Hz 1H), 2.46 (s, 6H), 2.16 (dd, J = 15.0, 12.4 Hz 1H), 2.12 – 
2.04 (m, 1H), 1.88 (q, J = 13.0 Hz, 1H), 1.74 – 1.56 (m, 3H), 1.56 – 1.46 (m, 1H), 1.33 – 
1.17 (m, 1H), 1.04 (d, J = 6.7 Hz, 3H) 
13C NMR (176 MHz, CDCl3) δ 172.71, 164.50, 148.88, 144.7, 137.33, 131.84, 130.19, 
129.55, 125.00, 121.49, 121.20, 113.89, 80.90, 66.98, 65.69, 53.91, 44.69, 34.92, 30.15, 
25.65, 24.49, 19.98, 16.60. 
The fully substituted triazole carbon was detected at 144.7 ppm by HMBC.   
HRMS (ESI) m/z calculated for [M+H]+ 457.2445, found 457.2449.   
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Chemical synthesis of (3R,8S,12S,13S)-8-hydroxy-12-methyl-7-oxo-1,6-
dioxaspiro[2.10]tridecan-13-yl-4-(4-((dimethylamino)methyl)-1H-1,2,3-triazol-1-
yl)benzoate: 
An oven-dried vial equipped with stir bar was charged with 2.4 mg (0.0064 mmol) of 
(5S,6S,10S)-10-hydroxy-6-methyl-4-methylene-11-oxooxacycloundecan-5-yl 4-
azidobenzoate and suspended in 1 mL of CH2Cl2.  0.007 g of 70% w/w mCPBA was then 
added in a single portion.  After consumption of the starting material as judged by TLC, 
the reaction was quenched with 1M NaOH, and the aqueous layer extracted three times 
with CH2Cl2.  The organic layers were combined, dried over Na2SO4, filtered, and 
concentrated.  The 1H NMR revealed a 94:6 mixture of diastereomers.  The crude 
material was carried on directly to the CuAAC cyclization.   
Following the general CuAAC reaction procedure, the reaction of 0.0064 mmol of 
(8S,12S,13S)-8-hydroxy-12-methyl-7-oxo-1,6-dioxaspiro[2.10]tridecan-13-yl 4-
azidobenzoate, 0.007 mL (0.064 mmol) N,N-diethylprop-2-yn-1-amine, 3.20x10-4 mmol 
CuSO4•5H2O, and 3.20x10-3 mmol of sodium ascorbate in 1.0 mL of H2O/t-BuOH (1:1) 
afforded 0.002 g (67% over two steps) of the title compound as a clear oil after purification 
by column chromatography (gradient CH2Cl2 to 10% MeOH/CH2Cl2) 
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The 1H NMR of the chemically prepared standard (vide supra) matched that of the 
analogous product obtained through enzymatic oxidation.  
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5.3.6 Stereochemical Determination and Chemical Correlation 
 
Figure 5.12: Stereochemical assignment of the hydroxyl group in 35B by Mosher Ester 
derivatization.  Assignments were made following the protocol established by Hoye et. al. 
where protons shielded by the phenyl group in the conformations shown are shifted 
upfield in the 1H NMR.133   
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Figure 5.13: Stereochemical assignment of compound 45 by Mosher ester derivatization.   
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Figure 5.14: Stereochemical assignment of compound 56j by Mosher ester 
derivatization.   
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Figure 5.15: Stereochemical assignment of 57l by Mosher ester derivatization.   
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Figure 5.16: Stereochemical assignment of 56l by Mosher ester derivatization.   
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Figure 5.17: Comparison of the 1H NMR spectra of 46 obtained through PikC oxidation 
and chemical oxidation.   
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Figure 5.18: Comparison of the 1H NMR spectra of 44j obtained through PikC oxidation 
and chemical oxidation.  A: 1H NMR obtained through chemical synthesis.  B: 1H NMR 
obtained through PikC oxidation.   
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Figure 5.19: Comparison of the 1H NMR of the 12-membered macrolactone allylic 
oxidation product.  A: 1H NMR of the allylic oxidation product from S19.  B: 1H NMR of 
56j from the PikC oxidation of 55j.   
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Figure 5.20: Comparison of the 1H NMR of epoxidized macrocycles obtained through A: 
mCPBA and B: Fe(S,S-PDP) oxidation.   
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